
<html lang="en"     class="pb-page"  data-request-id="7768c77c-c167-4672-a868-243f0a44136d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.5b01064;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2015.58.issue-24;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections" /></meta><meta name="dc.Creator" content="Suhui  Yang" /></meta><meta name="dc.Creator" content="Jyothi  K.R." /></meta><meta name="dc.Creator" content="Sangbin  Lim" /></meta><meta name="dc.Creator" content="Tae Gyu  Choi" /></meta><meta name="dc.Creator" content="Jin-Hwan  Kim" /></meta><meta name="dc.Creator" content="Salima  Akter" /></meta><meta name="dc.Creator" content="Miran  Jang" /></meta><meta name="dc.Creator" content="Hyun-Jong  Ahn" /></meta><meta name="dc.Creator" content="Hee-Young  Kim" /></meta><meta name="dc.Creator" content="Marc P.  Windisch" /></meta><meta name="dc.Creator" content="Daulat B.  Khadka" /></meta><meta name="dc.Creator" content="Chao  Zhao" /></meta><meta name="dc.Creator" content="Yifeng  Jin" /></meta><meta name="dc.Creator" content="Insug  Kang" /></meta><meta name="dc.Creator" content="Joohun  Ha" /></meta><meta name="dc.Creator" content="Byung-Chul  Oh" /></meta><meta name="dc.Creator" content="Meehyein  Kim" /></meta><meta name="dc.Creator" content="Sung Soo  Kim" /></meta><meta name="dc.Creator" content="Won-Jea  Cho" /></meta><meta name="dc.Description" content="Hepatitis C virus (HCV) is a major cause of end-stage liver disease. Direct-acting antivirals (DAAs), including inhibitors of nonstructural proteins (NS3/4A protease, NS5A, and NS5B polymerase), re..." /></meta><meta name="Description" content="Hepatitis C virus (HCV) is a major cause of end-stage liver disease. Direct-acting antivirals (DAAs), including inhibitors of nonstructural proteins (NS3/4A protease, NS5A, and NS5B polymerase), re..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 8, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01064" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01064" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01064" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01064" /></link>
        
    
    

<title>Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01064" /></meta><meta property="og:title" content="Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0012.jpeg" /></meta><meta property="og:description" content="Hepatitis C virus (HCV) is a major cause of end-stage liver disease. Direct-acting antivirals (DAAs), including inhibitors of nonstructural proteins (NS3/4A protease, NS5A, and NS5B polymerase), represent key components of anti-HCV treatment, but these are associated with increased drug resistance and toxicity. Thus, the development of host-targeted antiviral agents, such as cyclophilin A inhibitors, is an alternative approach for more effective, selective, and safer treatment. Starting with the discovery of a bis-amide derivative 5 through virtual screening, the lead compound 25 was developed using molecular modeling-based design and systematic exploration of the structure–activity relationship. The lead 25 lacked cytotoxicity, had potent anti-HCV activity, and showed selective and high binding affinity for CypA. Unlike cyclosporin A, 25 lacked immunosuppressive effects, successfully inhibited the HCV replication, restored host immune responses without acute toxicity in vitro and in vivo, and exhibited a high synergistic effect in combination with other drugs. These findings suggest that the bis-amides have significant potential to extend the arsenal of HCV therapeutics." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Hepatitis C virus (HCV) is a major cause of end-stage liver disease. Direct-acting antivirals (DAAs), including inhibitors of nonstructural proteins (NS3/4A protease, NS5A, and NS5B polymerase), represent key components of anti-HCV treatment, but these are associated with increased drug resistance and toxicity. Thus, the development of host-targeted antiviral agents, such as cyclophilin A inhibitors, is an alternative approach for more effective, selective, and safer treatment. Starting with the discovery of a bis-amide derivative 5 through virtual screening, the lead compound 25 was developed using molecular modeling-based design and systematic exploration of the structure–activity relationship. The lead 25 lacked cytotoxicity, had potent anti-HCV activity, and showed selective and high binding affinity for CypA. Unlike cyclosporin A, 25 lacked immunosuppressive effects, successfully inhibited the HCV replication, restored host immune responses without acute toxicity in vitro and in vivo, and exhibited a high synergistic effect in combination with other drugs. These findings suggest that the bis-amides have significant potential to extend the arsenal of HCV therapeutics." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0012.jpeg" /></meta><meta name="twitter:title" content="Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01064"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01064">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01064&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01064&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01064&amp;href=/doi/10.1021/acs.jmedchem.5b01064" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 9546-9561</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01062" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01110" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Suhui++Yang">Suhui Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jyothi++K.R.">Jyothi K.R.</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sangbin++Lim">Sangbin Lim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tae+Gyu++Choi">Tae Gyu Choi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jin-Hwan++Kim">Jin-Hwan Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Salima++Akter">Salima Akter</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Miran++Jang">Miran Jang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hyun-Jong++Ahn">Hyun-Jong Ahn</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hee-Young++Kim">Hee-Young Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marc+P.++Windisch">Marc P. Windisch</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daulat+B.++Khadka">Daulat B. Khadka</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chao++Zhao">Chao Zhao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yifeng++Jin">Yifeng Jin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Insug++Kang">Insug Kang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joohun++Ha">Joohun Ha</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Byung-Chul++Oh">Byung-Chul Oh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Meehyein++Kim">Meehyein Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sung+Soo++Kim">Sung Soo Kim</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Won-Jea++Cho">Won-Jea Cho</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 500-757, Republic of Korea</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Department of Microbiology, School of Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Applied Molecular Virology, Institute Pasteur Korea, Gyeonggi-do 463-400, Republic of Korea</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">Lee Gil Ya Cancer and Diabetes Institute, Gachon University of Medicine and Science, Incheon 406-840, Republic of Korea</span></div><div class="aff-info" id="aff6"><span class="aff-symbol">#</span> <span class="aff-text">Virus Research and Testing Group, Korea Research Institute of Chemical Technology, Daejeon 305-600, Republic of Korea</span></div><div class="corresp-info"><strong>*</strong>S.S.K.: phone, +82-2-961-0524; fax, +82-2-959-8168; e-mail, <a href="/cdn-cgi/l/email-protection#067561756d6f6b466d6e73286765286d74"><span class="__cf_email__" data-cfemail="a8dbcfdbc3c1c5e8c3c0dd86c9cb86c3da">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>W.-J.C.: phone, +82-62-530-2933; fax, +82-62-530-2911; e-mail, <a href="/cdn-cgi/l/email-protection#e99e838a8186a983879cc7888ac7829b"><span class="__cf_email__" data-cfemail="a9dec3cac1c6e9c3c7dc87c8ca87c2db">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01064&amp;href=/doi/10.1021%2Facs.jmedchem.5b01064" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 9546–9561</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 27, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 July 2015</li><li><span class="item_label"><b>Published</b> online</span>8 December 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 December 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01064" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01064</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9546%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSuhui%2BYang%252C%2BJyothi%2BK.R.%252C%2BSangbin%2BLim%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D24%26contentID%3Dacs.jmedchem.5b01064%26title%3DStructure-Based%2BDiscovery%2Bof%2BNovel%2BCyclophilin%2BA%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BHepatitis%2BC%2BVirus%2BInfections%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9561%26publicationDate%3DDecember%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01064"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2250</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">9</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01064" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Suhui&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Jyothi&quot;,&quot;last_name&quot;:&quot;K.R.&quot;},{&quot;first_name&quot;:&quot;Sangbin&quot;,&quot;last_name&quot;:&quot;Lim&quot;},{&quot;first_name&quot;:&quot;Tae&quot;,&quot;last_name&quot;:&quot;Gyu Choi&quot;},{&quot;first_name&quot;:&quot;Jin-Hwan&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Salima&quot;,&quot;last_name&quot;:&quot;Akter&quot;},{&quot;first_name&quot;:&quot;Miran&quot;,&quot;last_name&quot;:&quot;Jang&quot;},{&quot;first_name&quot;:&quot;Hyun-Jong&quot;,&quot;last_name&quot;:&quot;Ahn&quot;},{&quot;first_name&quot;:&quot;Hee-Young&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Marc&quot;,&quot;last_name&quot;:&quot;P. Windisch&quot;},{&quot;first_name&quot;:&quot;Daulat&quot;,&quot;last_name&quot;:&quot;B. Khadka&quot;},{&quot;first_name&quot;:&quot;Chao&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Yifeng&quot;,&quot;last_name&quot;:&quot;Jin&quot;},{&quot;first_name&quot;:&quot;Insug&quot;,&quot;last_name&quot;:&quot;Kang&quot;},{&quot;first_name&quot;:&quot;Joohun&quot;,&quot;last_name&quot;:&quot;Ha&quot;},{&quot;first_name&quot;:&quot;Byung-Chul&quot;,&quot;last_name&quot;:&quot;Oh&quot;},{&quot;first_name&quot;:&quot;Meehyein&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Sung&quot;,&quot;last_name&quot;:&quot;Soo Kim&quot;},{&quot;first_name&quot;:&quot;Won-Jea&quot;,&quot;last_name&quot;:&quot;Cho&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;9546-9561&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01064&quot;},&quot;abstract&quot;:&quot;Hepatitis C virus (HCV) is a major cause of end-stage liver disease. Direct-acting antivirals (DAAs), including inhibitors of nonstructural proteins (NS3/4A protease, NS5A, and NS5B polymerase), represent key components of anti-HCV treatment, but these are associated with increased drug resistance and toxicity. Thus, the development of host-targeted antiviral agents, such as cyclophilin A inhibitors, is an alternative approach for more effective, selective, and safer treatment. Starting with the discovery of a bis-amide derivative 5 through virtual screening, the lead compound 25 was developed using molecular modeling-based design and systematic exploration of the structure–activity relationship. The lead 25 lacked cytotoxicity, had potent anti-HCV activity, and showed selective and high binding affinity for CypA. Unlike cyclosporin A, 25 lacked immunosuppressive effects, successfully inhibited the HCV replication, restored host immune responses without acute toxicity in vitro and in vivo, and exhibited a hig&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01064&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01064" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01064&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01064" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01064&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01064" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01064&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01064&amp;href=/doi/10.1021/acs.jmedchem.5b01064" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01064" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01064" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01064%26sid%3Dliteratum%253Aachs%26pmid%3D26613291%26genre%3Darticle%26aulast%3DYang%26date%3D2015%26atitle%3DStructure-Based%2BDiscovery%2Bof%2BNovel%2BCyclophilin%2BA%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BHepatitis%2BC%2BVirus%2BInfections%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D24%26spage%3D9546%26epage%3D9561%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/24" title="Go to Volume 58, Issue 24"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/jmcmar.2015.58.issue-24/20151224/jmcmar.2015.58.issue-24.largecover.jpg" alt="Go to Volume 58, Issue 24"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Hepatitis C virus (HCV) is a major cause of end-stage liver disease. Direct-acting antivirals (DAAs), including inhibitors of nonstructural proteins (NS3/4A protease, NS5A, and NS5B polymerase), represent key components of anti-HCV treatment, but these are associated with increased drug resistance and toxicity. Thus, the development of host-targeted antiviral agents, such as cyclophilin A inhibitors, is an alternative approach for more effective, selective, and safer treatment. Starting with the discovery of a bis-amide derivative <b>5</b> through virtual screening, the lead compound <b>25</b> was developed using molecular modeling-based design and systematic exploration of the structure–activity relationship. The lead <b>25</b> lacked cytotoxicity, had potent anti-HCV activity, and showed selective and high binding affinity for CypA. Unlike cyclosporin A, <b>25</b> lacked immunosuppressive effects, successfully inhibited the HCV replication, restored host immune responses without acute toxicity in vitro and in vivo, and exhibited a high synergistic effect in combination with other drugs. These findings suggest that the bis-amides have significant potential to extend the arsenal of HCV therapeutics.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60303" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60303" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hepatitis C is an infectious disease affecting primarily the liver and is caused by the hepatitis C virus (HCV). Chronic infection with HCV is a high risk factor for developing serious liver diseases, particularly cirrhosis and hepatocarcinoma.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> HCV patients were treated with a combination of pegylated interferon α (pegIFN-α) and ribavirin until 2011.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> A sustained virologic response (SVR) to the treatment or the state of aviremia was achieved in 54–56% of the patients treated.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Since the approval of the first direct-acting antivirals (DAAs), telaprevir and boceprevir (viral nonstructrural protein, NS3/4A protease, inhibitors), triple combination therapy including DAA became a standard treatment for chronic HCV infection.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> Triple combination therapy regimens demonstrated a notable improvement in cure rates of HCV genotype 1, the most common type.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> Triple combination therapy achieved a SVR in 75% of patients. The SVR increased to >79% when telaprevir or boceprevir were replaced by simeprevir, an NS3/4A protease inhibitor.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> With the approval of a new combination treatment employing sofosbuvir (NS5B polymerase inhibitor) and ledipasvir (NS5A inhibitor) that achieved >94% SVR in patients with HCV genotype 1 infection, pegIFN-α-free regimens with or without ribavirin have become common for HCV treatment. In addition to these DAAs, ombitasvir (NS5A inhibitor), paritaprevir (NS3/4A protease inhibitor), dasabuvir (NS5B polymerase inhibitor), and daclatasvir (NS5A inhibitor) in pegIFN-α-free regimens have been assessed for the treatment of HCV genotypes 1–6.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13 ref14 ref15 ref16">(10-16)</a></div><div class="NLM_p">Although DAAs show potent antiviral activity and acceptable safety profiles, DAA-based treatment regimens have several distinct limitations; these include treatment-emergent viral mutations and drug resistance, cross-resistance between DAAs of the same family, a prevalence of HCV variants with a natural polymorphism associated with DAA resistance, and HCV genotype-dependent differences in antiviral activities.<a onclick="showRef(event, 'ref5 ref17 ref18 ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref5 ref17 ref18 ref19 ref20 ref21 ref22 ref23">(5, 17-23)</a> These issues spurred us to develop indirectly acting, host-targeting antiviral drugs such as inhibitors of cyclophilin, which is required for HCV replication. Combination therapy with cyclophilin inhibitors may provide an alternative and complementary strategy with a multigenotypic high barrier of resistance for HCV infection.</div><div class="NLM_p">Since cyclosporin A (CsA) shows antiviral effects via cyclophilin A (CypA) inhibition, CypA has become a target for HCV treatment (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Cyps are a family of highly conserved cellular peptidyl-prolyl cis–trans isomerases (PPIase) and are involved in cellular processes including protein folding and trafficking. CypA is the most abundant family member, and its critical role in supporting HCV-specific RNA replication and viral protein expression has been reported in several studies.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a> Though CsA has antiviral efficacy, the CsA-CypA complex also blocks the dephosphorylation-driven nuclear translocation of nuclear factor of activated T cells (NFAT), eventually leading to the clinical use of CsA as an immunosuppressant.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Therefore, nonimmunosuppressive CsA analogs, such as NIM-811,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> SCY-635,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and alisporivir (Debio-025),<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> have been developed through chemical modification at either position 3 or 4 of CsA. These analogs have been shown to possess not only potent efficacy against HCV replication but also a long lasting antiviral response and a higher genetic barrier to resistance compared to those of DAAs (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). However, the clinical safety profile of these inhibitors has yet to be resolved. Besides, CsA-based inhibitors share the same backbone scaffold and may possibly have broad specificity to Cyp isoforms. Taking into consideration the potential limitations of CsA-based inhibitors and the strong involvement of CypA in HCV replication, we herein report the identification and development of a novel series of potent and selective CypA inhibitors as anti-HCV agents.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of four CypA inhibitors: CsA, NIM-811, SCY-635, and alisporivir.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51615" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51615" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As the conserved amino acid residues making up the catalytically active site for the PPIase domain of CypA were identified,<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> we searched for compounds targeting this region in order to attain a high specificity for CypA. Over 200 000 compounds were screened for their binding affinity for the ligand binding domain (LBD) of the CsA-CypA complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1CWA">1CWA</a>) to discover potential inhibitors of CypA PPIase activity (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_002.pdf" class="ext-link">Figure S1</a>).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The binding affinities were predicted based on five different scoring functions and consensus scores by applying Surflex-Dock. Of the high scoring compounds, <b>5</b> emerged as a promising hit (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). The computational binding mode of <b>5</b> with CypA shows that the carbonyl oxygen of two amides and the nitro group of the ring (B) of the bis-amide interact with the amino acid residues Arg55, Trp121, and Lys125 of CypA through H-bonds. A hydrophobic interaction is observed between the cyclohexyl ring (A) and Phe113. However, the phenylethyl moiety (D) is entirely devoid of chemical interactions; the moiety projects outward from the protein core and lacks contact with any amino acid. Thus, we reasoned that modification of the flexible phenylethyl group to a constrained indolylmethyl or a phenyl moiety might be advantageous, since this modification would place the rigid aromatic ring over the indole of Trp121 to establish a π–π stacking interaction.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structure of <b>5</b> and its binding mode inside CypA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Various novel analogs of bis-amide <b>5</b> were prepared by employing Ugi multicomponent reaction as extension of the Passerini three-component reaction.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> In general, Ugi four-component condensation involves the in situ formation of an imine from an aldehyde <b>2</b> and an amine <b>3</b>. The subsequent reaction of the imine with carboxylic acid <b>4</b> and an isocyanide <b>1</b> produces an intermediate, which rearranges via an acyl transfer to yield the bis-amides (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The Ugi multicomponent reaction offers the major advantage that most Ugi products can be isolated as solids without the need for further purification steps, which saves time and effort.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Therefore, this reaction type is a highly efficient method for creating molecular diversity in a single reaction vessel. Prior to synthesis, we investigated the effect of several reaction parameters including temperature, solvent, and microwave irradiation (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_002.pdf" class="ext-link">Tables S2 and S3</a>). On the basis of these findings, a total of 21 bis-amides (<b>5</b>–<b>25</b>) were prepared by the Ugi reaction using the polar protic solvents such as methanol, ethanol, or 2,2,2-trifluoroethanol (TFE) at room temperature or at 55 °C (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> and <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Bis-amides <b>5</b>–<b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Isocyanides <b>1</b>, aldehydes <b>2</b>, amines <b>3</b>, and carboxylic acids <b>4</b> are listed in <a href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_002.pdf" class="ext-link">Table S1</a>.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Cytotoxicity and Anti-HCV Activity of the Bis-amides <b>5</b>–<b>25</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0011.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">CC<sub>50</sub>: half maximal cytotoxic concentration.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">EC<sub>50</sub>: half maximal effective concentration.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">SI: selectivity index (CC<sub>50</sub>/EC<sub>50</sub>).</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Not active.</p></div></div><div></div></div><div class="NLM_p">The newly synthesized bis-amide analogs were initially screened for their effect on the viability of mock-infected and chemical-treated Huh7.5 cells and for their anti-HCV activity (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36-38)</a> The antiviral activity of the hit <b>5</b> (half maximal effective concentration EC<sub>50</sub> = 6.1 ± 4.7 μM) was similar to that of IFN-α (EC<sub>50</sub> = 6.2 ± 1.6 μM). Furthermore, the derivatives <b>6</b> (EC<sub>50</sub> = 3.3 μM) and <b>7</b> (EC<sub>50</sub> = 2.5 ± 0.1 μM) displayed even more potent antiviral activities. However, these compounds were cytotoxic (half maximal cytotoxic concentration CC<sub>50</sub> ≤ 10 μM). Bis-amides <b>8</b>–<b>13</b> were less cytotoxic (CC<sub>50</sub> > 22 μM) but showed lower antiviral activities, with EC<sub>50</sub> values that were greater than their CC<sub>50</sub> values. Derivatives <b>14</b>–<b>18</b> were not cytotoxic (CC<sub>50</sub> > 36 μM) and displayed low to moderate antiviral effects (selectivity index [SI, CC<sub>50</sub>/EC<sub>50</sub>]: 1.8–3.3). Analogs <b>19</b>–<b>22</b> were even less cytotoxic (CC<sub>50</sub> > 64 μM) and displayed potent anti-HCV activity (SI: 6.1–9.6). Bis-amides <b>23</b>–<b>25</b> were the most active compounds in the series. They displayed no apparent cytotoxicity and had potent anti-HCV activity, with SI values of >11.2, >13.8, and >19.2 for <b>23</b>, <b>24</b>, and <b>25</b>, respectively; these compared favorably to those of ribavirin (SI > 6.1) and INF-α (SI > 16.1).</div><div class="NLM_p">The cytotoxicity and anti-HCV activity of bis-amides were dependent upon the isocyanide, aldehyde, amine, and carboxylic acid used for the synthesis (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). For a preliminary structure–activity relationship study, 13 bis-amides (<b>6</b>, <b>7</b>, <b>14</b>, <b>15</b>, and <b>17</b>–<b>25</b>) that had SI values greater than 2 were considered. Their antiviral effects seemed to vary greatly, depending on the substituent of the phenyl ring at the R<sup>2</sup> position. Bis-amide <b>6</b>, with a chlorine group at the para position of the phenyl moiety, showed about 5-fold stronger anti-HCV activity than compound <b>14</b>, with trimethoxy substituents. Furthermore, the antiviral activity of bis-amide <b>7</b>, with a nitro group, was 10-fold greater than that of compound <b>18</b>, with a fluorine group. In fact, bis-amide <b>7</b> showed the most potent anti-HCV activity (EC<sub>50</sub> = 2.5 ± 0.1 μM). The potent antiviral activity of bis-amide <b>7</b> indicates that the NO<sub>2</sub> of this compound orients in similar direction as that of the hit compound <b>5</b>, to interact with Lys125 of CypA.</div><div class="NLM_p">Varying the substitution on the phenyl ring at the R<sup>3</sup> position also had a significant impact on compound cytotoxicity and anti-HCV activity. Introduction of a para isopropyl substituent on the phenyl ring (<b>25</b>) led to a 3-fold increase in antiviral activity, as compared to <b>14</b>; interestingly, compound <b>25</b> was noncytotoxic, resulting in a remarkable increase in SI (>19.2). Furthermore, modification at the R<sup>4</sup> position produced variable effects on cytotoxicity and anti-HCV activity. The dimethylphenyl substituted compound <b>19</b> had a slightly more active anti-HCV activity (about 1.3-fold) than the bis-amide <b>15</b>, with a meta methoxyphenylethyl moiety. Comparison of the structures of <b>17</b> and <b>23</b> showed that the anti-HCV activity of the nonsubstituted phenyl ring at R<sup>4</sup> (<b>23</b>) was about 4-fold greater than that of the substituted ring (<b>17</b>). Moreover, replacement of the phenyl ring (<b>20</b>) by a methyl substitution (<b>21</b>) at R<sup>4</sup> was also favorable and produced a slight (1.5-fold) increase in anti-HCV activity.</div><div class="NLM_p">Taken together, four bis-amides (<b>6</b>, <b>7</b>, <b>20</b>, and <b>25</b>) exhibited low micromolar EC<sub>50</sub> values that were similar to or greater than those of the hit compound <b>5</b>, ribavirin, and INF-α. Among these compounds, the bis-amide <b>25</b> seemed to be optimal for further studies because of its low cytotoxicity (CC<sub>50</sub>). Moreover, investigation of the inhibitory effect of the hit <b>5</b> and the bis-amide <b>25</b> on CypA PPIase activity revealed that compound <b>25</b> produced a substantial low-nanomolar inhibition effect (IC<sub>50</sub> = 5.5 nM), which was greater than that of the hit <b>5</b> (IC<sub>50</sub> = 11.2 nM). Thus, in view of its low cytotoxicity, potent anti-HCV effect, and effective inhibition of CypA PPIase activity, the bis-amide <b>25</b> was selected as a lead novel CypA inhibitor.</div><div class="NLM_p">Similar to that of the hit <b>5</b>, the hydrophobic interaction between Phe113 of CypA and the cyclohexyl ring (A) of <b>25</b> remained intact (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A and <a href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_002.pdf" class="ext-link">S2</a>). Bis-amide <b>25</b> strongly interacted with Arg55, Trp121, and Lys125 of CypA through 4 H-bonds by an oxygen atom of trimethoxyphenyl (B) and each carbonyl oxygen from two amides. The branched isopropyl group (C) was more likely to fit into the hydrophobic region of the intact vicinity than that observed for the bromo group of the hit <b>5</b>. Rigidification of the phenylethyl group to the indolylmethyl moiety (D) appeared to generate a π–π interaction with Trp121 as expected. The binding mode of the <b>25</b> was consistent with that of the proposed mechanism. The binding mode was further supported by the potent antiviral activity of bis-amides <b>20</b> and <b>21</b>, with an isopropyl phenyl ring (C), and compounds <b>19</b>, <b>20</b>, and <b>22</b>–<b>24</b>, with a rigid aromatic ring (D).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Chemical structure of <b>25</b> and its binding mode. (B) Sensograms showing <b>25</b> and CsA binding to CypA and CypB (upper and lower panels, respectively). (C) Relative response in resonance units showing interactions of <b>25</b> with CypA and CypB (upper and lower panels, respectively) at the different concentrations indicated. The <i>K</i><sub>D</sub> values (±sd) were calculated from three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, surface plasmon resonance (SPR) was used to evaluate the binding affinity of <b>25</b> for CypA. Bis-amide <b>25</b> had a slower dissociation rate from CypA (<i>K</i><sub>on</sub> = 8.1 × 10<sup>3</sup> M<sup>–1</sup> s<sup>–1</sup>, <i>K</i><sub>off</sub> = 6.0 × 10<sup>–4</sup> s<sup>–1</sup>) than that of CsA (<i>K</i><sub>on</sub> = 7.6 × 10<sup>3</sup> M<sup>–1</sup> s<sup>–1</sup>, <i>K</i><sub>off</sub> = 2.5 × 10<sup>–2</sup> s<sup>–1</sup>), indicating stronger affinity of <b>25</b> for CypA compared to that of CsA (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B, upper panel). But the dissociation rates of <b>25</b> and CsA for CypB reversed (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B, lower panel). Intriguingly, the dissociation constant (<i>K</i><sub>D</sub>) calculated from SPR-based kinetic analysis indicated a much stronger binding affinity of <b>25</b> for CypA (<i>K</i><sub>D</sub> = 570 ± 20 nM) than for CypB (<i>K</i><sub>D</sub> = 2.1 ± 4 μM), confirming its selectivity for CypA (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>C). To further confirm the binding affinity of <b>25</b> and the associated thermodynamic properties, isothermal titration calorimetry (ITC)<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> was performed, and a reasonable fit with a two-site set model was achieved (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_002.pdf" class="ext-link">Figure S3 and Table S4</a>). In addition, the enzyme kinetic studies illustrated that the CypA PPIase activity inhibition by <b>25</b> (IC<sub>50</sub> of 5.5 ± 1.6 nM) was about 1.3-fold greater than that of CsA (IC<sub>50</sub> of 7.2 ± 1.7 nM) (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_002.pdf" class="ext-link">Figure S4</a>). Its strong binding affinity and anti-PPIase activity highly suggest that <b>25</b> is a potent and selective CypA inhibitor.</div><div class="NLM_p">Antigens activate immune cells by increasing the level of intracellular Ca<sup>2+</sup>, causing the activation of the calmodulin-dependent phosphatase calcineurin. Subsequently, calcineurin dephosphorylates NFAT, resulting in translocation of NFAT to the nucleus and the induction of interleukin 2 (IL-2) secretion.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Since the adaptive immune response is essential to eradication of HCV, CsA, a well-known immunosuppressant, cannot be used as an anti-HCV agent, spurring the development of nonimmunosuppressive CsA analogs.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> To verify <b>25</b> as a nonimmunosuppressive CypA inhibitor, we explored its effect on the calcineurin/NFAT/IL-2 signaling pathway in ionophore-stimulated mouse splenocytes. Unlike CsA, <b>25</b> neither was cytotoxic (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A) nor inhibited calcineurin phosphatase activity (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B). Moreover, <b>25</b> maintained the dephosphorylated state of NFAT1 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C), allowing for nuclear translocation of NFAT1 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>D) and, consequently, constant IL-2 production. On the other hand, CsA profoundly blocked IL-2 secretion as previously described by others (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>E).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Nonimmunosuppressive activity of <b>25</b>: effects of CsA and <b>25</b> on (A) mouse splenocyte viability, (B) calcineurin phosphatase activity, (C) phosphorylation of NFAT1, (D) nuclear translocation of NFAT1, and (E) IL-2 production. All data are representative of at least three different experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is known that disruption of CypA interaction with viral proteins results in formation of an ineffective replication complex and a significant decrease in viral RNA synthesis.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> We found that <b>25</b> efficiently reduced HCV RNA replication levels (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A), and the expression of the viral proteins NS5A and NS5B in total cell lysates (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B) and membrane fractions (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C). The decrease in NS5A and NS5B levels was further confirmed by confocal microscopy studies (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>D). Importantly, the reduced CypA level in the membrane fraction without a change in the total protein level suggested that <b>25</b> blocked recruitment of CypA to the membrane to form the replication complex. The lead <b>25</b> also prevented the binding of CypA to NS5A and NS5B (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_002.pdf" class="ext-link">Figure S5</a>). Furthermore, <b>25</b> exhibited potent antiviral activity in Con1b (genotype 1b) and JFH1 (genotype 2a) replicon cells with low cytotoxicity (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>E and <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>F). These results provide strong evidence that <b>25</b> possesses potent antiviral activity by disturbing the interaction of CypA with viral proteins and thus suppresses CypA PPIase activity to prevent HCV replication.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of <b>25</b> in HCV replicon cells. (A) HCV RNA levels at increasing concentrations of CsA and <b>25</b>. (B) Western blot analysis. HCV replicon cells were treated with increasing concentrations of CsA or <b>25</b> and were analyzed for NS5A (upper panels) and NS5B (middle panels) expression. All data are representative of at least three different experiments. (C) HCV Con1b replicon cells were treated with 2 μM CsA or <b>25</b>, and the total lysates and subcellular fractionated membranes were used to analyze the replication complex. (D) Confocal microscopy images. The cells were stained with an Alexa red- and Alexa green-conjugated antibody against NS5A and NS5B, respectively, and with DAPI for nuclear staining. Colocalization of merged red and green colors are shown in yellow. The images are representative of at least three different experiments. (E) Real-time image analysis. The potency of <b>25</b> was determined by the percentage of fluorescent cells in each image using subgenotype 1b replicon cells. The EC<sub>50</sub> and CC<sub>50</sub> were calculated by nonlinear regression analysis using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA). Shown is quantification of the GFP expression levels (left panel). GFP images of replicon levels were acquired at increasing concentrations of <b>25</b> (right panel). (F) Same as part E except for the use of JFH1 genotype 2a replicon cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">CypA inhibitors are also known to exert antiviral activity by modulating the host cell’s innate immune response via IFN-α,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> whose production is reduced by HCV via the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> In fact, HCV upregulates IL-8 expression, which reduces the induction of IFN-stimulated genes (ISGs) triggered by IFN-α. This is demonstrated in HCV patients that show increased levels of serum IL-8.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The lead <b>25</b> stimulated the expression of IFN-α signaling molecules (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A and <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>B) but strongly reduced the mRNA and protein levels of IL-8 (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>C and <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>D) in a time-dependent manner. It also upregulated IFN-α mRNA (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>E) and protein levels (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>F) in HCV replicon cells. To combat the high rate of emerging viral resistance, a combination of multiple drugs, each with a different mechanism of action, is of utmost importance. For example, the combination of CypA inhibitors with IFN-α resulted in a higher antiviral response than that observed for IFN-α alone.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Next, we measured the antiviral effects of <b>25</b> combined with IFN-α, ribavirin, or telaprevir. Combination of <b>25</b> with each antiviral agent displayed a notable synergistic inhibition on HCV-specific RNA and IL-8 levels compared to CsA-drug combinations (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A and <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>B). Furthermore, the treatment of <b>25</b> combined with each agent such as IFN-α, ribavirin, or telaprevir showed no or little cytotoxicity, in contrast to that observed for the CsA-drug combinations (about 20–40% cell death, <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>C). Taken together, <b>25</b> restores the innate antiviral response by suppressing IL-8 levels and inducing IFN-α production and may prove to be a new valuable drug in anti-HCV combination therapy.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Lead <b>25</b> stimulates IFN signals and inhibits IL-8 production in HCV replicon cells. (A) Real time qRT-PCR analysis with 2 μM CsA or <b>25</b> at different time intervals. (B) Western blot analysis with the indicated antibodies. (C) Same as part A except that changes in the IL-8 mRNA expression were analyzed. (D) ELISA analysis of the IL-8 levels. (E) Real time qRT-PCR analysis of IFN-α. The results were normalized to human glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (F) ELISA analysis of IFN-α secretion in the culture media. All data are representative of three different experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Combination treatment consisting of <b>25</b> and IFN-α, ribavirin, or telaprevir enhances the antiviral effect. (A) Real-time qRT-PCR analysis for HCV replicon RNA levels: (∗∗) <i>P</i> < 0.001 vs the cells treated with IFN-α, ribavirin, or telaprevir. (B) ELISA analysis of the IL-8 levels: (∗∗) <i>P</i> < 0.01 vs the cells treated with IFN-α; (∗∗∗) <i>P</i> < 0.001 vs the cells treated with ribavirin or telaprevir. (C) MTT assay: (∗) <i>P</i> < 0.05 vs the cells treated with CsA combined with IFN-α, (∗∗) <i>P</i> < 0.01 vs the cells treated with CsA combined with ribavirin, (∗∗∗) <i>P</i> < 0.001 vs the cells treated with CsA combined with telaprevir.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To explore the in vivo antiviral effect of <b>25</b>, we engrafted immunodeficient NOD/SCID mice with control Huh7 cells or Huh7 cells containing the HCV-Con1b replicon by intrasplenic injection.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Six weeks after the cell transplantation, two groups of five mice were treated with CsA or <b>25</b> for 2 weeks (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A). The liver-engrafted cells were analyzed using hematoxylin and eosin (H&E) staining (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>B). Mice treated with <b>25</b> showed no change in body weight, contrary to CsA-treated mice (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>C). Importantly, HCV RNA levels were lower in the <b>25</b>-treated mice compared to that in the CsA-treated mice (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>D). Furthermore, Western blot and confocal microscopy analysis showed that <b>25</b> strongly inhibited NS5A and NS5B protein levels in the mouse liver tissue (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>E and <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>F). Intriguingly, the in vivo acute toxicity assay using BALB/c mice showed that <b>25</b> did not affect the body weight or serum hepatic enzyme and creatinine levels remarkably, indicating that <b>25</b> did not cause hepatotoxicity or nephrotoxicity (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_002.pdf" class="ext-link">Figure S6</a>).</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Lead <b>25</b> abolishes viral replication in an HCV mouse model. (A) Schematic representation of the in vivo experiments using NOD/SCID mice. (B) Hematoxylin and eosin staining: histological examination of control and HCV replicon cells transplanted in mouse liver tissue. (C) Body weight changes of the mice. (D) HCV RNA levels in the liver of the mice assessed by real time qRT-PCR analysis. (E) HCV NS5A expression level after treatment with CsA or <b>25</b>. (F) Confocal microscopy analysis of Huh7 cells or Huh7 cells containing the HCV-Con1b replicon for human hepatocytes (green) and HCV NS5A (red). The nuclei were stained with DAPI (blue). The colocalization of human hepatocytes with HCV NS5A is shown in yellow. All data are representative of three different experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04638" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04638" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We identified bis-amides as novel CypA inhibitors through virtual screening. To our knowledge, this is the first report on bis-amides as enzymatically active, site-directed inhibitors of CypA. The lead <b>25</b> is a selective, nonimmunosuppressive, and potent CypA inhibitor with a structure highly distinct from that of CsA-based inhibitors, showing higher binding affinity, CypA specificity, and stronger anti-PPIase activity compared to those of CsA. It also effectively reduced HCV replication without acute toxicity in vitro and in vivo through the direct inhibition of viral proteins. Furthermore, this inhibition contributed to the reactivation of the host immune response. The combination of <b>25</b> with other antiviral agents resulted in a strong synergistic therapeutic activity compared to that of monotherapy or to that of CsA-drug combinations. On the basis of these findings, we believe that <b>25</b> may be a promising host-targeted anti-HCV drug in the next generation of combinatorial HCV treatments.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40043" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40043" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Chemistry</h3><div class="NLM_p last">Melting points were determined by the capillary method with a MEL-TEMP capillary melting point apparatus and were uncorrected. IR spectra were obtained on a JASCO FT/IR 300E Fourier transform infrared spectrometer using KBr pellets. <sup>1</sup>H NMR, <sup>13</sup>C NMR, <sup>1</sup>H–<sup>1</sup>H COSY, and HSQC spectra were recorded with Varian Unity Plus 300 MHz, Varian Unity Inova 500 MHz, and Varian VNMRS 600 MHz spectrometers at the Korea Basic Science Institute. The chemical shifts are reported in ppm downfield to TMS (δ = 0). The coupling constant (<i>J</i>) is shown in Hz. The data are reported in the following order: chemical shift, multiplicity (s, singlet; bs, broad singlet; b, broad; d, doublet; t, triplet; q, quartet; m, multiplet; dd, double doublet), coupling constant, and number of protons. Mass spectra were obtained on a Shimadzu LCMS-2010 EV liquid chromatograph mass spectrometer using the electron spray ionization (ESI) method. HRMS results were obtained on a Waters Synapt G2 high definition mass spectrometer. Elemental analyses were performed using the Thermo Fisher Flash 2000 elemental analyzer, and the values obtained were within ±0.4% of the theoretical values. The purity of the compounds was determined by HPLC. The purity was established by integration of the areas of all peaks detected and was reported for each final compound. The specifications of the HPLC analysis were as follows: column, ACE 5 C18-HL, 250 mm × 2.1 mm id; flow rate, 0.2 mL/min; mobile phase, acetonitrile/water = 9:1. Column chromatography (gravity) and medium performance liquid chromatography (MPLC, flow rate, 10 mL/min; make, Yamazen) were performed with a Merck silica gel 60 (70–230 mesh). TLC was performed using plates coated with silica gel 60 F<sub>254</sub> (Merck). All chemical reagents were purchased from Sigma-Aldrich and Tokyo Chemical Industry Co., Ltd., Japan, and were used without further purification. The solvents were distilled prior to use. All reactions were conducted in oven-dried glassware with magnetic stirring.</div></div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> <i>N</i>-(4-Bromophenyl)-<i>N</i>-[cyclohexylcarbamoyl-(4-nitrophenyl)methyl]-3-(4-methoxyphenyl)propionamide (<b>5</b>)</h3><div class="NLM_p last">A mixture of 4-nitrobenzaldehyde <b>2a</b> (100 mg, 0.66 mmol) and 4-bromoaniline <b>3a</b> (141 mg, 0.82 mmol) in methanol was stirred overnight at rt. Cyclohexyl isocyanide <b>1a</b> (72 mg, 0.66 mmol) and 3-(4-methoxyphenyl)propionic acid <b>4a</b> (180 mg, 1.00 mmol) were added to the mixture. The resulting reaction mixture was stirred at rt. The precipitate thus obtained was filtered off to obtain <b>5</b> as a light yellow solid (128 mg, 32%). Mp: 255.2–265.8 °C (decomposed). IR (cm<sup>–1</sup>): 3269, 1646. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 8.34 (d, <i>J</i> = 8.7 Hz, 2H), 8.06 (t, <i>J</i> = 9.0 Hz, 4H), 7.14 (d, <i>J</i> = 8.4 Hz, 2H), 6.97 (d, <i>J</i> = 8.7 Hz, 2H), 6.78 (d, <i>J</i> = 8.7 Hz, 2H), 6.06 (s, 1H), 5.76 (d, <i>J</i> = 8.4 Hz, 1H), 3.85–3.77 (m, 4H), 2.85 (t, <i>J</i> = 7.5 Hz, 2H), 2.34–2.28 (m, 2H), 1.96–1.82 (m, 2H), 1.73–1.64 (m, 3H), 1.39–1.32 (m, 2H), 1.19–1.02 (m, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 171.1, 167.5, 157.5, 146.7, 143.2, 141.3, 138.7, 132.9, 132.7, 132.2, 131.1, 129.8, 129.1, 124.0, 123.5, 123.0, 113.7, 54.9, 47.9, 36.6, 32.1, 29.8, 25.1, 24.5, 24.4. MS (ESI) <i>m</i>/<i>z</i>: 592 (M – H)<sup>−</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: 618.1404 (M + Na)<sup>+</sup> (calcd for C<sub>30</sub>H<sub>32</sub><sup>81</sup>BrN<sub>3</sub>NaO<sub>5</sub>, 618.1403), 616.1419 (M + Na)<sup>+</sup> (calcd for C<sub>30</sub>H<sub>32</sub><sup>79</sup>BrN<sub>3</sub>NaO<sub>5</sub>, 616.1423), 596.1582 (M + H)<sup>+</sup> (calcd for C<sub>30</sub>H<sub>33</sub><sup>81</sup>BrN<sub>3</sub>O<sub>5</sub>, 596.1583), 594.1601 (M + H)<sup>+</sup> (calcd for C<sub>30</sub>H<sub>33</sub><sup>79</sup>BrN<sub>3</sub>O<sub>5</sub>, 594.1604). HPLC: purity 97.5%.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> 2-(4-Chlorophenyl)-<i>N</i>-cyclohexyl-2-[(2-1<i>H</i>-indol-3-ylacetyl)phenylamino]acetamide (<b>6</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>5</b> were used with cyclohexyl isocyanide <b>1a</b> (78 mg, 0.71 mmol), 4-chlorobenzaldehyde <b>2b</b> (100 mg, 0.71 mmol), aniline <b>3b</b> (83 mg, 0.89 mmol), 3-indoleacetic acid <b>4b</b> (187 mg, 1.06 mmol), and 2,2,2-trifluoroethanol at rt to obtain bis-amide <b>6</b> as a light yellow solid (97 mg, 27%) after extraction and purification by column chromatography (<i>n</i>-hexane/EtOAc = 3:1). Mp: 203.9–205.8 °C. IR (cm<sup>–1</sup>): 3267, 1623. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.97 (s, 1H), 7.40–7.30 (m, 5H), 7.22–7.02 (m, 8H), 6.92 (d, <i>J</i> = 2.4 Hz, 1H), 6.04 (s, 1H), 5.79–5.73 (m, 1H), 3.77–3.75 (m, 1H), 3.58 (s, 2H), 1.87–1.76 (m, 2H), 1.65–1.54 (m, 3H), 1.33–1.19 (m, 2H), 1.09–0.95 (m, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 172.1, 168.3, 139.9, 135.9, 134.2, 133.1, 131.7, 130.2, 128.9, 128.3, 127.1, 123.1, 121.9, 119.4, 118.8, 110.9, 109.164.3, 48.6, 32.6, 31.9, 25.3, 24.7, 24.6. MS (ESI): <i>m</i>/<i>z</i> 522 (M + Na)<sup>+</sup>, 498 (M – H)<sup>−</sup>. HRMS (ESI): <i>m</i>/<i>z</i> 522.1921 (M + Na)<sup>+</sup> (calcd for C<sub>30</sub>H<sub>30</sub>ClN<sub>3</sub>NaO<sub>2</sub>, 522.1924), 500.2103 (M + H)<sup>+</sup> (calcd for C<sub>30</sub>H<sub>31</sub>ClN<sub>3</sub>O<sub>2</sub>, 500.2105). HPLC: purity 99.2%.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> <i>N</i>-Cyclohexyl-2-[(2-1<i>H</i>-indol-3-ylacetyl)-(4-methoxyphenyl)amino]-2-(4-nitrophenyl)acetamide (<b>7</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>5</b> were used with cyclohexyl isocyanide <b>1a</b> (72 mg, 0.66 mmol), 4-nitrobenzaldehyde <b>2a</b> (100 mg, 0.66 mmol), 4-methoxyaniline <b>3c</b> (123 mg, 0.82 mmol), 3-indoleacetic acid <b>4b</b> (103 mg, 0.66 mmol), and 2,2,2-trifluoroethanol at rt to obtain bis-amide <b>7</b> as a light yellow solid (30 mg, 8%). Mp: 205.5–207.9 °C. IR (cm<sup>–1</sup>): 3310, 1634. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) 8.19 (s, 1H), 7.99 (d, <i>J</i> = 8.5 Hz, 2H), 7.41 (d, <i>J</i> = 7.5 Hz, 1H), 7.30 (d, <i>J</i> = 8.0 Hz, 3H), 7.15 (t, <i>J</i> = 7.7 Hz, 1H), 7.05 (t, <i>J</i> = 7.5 Hz, 1H), 6.83 (s, 1H), 6.75–6.64 (b, 4H), 6.19 (s, 1H), 6.09 (d, <i>J</i> = 8.0 Hz, 1H), 3.76–3.70 (m, 4H), 3.60 (s, 2H), 1.81–1.75 (m, 2H), 1.62–1.53 (m, 3H), 1.32–1.23 (m, 2H), 1.08–1.01 (m, 1H), 0.94–0.87 (m, 2H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 172.8, 167.8, 159.3, 147.4, 141.8, 135.9, 132.0, 131.2, 131.0, 127.0, 123.0, 122.0, 119.5, 118.8, 114.2, 111.0, 108.7, 63.9, 55.3, 48.6, 32.48, 32.45, 31.8, 25.2, 24.68, 24.62. MS (ESI): <i>m</i>/<i>z</i> 563 (M + Na)<sup>+</sup>, 539 (M – H)<sup>−</sup>. Anal. Calcd for C<sub>31</sub>H<sub>32</sub>N<sub>4</sub>O<sub>5</sub>·0.02CH<sub>2</sub>Cl<sub>2</sub>: C, 68.69; H, 5.95; N, 10.33. Found: C, 68.44; H, 5.86; N, 10.58. HPLC: purity 99.6%.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> <i>N</i>-Cyclohexyl-2-[(2-1<i>H</i>-indol-3-ylacetyl)phenylamino]-2-phenylacetamide (<b>8</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>5</b> were used with cyclohexyl isocyanide <b>1a</b> (51 mg, 0.47 mmol), benzaldehyde <b>2c</b> (50 mg, 0.47 mmol), aniline <b>3b</b> (53 mg, 0.57 mmol), 3-indoleacetic acid <b>4b</b> (165 mg, 0.94 mmol), and methanol to obtain bis-amide <b>8</b> as a white solid (163 mg, 74%) after extraction and purification by column chromatography (<i>n</i>-hexane/EtOAc = 5:1, 1:1). Mp: 189–192 °C. IR (cm<sup>–1</sup>): 3319, 1644. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 8.03 (bs, 1H), 7.36 (d, <i>J</i> = 8.1 Hz, 1H), 7.31 (d, <i>J</i> = 8.1 Hz, 2H), 7.25–7.12 (m, 9H), 7.06–6.99 (m, 3H), 6.06 (s, 1H), 5.68 (d, <i>J</i> = 8.7 Hz, 1H), 3.84–3.73 (m, 1H), 3.58 (s, 2H), 1.90–1.80 (m, 2H), 1.63–1.51 (m, 3H), 1.38–1.22 (m, 2H), 1.11–0.89 (m, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 172.0, 168.7, 140.2, 135.9, 134.7, 130.38, 130.3, 128.7, 128.2, 128.0, 127.2, 123.2, 121.7, 119.2, 118.8, 110.9, 109.2, 65.3, 48.6, 32.6, 31.8, 25.4, 24.7, 24.6. MS (ESI): <i>m</i>/<i>z</i> 488 (M + Na)<sup>+</sup>, 464 (M – H)<sup>−</sup>. HRMS (ESI): <i>m</i>/<i>z</i> 488.2314 (M + Na)<sup>+</sup> (calcd for C<sub>30</sub>H<sub>31</sub>N<sub>3</sub>NaO<sub>2</sub>, 488.2314), 466.2493 (M + H)<sup>+</sup> (calcd for C<sub>30</sub>H<sub>32</sub>N<sub>3</sub>O<sub>2</sub>, 466.2495). HPLC: purity 97.0%.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> <i>N</i>-Cyclohexyl-2-[(2-1<i>H</i>-indol-3-ylacetyl)-(2-methoxyphenyl)amino]-2-(3,4,5-trimethoxyphenyl)acetamide (<b>9</b>)</h3><div class="NLM_p last">A mixture of 3,4,5-trimethoxybenzaldehyde <b>2d</b> (100 mg, 0.51 mmol) and <i>o</i>-anisidine <b>3d</b> (77 mg, 0.63 mmol) in methanol was stirred at 55 °C for 22 h. To the mixture was added cyclohexyl isocyanide <b>1a</b> (56 mg, 0.51 mmol) and 3-indoleacetic acid <b>4b</b> (110 mg, 0.63 mmol). The resulting reaction mixture was further heated at 55 °C for 45 h. The mixture was evaporated to dryness, washed with saturated NaHCO<sub>3</sub> solution, and extracted with EtOAc. The organic phase was dried over anhydrous sodium sulfate and was concentrated under reduced pressure. The residue was purified by column chromatography (<i>n</i>-hexane/EtOAc = 3:1, 1:1, EtOAc, MeOH) to obtain bis-amide <b>9</b> as a yellow solid (24 mg, 8%). Mp: 187.6–190.3 °C. IR (cm<sup>–1</sup>): 3343, 1630. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.97 (s, 1H), 7.46–7.37 (m, 2H), 7.32–7.27 (m, 2H), 7.25–7.11 (m, 3H), 7.07–6.99 (m, 1H), 6.94 (d, <i>J</i> = 2.1 Hz, 1H), 6.35 (s, 2H), 6.01 (d, <i>J</i> = 8.1 Hz, 1H), 5.94 (s, 1H), 3.81–3.72 (m, 1H), 3.73 (s, 3H), 3.61–3.56 (m, 9H), 3.39 (s, 2H), 1.95–1.79 (m, 2H), 1.65–1.48 (m, 3H), 1.32–1.23 (m, 2H), 1.19–0.94 (m, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 172.5, 168.8, 155.6, 152.5, 152.0, 135.9, 132.0, 131.4, 129.4, 128.8, 127.3, 123.1, 121.8, 121.0, 120.5, 119.3, 118.9, 111.2, 110.9, 109.3, 107.9, 64.5, 60.6, 55.8, 54.9, 48.7, 32.7, 32.6, 31.5, 25.4, 24.7. MS (ESI): <i>m</i>/<i>z</i> 608 (M + Na)<sup>+</sup>, 584 (M – H)<sup>−</sup>. HRMS (ESI): <i>m</i>/<i>z</i> 608.2736 (M + Na)<sup>+</sup> (calcd for C<sub>34</sub>H<sub>39</sub>N<sub>3</sub>NaO<sub>6</sub>, 608.2737), 586.2916 (M + H)<sup>+</sup> (calcd for C<sub>34</sub>H<sub>40</sub>N<sub>3</sub>O<sub>6</sub>, 586.2917). HPLC: purity 99.7%.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> <i>N</i>-Cyclohexyl-2-[(3,4-dimethoxyphenyl)-(2-1<i>H</i>-indol-3-ylacetyl)amino]-2-(2,3,4-trimethoxyphenyl)acetamide (<b>10</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>5</b> were used with cyclohexyl isocyanide <b>1a</b> (55 mg, 0.50 mmol), 2,3,4-trimethoxybenzaldehyde <b>2e</b> (100 mg, 0.51 mmol), 4-aminoveratrole <b>3e</b> (97 mg, 0.63 mmol), 3-indoleacetic acid <b>4b</b> (88 mg, 0.50 mmol), and 2,2,2-trifluoroethanol at rt to obtain bis-amide <b>10</b> as a light orange solid (253 mg, 80%) after extraction and purification by column chromatography (EtOAc). Mp: 113.8–115.8 °C. IR (cm<sup>–1</sup>): 3356, 1647. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 8.20 (s, 1H), 7.34–7.28 (m, 3H), 7.14–7.09 (m, 1H), 7.04–6.98 (m, 2H), 6.69–6.53 (m, 2H), 6.38 (s, 1H), 6.34 (d, <i>J</i> = 8.7 Hz, 1H), 5.93 (bs, 1H), 5.64 (d, <i>J</i> = 8.1 Hz, 1H), 3.83–3.76 (m, 15H), 3.60 (s, 2H), 3.36 (bs, 1H), 1.90–1.82 (m, 2H), 1.66–1.53 (m, 3H), 1.37–1.23 (m, 2H), 1.13–0.92 (m, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 172.2, 169.3, 153.7, 152.2, 148.3, 141.2, 135.9, 132.9, 127.2, 125.8, 123.0, 121.7, 120.5, 119.2, 118.8, 113.2, 110.8, 110.1, 109.6, 106.4, 61.0, 60.5, 58.3, 55.8, 55.7, 48.5, 32.7, 31.8, 25.4, 24.8, 24.7. MS (ESI): <i>m</i>/<i>z</i> 638 (M + Na)<sup>+</sup>, 614 (M – H)<sup>−</sup>. HRMS (ESI): <i>m</i>/<i>z</i> 638.2839 (M + Na)<sup>+</sup> (calcd for C<sub>35</sub>H<sub>41</sub>N<sub>3</sub>NaO<sub>7</sub>, 638.2842), 616.3014 (M + H)<sup>+</sup> (calcd for C<sub>35</sub>H<sub>42</sub>N<sub>3</sub>O<sub>7</sub>, 616.3023). HPLC: purity 99.9%.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> <i>N</i>-(1-(4-Chlorophenyl)-2-(cyclohexylamino)-2-oxoethyl)-<i>N</i>-(4-isopropylphenyl)-3-(4-methoxyphenyl)propanamide (<b>11</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>5</b> were used with cyclohexyl isocyanide <b>1a</b> (77 mg, 0.71 mmol), 4-chlorobenzaldehyde <b>2b</b> (100 mg, 0.71 mmol), 4-isopropylaniline <b>3f</b> (120 mg, 0.89 mmol), 3-(4-methoxyphenyl)propionic acid <b>4a</b> (193 mg, 1.07 mmol), and 2,2,2-trifluoroethanol at rt to obtain bis-amide <b>11</b> as a white solid (120 mg, 30%). Mp: 205.1–207.8 °C. IR (cm<sup>–1</sup>): 3258, 1643. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.15–7.12 (m, 2H), 7.05–7.02 (m, 6H), 6.96–6.94 (m, 2H), 6.76–6.74 (m, 2H), 5.89 (s, 1H), 5.80–5.77 (m, 1H), 3.80–3.72 (m, 1H), 3.75 (s, 3H), 2.87–2.82 (m, 3H), 2.36–2.30 (m, 2H), 1.93–1.80 (m, 2H), 1.67–1.55 (m, 3H), 1.38–1.26 (m, 2H), 1.20–1.00 (m, 3H), 1.18 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 173.1, 168.3, 157.8, 149.1, 137.4, 134.1, 133.3, 133.1, 131.5, 129.7, 129.3, 128.2, 127.0, 113.6, 64.6, 55.2, 48.6, 36.8, 33.6, 32.8, 32.7, 30.5, 25.4, 24.7, 23.9, 23.8. MS (ESI): <i>m</i>/<i>z</i> 569 (M + Na)<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> 569.2549 (M + Na)<sup>+</sup> (calcd for C<sub>33</sub>H<sub>39</sub>ClN<sub>2</sub>NaO<sub>3</sub>, 569.2547), 547.2729 (M + H)<sup>+</sup> (calcd for C<sub>33</sub>H<sub>40</sub>ClN<sub>2</sub>O<sub>3</sub>, 547.2727). HPLC: purity 97.1%.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> <i>N</i>-Cyclohexyl-2-(3,4-dimethoxyphenyl)-2-[(2-1<i>H</i>-indol-3-ylacetyl)phenylamino]acetamide (<b>12</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>9</b> were used with cyclohexyl isocyanide <b>1a</b> (65 mg, 0.60 mmol), 3,4-dimethoxybenzaldehyde <b>2f</b> (100 mg, 0.60 mmol), aniline <b>3b</b> (70 mg, 0.75 mmol), 3-indoleacetic acid <b>4b</b> (126 mg, 0.72 mmol), and methanol to obtain bis-amide <b>12</b> as a white solid (86 mg, 27%). Mp: 183.0–187.9 °C. IR (cm<sup>–1</sup>): 3293, 1661. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 8.06 (s, 1H), 7.39 (d, <i>J</i> = 7.8 Hz, 1H), 7.30 (d, <i>J</i> = 8.1 Hz, 1H), 7.19–7.11 (m, 5H), 7.06–6.97 (m, 2H), 6.77–6.64 (m, 3H), 6.52 (s, 1H), 6.07 (s, 1H), 5.69 (d, <i>J</i> = 8.1 Hz, 1H), 3.81 (s, 3H), 3.79–3.73 (m, 1H), 3.58 (s, 2H), 3.53 (s, 3H), 1.89–1.79 (m, 2H), 1.63–1.53 (m, 3H), 1.34–1.23 (m, 2H), 1.13–0.91 (m, 3H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ: 171.9, 168.9, 148.8, 148.2, 140.0, 135.9, 130.5, 128.7, 128.0, 127.2, 126.9, 123.2, 123.2, 121.7, 119.2, 118.8, 113.2, 110.9, 110.3, 109.2, 64.3, 55.6, 55.5, 48.6, 32.7, 32.6, 31.8, 25.4, 24.7, 24.6. MS (ESI): <i>m</i>/<i>z</i> 548 (M + Na)<sup>+</sup>, 524 (M – H)<sup>−</sup>. Anal. Calcd for C<sub>32</sub>H<sub>35</sub>N<sub>3</sub>O<sub>4</sub>·0.05CH<sub>2</sub>Cl<sub>2</sub>: C, 72.66; H, 6.68; N, 7.93. Found: C, 72.68; H, 6.68; N, 8.20. HPLC: purity 99.9%.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> <i>N</i>-(1-(Benzo[<i>d</i>][1,3]dioxol-5-yl)-2-oxo-2-(pentylamino)ethyl)-<i>N</i>-(3,4-dimethoxyphenyl)pentanamide (<b>13</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>5</b> were used with 1-pentyl isocyanide <b>1b</b> (65 mg, 0.67 mol), piperonal <b>2g</b> (100 mg, 0.67 mmol), 4-aminoveratrole <b>3e</b> (128 mg, 0.83 mmol), valeric acid <b>4c</b> (85 mg, 0.83 mmol), and methanol at rt to obtain bis-amide <b>13</b> as a yellow solid (178 mg, 55%) after purification by column chromatography (<i>n</i>-hexane/EtOAc = 1:1). Mp: 98.9–100.8 °C. IR (cm<sup>–1</sup>): 3278, 1651. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 6.83–6.50 (m, 5H), 6.32–6.01 (m, 2H), 5.89 (s, 2H), 5.76 (bs, 1H), 3.84 (s, 4H), 3.71 (bs, 2H), 3.26 (q, <i>J</i> = 7.2 Hz, 2H), 2.09–2.03 (m, 2H), 1.59–1.51 (m, 2H), 1.49–1.42 (m, 2H), 1.30–1.18 (m, 6H), 0.88–0.78 (m, 6H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ: 174.1, 169.8, 148.6, 148.4, 147.5, 132.8, 128.5, 124.2, 122.7, 113.4, 110.3, 107.9, 101.1, 64.6, 55.9, 55.8, 39.8, 34.3, 29.1, 28.9, 27.5, 22.3, 22.2, 13.9, 13.8. MS (ESI): <i>m</i>/<i>z</i> 507 (M + Na)<sup>+</sup>. Anal. Calcd for C<sub>27</sub>H<sub>36</sub>N<sub>2</sub>O<sub>6</sub>: C, 66.92; H, 7.49; N, 5.78. Found: C, 66.88; H, 7.42; N, 5.92. HPLC: purity 95.0%.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> <i>N</i>-Cyclohexyl-2-[(2-1<i>H</i>-indol-3-ylacetyl)phenylamino]-2-(3,4,5-trimethoxyphenyl)acetamide (<b>14</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>9</b> were used with cyclohexyl isocyanide <b>1a</b> (38 mg, 0.35 mmol), 3,4,5-trimethoxybenzaldehyde <b>2d</b> (70 mg, 0.35 mmol), aniline <b>3b</b> (41 mg, 0.44 mmol), 3-indoleacetic acid <b>4b</b> (130 mg, 0.74 mmol), and methanol to obtain bis-amide <b>14</b> as a beige ash (118 mg, 59%) after extraction and purification by MPLC (<i>n</i>-hexane/EtOAc = 3:1, 1:1 and EtOAc). Mp: 156–158 °C. IR (cm<sup>–1</sup>): 3261, 1650. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 8.00 (s, 1H), 7.41 (d, <i>J</i> = 7.8 Hz, 2H), 7.31 (d, <i>J</i> = 8.1 Hz, 2H), 7.24–7.19 (m, 2H), 7.14 (t, <i>J</i> = 7.2 Hz, 2H), 7.04 (t, <i>J</i> = 7.2 Hz, 1H), 6.95 (s, 1H), 6.30 (s, 2H), 6.07 (s, 1H), 5.75 (d, <i>J</i> = 7.8 Hz, 1H), 3.83–3.71 (m, 1H), 3.76 (s, 3H), 3.60 (s, 2H), 3.58 (s, 6H), 1.89–1.80 (m, 2H), 1.68–1.56 (m, 3H), 1.38–1.23 (m, 2H), 1.14–0.92 (m, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 171.9, 168.6, 152.6, 140.0, 137.8, 135.9, 130.5, 129.8, 128.7, 128.1, 127.2, 123.1, 121.8, 119.3, 118.9, 110.9, 109.2, 107.6, 64.5, 60.7, 55.9, 48.6, 32.7, 31.9, 25.4, 24.8, 24.7. MS (ESI): <i>m</i>/<i>z</i> 578 (M + Na)<sup>+</sup>, 554 (M – H)<sup>−</sup>. HRMS (ESI): <i>m</i>/<i>z</i> 578.2629 (M + Na)<sup>+</sup> (calcd for C<sub>33</sub>H<sub>37</sub>N<sub>3</sub>NaO<sub>5</sub>, 578.2631), 556.2809 (M + H)<sup>+</sup> (calcd for C<sub>33</sub>H<sub>38</sub>N<sub>3</sub>O<sub>5</sub>, 556.2811). HPLC: purity 99.5%.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> <i>N</i>-[Cyclohexylcarbamoyl-(4-hydroxyphenyl)methyl]-<i>N</i>-(3,4-dimethoxyphenyl)-3-(3-methoxyphenyl)propionamide (<b>15</b>)</h3><div class="NLM_p last">A mixture of 4-hydroxybenzaldehyde <b>2h</b> (500 mg, 4.15 mmol) and 4-aminoveratrole <b>3e</b> (950 mg, 6.23 mmol) in methanol was stirred at rt. The solid thus formed was filtered off to obtain imine. The imine (150 mg, 0.60 mmol) was added to the mixture of cyclohexyl isocyanide <b>1a</b> (80 mg, 0.73 mmol) and 3-(3-methoxyphenyl)propionic acid <b>4d</b> (170 mg, 0.90 mmol) in methanol, and the resulting reaction mixture was stirred at rt to obtain bis-amide <b>15</b> as a white solid (116 mg, 36%) after filtration. Mp: 187.5–189.1 °C. IR (cm<sup>–1</sup>): 3283, 1660. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.12 (t, <i>J</i> = 8.1 Hz, 1H), 6.93 (d, <i>J</i> = 8.1 Hz, 2H), 6.70–6.59 (m, 4H), 6.46 (bs, 1H), 6.16 (bs, 1H), 5.95 (bs, 2H), 5.85 (bs, 1H), 5.64–5.62 (m, 1H), 3.79 (bs, 6H), 3.74 (s, 3H), 3.50–3.42 (m, 1H), 2.89 (t, <i>J</i> = 7.8 Hz, 2H), 2.42–2.33 (m, 2H), 1.94–1.80 (m, 2H), 1.59–1.56 (m, 3H), 1.35–1.26 (m, 2H), 1.16–0.95 (m, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 173.2, 159.4, 156.3, 148.4, 142.7, 132.5, 131.8, 129.2, 126.2, 122.7, 120.7, 115.2, 114.1, 113.4, 111.2, 110.4, 64.4, 55.7, 55.0, 48.7, 36.4, 32.7, 31.6, 25.4, 24.7, 24.6. MS (ESI): <i>m</i>/<i>z</i> 569 (M + Na)<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> 569.2626 (M + Na)<sup>+</sup> (calcd for C<sub>32</sub>H<sub>38</sub>N<sub>2</sub>NaO<sub>6</sub>, 569.2628), 547.2808 (M + H)<sup>+</sup> (calcd for C<sub>32</sub>H<sub>39</sub>N<sub>2</sub>O<sub>6</sub>, 547.2808). HPLC: purity 99.7%.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>N</i>-(1-(4-Chlorophenyl)-2-(cyclohexylamino)-2-oxoethyl)-<i>N</i>-(3,4-dimethoxyphenyl)-3-(4-methoxyphenyl)propanamide (<b>16</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>5</b> were used with cyclohexyl isocyanide <b>1a</b> (77 mg, 0.71 mmol), 4-chlorobenzaldehyde <b>2b</b> (100 mg, 0.7 mmol), 4-aminoveratrole <b>3e</b> (128 mg, 0.91 mmol), 3-(4-methoxyphenyl)propionic acid <b>4a</b> (200 mg, 1.10 mmol), and methanol at rt to obtain bis-amide <b>16</b> as a white solid (55 mg, 14%) after purification by column chromatography (<i>n</i>-hexane/EtOAc = 1:1). Mp: 195.6–197.3 °C. IR (cm<sup>–1</sup>): 3286, 1650. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.15 (d, <i>J</i> = 8.1 Hz, 2H), 7.04 (d, <i>J</i> = 8.1 Hz, 2H), 6.98 (d, <i>J</i> = 8.7 Hz, 3H), 6.96 (d, <i>J</i> = 8.7 Hz, 3H), 6.50 (bs, 1H), 5.99 (s, 1H), 5.65 (bs, 1H), 3.82 (s, 6H), 3.76 (s, 3H), 3.51–3.46 (m, 1H), 2.86 (t, <i>J</i> = 7.5 Hz, 2H), 2.38–2.31 (m, 2H), 1.96–1.81 (m, 2H), 1.71–1.62 (m, 3H), 1.41–1.26 (m, 2H), 1.18–1.05 (m, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 173.3,157.8, 148.6, 134.3, 133.1, 132.2, 131.8, 129.3, 128.4, 122.7, 113.7, 113.3, 110.5, 63.9, 55.8, 55.7, 55.2, 55.1, 48.7, 36.5, 32.8, 30.6, 25.4, 24.8, 24.7. MS (ESI): <i>m</i>/<i>z</i> 587 (M + Na)<sup>+</sup>, 563 (M – H)<sup>−</sup>. HRMS (ESI): <i>m</i>/<i>z</i> 587.2287 (M + Na)<sup>+</sup> (calcd for C<sub>32</sub>H<sub>37</sub>ClN<sub>2</sub>NaO<sub>5</sub>, 587.2289), 565.2470 (M + H)<sup>+</sup> (calcd for C<sub>32</sub>H<sub>38</sub>ClN<sub>2</sub>O<sub>5</sub>, 565.2469). HPLC: purity 99.6%.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> <i>N</i>-[Cyclohexylcarbamoyl-(4-nitrophenyl)methyl]-<i>N</i>-[2-(3,4-dimethoxyphenyl)ethyl]-5-methoxy-2-nitrobenzamide (<b>17</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>15</b> were used with cyclohexyl isocyanide <b>1a</b> (35 mg, 0.32 mmol), imine formed by reaction of 4-nitrobenzaldehyde <b>2a</b>, and 3,4-dimethoxyphenethylamine <b>3g</b> in methanol (100 mg, 0.32 mmol), 5-methoxy-2-nitrobenzoic acid <b>4e</b> (79 mg, 0.40 mmol), and methanol at rt to obtain bis-amide <b>17</b> as a yellow solid (196 mg, 99%) after purification by column chromatography (<i>n</i>-hexane/EtOAc = 3:1). Mp: 104.5–107.6 °C. IR (cm<sup>–1</sup>): 3327, 1642. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 8.31–8.22 (m, 3H), 7.78 (bs, 2H), 7.02 (dd, <i>J</i> = 9.3, 2.7 Hz, 1H), 6.77–6.62 (m, 3H), 6.24 (d, <i>J</i> = 7.8 Hz, 1H), 6.14 (s, 1H), 5.94–5.83 (m, 1H), 3.97–3.91 (m, 1H), 3.92 (s, 3H), 3.79 (s, 3H), 3.69 (s, 3H), 3.38–3.32 (m, 2H), 2.70–2.57 (m, 2H), 2.04–1.98 (m, 2H), 1.75–1.64 (m, 3H), 1.41–1.32 (m, 2H), 1.28–1.19 (m, 3H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ: 168.3, 166.5, 164.3, 148.9, 147.8, 137.5, 130.5, 129.8, 129.5, 127.5, 123.8, 120.2, 114.5, 114.3, 113.9, 113.6, 111.2, 111.1, 63.4, 62.6, 56.3, 55.8, 55.6, 51.2, 50.8, 49.0, 34.9, 32.7, 32.6, 25.3, 24.7. MS (ESI): <i>m</i>/<i>z</i> 643 (M + Na)<sup>+</sup>, 619 (M – H)<sup>−</sup>. HRMS (ESI): <i>m</i>/<i>z</i> 643.2373 (M + Na)<sup>+</sup> (calcd for C<sub>32</sub>H<sub>36</sub>N<sub>4</sub>NaO<sub>9</sub>, 643.2380), 621.2551 (M + H)<sup>+</sup> (calcd for C<sub>32</sub>H<sub>37</sub>N<sub>4</sub>O<sub>9</sub>, 621.2561). HPLC: purity 99.3%.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>N</i>-Cyclohexyl-2-(4-fluorophenyl)-2-[(2-1<i>H</i>-indol-3-ylacetyl)-(4-methoxyphenyl)amino]acetamide (<b>18</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>5</b> were used with cyclohexyl isocyanide <b>1a</b> (87 mg, 0.80 mmol), 4-fluorobenzaldehyde <b>2i</b> (100 mg, 0.80 mmol), 4-methoxyaniline <b>3c</b> (124 mg, 1.00 mmol), 3-indoleacetic acid <b>4b</b> (176 mg, 1.00 mmol), and methanol at rt to obtain bis-amide <b>18</b> as a white solid (290 mg, 70%). Mp: 209.3-213.8 °C. IR (cm<sup>–1</sup>): 3267, 1657. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 8.05 (s, 1H), 7.39 (d, <i>J</i> = 6.9 Hz, 2H), 7.33–7.30 (m, 1H), 7.17–7.01 (m, 4H), 6.97 (d, <i>J</i> = 2.1 Hz, 1H), 6.87–6.81 (m, 2H), 6.77–6.56 (m, 2H), 6.43–6.27 (m, 1H), 6.12 (s, 1H), 5.76 (d, <i>J</i> = 8.4 Hz, 1H), 3.79–3.69 (m, 1H), 3.75 (s, 3H), 3.57 (s, 2H), 1.87–1.77 (m, 2H), 1.64–1.53 (m, 3H), 1.35–1.23 (m, 2H), 1.11–0.88 (m, 3H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ: 172.5, 168.6, 163.2, 161.6, 159.0, 135.9, 132.3, 132.2, 131.4, 130.5,3 130.5, 127.2, 123.1, 121.8, 119.3, 118.9, 115.1, 115.0, 113.8, 110.9, 109.2, 63.7, 55.3, 48.5, 32.6, 31.8, 25.3, 24.7, 24.6. MS (ESI): <i>m</i>/<i>z</i> 536 (M + Na)<sup>+</sup>, 514 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>31</sub>H<sub>32</sub>FN<sub>3</sub>O<sub>3</sub>: C, 72.49; H, 6.28; N, 8.18. Found: C, 72.26; H, 6.12; N, 8.48. HPLC: purity 96.9%.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> <i>N</i>-[Cyclohexylcarbamoyl(4-hydroxyphenyl)methyl]-<i>N</i>-(3,4-dimethoxyphenyl)-2,3-dimethylbenzamide (<b>19</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>15</b> were used with cyclohexyl isocyanide <b>1a</b> (66 mg, 0.60 mmol), imine formed by the reaction of 4-hydroxybenzaldehyde <b>2h</b> and 4-aminoveratrole <b>3e</b> in methanol (150 mg, 0.60 mmol), 2,3-dimethylbenzoic acid <b>4f</b> (135 mg, 0.90 mmol), and methanol at rt to obtain bis-amide <b>19</b> as a white solid (170 mg, 56%). Mp: 157.2–161.2 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.05 (d, <i>J</i> = 8.1 Hz, 2H), 6.89–6.80 (m, 2H), 6.06 (d, <i>J</i> = 8.1 Hz, 2H), 6.56–6.46 (m, 2H), 6.39–6.35 (m, 2H), 6.18 (s, 1H), 5.69 (d, <i>J</i> = 8.4 Hz, 1H), 3.91–3.81 (m, 1H), 3.68 (s, 3H), 3.58 (s, 3H), 2.28 (s, 3H), 2.11 (s, 3H), 1.97–1.87 (m, 2H), 1.66–1.56 (m, 3H), 1.42–1.29 (m, 2H), 1.18–1.04 (m, 3H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 171.4, 169.8, 157.2, 147.6, 147.4, 138.7, 136.9, 133.0, 132.0, 129.6, 126.2, 125.1, 125.0, 123.9, 115.3, 110.2, 63.9, 55.8, 55.6, 48.6, 32.9, 32.8, 25.9, 25.3, 25.2, 20.2, 17.2. MS (ESI): <i>m</i>/<i>z</i> 539 (M + Na)<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> 539.2526 (M + Na)<sup>+</sup> (calcd for C<sub>31</sub>H<sub>36</sub>N<sub>2</sub>NaO<sub>5</sub>, 539.2522), 517.2706 (M + H)<sup>+</sup> (calcd for C<sub>31</sub>H<sub>37</sub>N<sub>2</sub>O<sub>5</sub>, 517.2702). HPLC: purity 98.9%.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>N</i>-(1-(4-Chlorophenyl)-2-(cyclohexylamino)-2-oxoethyl)-<i>N</i>-(4-isopropylphenyl)benzamide (<b>20</b>)</h3><div class="NLM_p last">The procedures applied for synthesis of <b>5</b> was used with cyclohexyl isocyanide <b>1a</b> (77 mg, 0.71 mmol), 4-chlorobenzaldehyde <b>2b</b> (100 mg, 0.71 mmol), 4-isopropylaniline <b>3f</b> (120 mg, 0.89 mmol), benzoic acid <b>4g</b> (131 mg, 1.07 mmol), and 2,2,2-trifluoroethanol at rt to obtain bis-amide <b>20</b> as a white solid (82 mg, 23%). Mp: 181.0–182.5 °C. IR (cm<sup>–1</sup>): 3276, 1658. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.31–7.28 (m, 2H), 7.23 (d, <i>J</i> = 1.5 Hz, 4H), 7.20–7.09 (m, 3H), 6.91–6.84 (m, 5H), 6.05 (s, 1H), 5.99 (d, <i>J</i> = 8.1 Hz, 1H), 3.91–3.82 (m, 1H), 2.74 (heptet, <i>J</i> = 6.9 Hz, 1H), 1.98–1.88 (m, 2H), 1.68–1.58 (m, 3H), 1.44–1.29 (m, 2H), 1.24–1.19 (m, 3H), 1.10 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 171.2, 168.2, 148.2, 138.9, 135.7, 134.2, 133.5, 131.3, 129.6, 128.57, 128.53, 127.5, 126.5, 66.4, 48.6, 33.4, 32.8, 25.4, 24.7, 24.6, 23.77, 23.74. MS (ESI) <i>m</i>/<i>z</i> = 511 (M + Na)<sup>+</sup>. HPLC: purity 99.2%.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 2-[Acetyl-(4-isopropylphenyl)amino]-2-(4-chlorophenyl)-<i>N</i>-cyclohexylacetamide (<b>21</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>15</b> were used with cyclohexyl isocyanide <b>1a</b> (55 mg, 0.48 mmol), the imine formed by the reaction of 4-chlorobenzaldehyde <b>2b</b> and 4-isopropylaniline <b>3f</b> in methanol (100 mg, 0.38 mmol), acetic acid <b>4h</b> (35 mg, 0.57 mmol), and methanol at rt to obtain bis-amide <b>21</b> as a white solid (40 mg, 24%) after filtration. Mp: 184.7–186.0 °C. IR (cm<sup>–1</sup>): 3272, 1658. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.17–7.13 (m, 2H), 7.10–7.05 (m, 4H), 6.96 (bs, 2H), 5.93 (s, 1H), 5.74 (d, <i>J</i> = 8.1 Hz, 1H), 3.85–3.75 (m, 1H), 2.85 (heptet, <i>J</i> = 6.9 Hz, 1H), 2.17–1.83 (m, 2H), 1.86 (s, 3H), 1.70–1.56 (m, 3H), 1.41–1.27 (m, 2H), 1.19 (d, <i>J</i> = 6.9 Hz, 6H), 1.18–1.07 (m, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 171.5, 168.4, 149.1, 138.1, 134.3, 133.3, 131.6, 129.7, 128.3, 127.0, 64.4, 48.7, 33.6, 32.8, 32.7, 25.4, 24.78, 24.71, 23.9, 23.8, 23.2. MS (ESI): <i>m</i>/<i>z</i> 449 (M + Na)<sup>+</sup>. Anal. Calcd for C<sub>25</sub>H<sub>31</sub>ClN<sub>2</sub>O<sub>2</sub>·0.25H<sub>2</sub>O: C, 69.59; H, 7.36; N, 6.49. Found: C, 69.56; H, 7.26; N, 6.58. HPLC: purity 98.7%.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>N</i>-[Cyclohexylcarbamoyl-(4-nitrophenyl)methyl]-<i>N</i>-(3,4-dimethoxyphenyl)-2,5-dimethylbenzamide (<b>22</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>15</b> were used with cyclohexyl isocyanide <b>1a</b> (47 mg, 0.35 mmol), the imine formed by the reaction of 4-nitrobenzaldehyde <b>2a</b> and 4-aminoveratrole <b>3e</b> in 2,2,2-trifluoroethanol (100 mg, 0.35 mmol), 2,5-dimethylbenzoic acid <b>4i</b> (66 mg, 0.44 mmol), and methanol at rt to obtain bis-amide <b>22</b> as a dark green solid (48 mg, 25%) after purification by column chromatography (<i>n</i>-hexane/EtOAc = 3:1). Mp: 175.9–177.9 °C. IR (cm<sup>–1</sup>): 3346, 1630. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ: 8.10 (d, <i>J</i> = 8.4 Hz, 2H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 6.88–6.85 (m, 3H), 6.63 (s, 1H), 6.46–6.40 (m, 2H), 6.29 (s, 1H), 6.07 (s, 1H), 3.92–3.86 (m, 1H), 3.70 (s, 3H), 3.61 (s, 3H), 2.31 (s, 3H), 2.14 (s, 3H), 2.02 (d, <i>J</i> = 10.8 Hz, 1H), 1.93 (d, <i>J</i> = 8.4 Hz, 1H) 1.74–1.60 (m, 3H), 1.44–1.34 (m, 2H), 1.23–1.10 (m, 3H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ: 172.6, 167.7, 148.2, 148.1, 147.6, 141.9, 135.7, 134.3, 133.4, 131.7, 131.1, 129.9, 129.5, 127.4, 123.4, 122.0, 113.2, 109.8, 55.8, 55.6, 48.9, 32.8, 25.4, 24.7, 24.6, 20.7, 18.9. MS (ESI): <i>m</i>/<i>z</i> 544 (M – H)<sup>−</sup>. Anal. Calcd for C<sub>31</sub>H<sub>35</sub>N<sub>3</sub>O<sub>6</sub>·1.05CH<sub>4</sub>O·0.4H<sub>2</sub>O: C, 65.64; H, 6.87; N, 7.16. Found: C, 65.39; H, 6.62; N, 6.90. HPLC: purity 98.0%.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>-[Cyclohexylcarbamoyl-(4-nitrophenyl)methyl]-<i>N</i>-[2-(3,4-dimethoxyphenyl)ethyl]benzamide (<b>23</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>15</b> were used with cyclohexyl isocyanide <b>1a</b> (35 mg, 0.32 mmol), the imine formed by the reaction of 4-nitrobenzaldehyde <b>2a</b> and 3,4-dimethoxyphenethylamine <b>3g</b> in methanol (100 mg, 0.32 mmol), benzoic acid <b>4g</b> (49 mg, 0.44 mmol), and methanol at rt to obtain bis-amide <b>23</b> as a white solid (112 mg, 64%) after filtration. Mp: 194.3–198.0 °C. IR (cm<sup>–1</sup>): 3266, 1675. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 8.25 (d, <i>J</i> = 8.5 Hz, 2H), 7.68 (bs, 2H), 7.50–7.43 (m, 5H), 6.75–6.26 (m, 2H), 6.25 (bs, 1H), 6.06–5.97 (m, 2H), 3.92–3.85 (m, 1H), 3.79 (s, 3H), 3.68 (s, 3H), 3.55 (bs, 2H), 2.67 (bs, 1H), 2.38–2.32 (m, 1H), 1.98–1.92 (m, 2H), 1.74–1.69 (m, 2H), 1.64–1.60 (m, 1H), 1.44–1.35 (m, 2H), 1.22–1.14 (m, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 148.8, 147.7, 147.6, 142.8, 135.7, 130.1, 129.4, 128.7, 126.6, 123.8, 120.5, 111.5, 111.1, 55.8, 55.7, 48.7, 32.78, 32.72, 25.4, 24.6. MS (ESI): <i>m</i>/<i>z</i> 568 (M + Na)<sup>+</sup>. Anal. Calcd for C<sub>31</sub>H<sub>35</sub>N<sub>3</sub>O<sub>6</sub>·0.7H<sub>2</sub>O: C, 66.7; H, 6.57; N, 7.53. Found: C, 66.62; H, 6.51; N, 7.63. HPLC: purity 95.0%.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 6-Chloro-<i>N</i>-[cyclohexylcarbamoyl-(4-nitrophenyl)methyl]-<i>N</i>-[2-(3-methoxyphenyl)ethyl]nicotinamide (<b>24</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>5</b> were used with cyclohexyl isocyanide <b>1a</b> (72 mg, 0.66 mmol), 4-nitrobenzaldehyde <b>2a</b> (100 mg, 0.66 mmol), 2-(3-methoxyphenyl)ethylamine <b>3h</b> (125 mg, 0.83 mmol), 6-chloronicotinic acid <b>4j</b> (131 mg, 0.83 mmol), and methanol at rt to obtain bis-amide <b>24</b> as a yellow solid (296 mg, 81%). Mp: 87.5–90.8 °C. IR (cm<sup>–1</sup>): 3286, 1636. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 8.40 (s, 1H), 8.26 (d, <i>J</i> = 8.5 Hz, 2H), 7.68–7.58 (m, 3H), 7.37 (d, <i>J</i> = 8.5 Hz, 1H), 7.08 (t, <i>J</i> = 7.7 Hz, 1H), 6.71–6.68 (m, 1H), 6.33–6.20 (m, 3H), 5.86 (bs, 1H), 3.90–3.82 (m, 1H), 3.69 (s, 3H), 3.61 (bs, 2H), 2.61 (bs, 1H), 2.39 (bs, 1H), 1.97–1.91 (m, 2H), 1.72–1.67 (m, 2H), 1.64–1.59 (m, 1H), 1.43–1.33 (m, 2H), 1.22–1.10 (m, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 159.7, 152.8, 147.9, 147.4, 137.2, 130.4, 129.9, 129.6, 124.3, 124.1, 120.8, 114.2, 112.0, 55.0, 49.0, 32.75, 32.72, 25.3, 24.68, 24.66. MS (ESI): <i>m</i>/<i>z</i> 549 (M – H)<sup>−</sup>. Anal. Calcd for C<sub>29</sub>H<sub>31</sub>ClN<sub>4</sub>O<sub>5</sub>·0.6H<sub>2</sub>O: C, 61.99; H, 5.78; N, 9.97. Found: C, 61.91; H, 5.78; N, 10.07. HPLC: purity 99.4%.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>N</i>-Cyclohexyl-2-[(2-1<i>H</i>-indol-3-ylacetyl)-(4-isopropylphenyl)amino]-2-(3,4,5-trimethoxyphenyl)acetamide (<b>25</b>)</h3><div class="NLM_p last">The procedures applied to the synthesis of <b>15</b> were used with cyclohexyl isocyanide <b>1a</b> (69 mg, 0.63 mmol), crude mixture containing imine formed by the reaction of 3,4,5-trimethoxybenzaldehyde <b>2d</b> and 4-isopropylaniline <b>3f</b> in ethanol under reflux condition (200 mg, ∼0.63 mmol), 3-indoleacetic acid <b>4b</b> (235 mg, 1.34 mmol), and methanol at 55 °C to obtain bis-amide <b>25</b> as an ivory solid (260 mg, 69%) after purification by column chromatography (<i>n</i>-hexane/EtOAc = 3:1, 1:1). Mp: 141–143 °C. IR (cm<sup>–1</sup>): 3315, 1644. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ: 8.29 (s, 1H), 7.37 (d, <i>J</i> = 7.8 Hz, 1H), 7.30 (d, <i>J</i> = 7.8 Hz, 1H), 7.14–6.94 (m, 4H, overlapped), 7.12 (t, <i>J</i> = 7.8 Hz, 1H, overlapped), 7.02 (t, <i>J</i> = 7.8 Hz, 1H, overlapped), 6.94 (d, <i>J</i> = 1.8 Hz, 1H, overlapped), 6.29 (s, 2H), 6.09 (s, 1H), 5.81 (d, <i>J</i> = 8.4 Hz, 1H), 3.80–3.74 (m, 1H, overlapped), 3.76 (s, 3H, overlapped), 3.60 (d, <i>J</i> = 2.4 Hz, 2H), 3.58 (s, 6H), 2.84 (heptet, <i>J</i> = 6.9 Hz, 1H), 1.83 (dd, <i>J</i> = 33.0, 9.6 Hz, 2H), 1.64–1.54 (m, 3H), 1.34–1.25 (m, 2H), 1.19 (d, <i>J</i> = 7.2 Hz, 6H), 1.10–0.95 (m, 3H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ: 172.2, 168.6, 152.6, 149.0, 137.6, 137.4, 135.9, 130.2, 129.9, 127.2, 126.7, 123.1, 121.8, 119.3, 118.9, 110.9, 109.3, 107.7, 64.3, 60.7, 55.8, 48.5, 33.7, 32.7, 32.6, 31.8, 25.4, 24.7, 24.7, 23.9, 23.8. MS (ESI): <i>m</i>/<i>z</i> 620 (M + Na)<sup>+</sup>, 636 (M + K)<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> 598.3279 (M + H)<sup>+</sup> (calcd for C<sub>36</sub>H<sub>44</sub>N<sub>3</sub>O<sub>5</sub>, 598.3281), 620.3098 (M + Na)<sup>+</sup> (calcd for C<sub>36</sub>H<sub>43</sub>N<sub>3</sub>NaO<sub>5</sub>, 620.3100). HPLC: purity 96.1%.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Virtual Screening</h3><div class="NLM_p last">Virtual screening was performed using Surflex-Dock in Sybyl, version 8.1.1 (Tripos Associates), operating under Red Hat Linux 4.0 with an IBM computer (Intel Pentium 4, 2.8 GHz CPU, and 1 GB memory). The crystallographic structure of CypA and CsA complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1CWA">1CWA</a>) available from the Protein Data Bank was refined with the structure preparation tool. The 2D structure of approximately 200 000 compounds available in the Asinex database was converted to 3D and minimized with the Tripos force field and Gasteiger–Huckel charge. The binding site was determined in a Protomol file. The binding affinity of the ligands was predicted by five different scoring functions and a consensus score to identify hit 5. After running Surflex-Dock, 20 docked models were selected for each ligand. The best scoring conformer was used to study the binding patterns at the active site. Similar approach was applied during docking to obtain the hypothetical binding mode of the lead <b>25</b>. The structure of <b>25</b> was drawn into the Sybyl package and was minimized with the Tripos force field and Gasteiger–Huckel charge and was used instead of a library of compounds.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Cell-Based Anti-HCV and MTT Assays</h3><div class="NLM_p last">An infectious recombinant isolate derived from a genotype 2a HCV clone (JFH1) JFH1-RLuc was prepared by in vitro transcription of its viral RNA from the cognate plasmid pJFH1-Luc (a gift from Dr. Xulin Chen, Wuhan Institute of Virology, China). In vitro transcripts were electroporated into Huh7.5 cells as previously described.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> This system was designed to examine the efficiency of viral infection and replication by measuring <i>Renilla</i> luciferase (RLuc) activity. Naive Huh7.5 cells (grown to 70% confluence) were seeded onto 48-well plates and were either mock-infected with culture medium [Dulbecco’s modified Eagle medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Invitrogen)] or infected with the JFH1-Luc virus at a multiplicity of infection (MOI) of 0.004 for 5 h at 37 °C in the absence or presence of serially (3-fold) diluted test chemicals. On day 3 postinfection, JFH1-Luc-infected and chemical-treated cells were lysed and the EC<sub>50</sub> were calculated by measuring <i>Renilla</i> luciferase activity (<i>Renilla</i> luciferase assay system; Promega, Madison, WI, USA). In parallel, the viability of mock-infected and chemical-treated Huh7.5 cells was tested by an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) (Sigma-Aldrich) assay and the CC<sub>50</sub> values were calculated as previously described.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Surface Plasmon Resonance</h3><div class="NLM_p last">The direct target binding of <b>25</b> or CsA was assessed using a dual channel SPR instrument (Reichert, Depew, NY, USA). CypA protein was immobilized to the sensor chip surface via free amine coupling by injecting a mixture of 0.1 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 0.05 M <i>N</i>-hydroxysuccinimide followed by quenching of the remaining activated carboxyl groups with 1 M ethanolamine, pH 8.5. A second reference cell was treated similarly, but the target protein was excluded. All working peptide dilutions were prepared in running buffer (PBS with 0.2% DMSO) and were injected for 3 min (association time) at a flow rate of 30 μL/min followed by a dissociation phase of 3 min. Nonspecific background binding was subtracted from each sensogram using the SPR V4017 data acquisition and alignment program (Reichert, Depew, NY, USA). The binding rates and constants were independent of the flow rate over a wide range. Best-fit kinetic parameters were obtained by global fitting analysis using Scrubber2 (BioLogic Software, Campbell, ACT, Australia).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Calcineurin Phosphatase Assay</h3><div class="NLM_p last">Calcium-dependent calcineurin activity was determined by measuring the dephosphorylation of the RII phosphopeptide using a calcineurin cellular activity assay kit (Enzo Life Sciences, Plymouth Meeting, PA, USA). Splenocytes (2 × 10<sup>6</sup> cells/well) were incubated with CsA or <b>25</b> for 20 h and either were left untreated or were stimulated with 1 μg/mL ionomycin (Calbiochem, La Jolla, CA, USA) for an additional 4 h. The cells were subsequently used to measure calcineurin activity.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> NFAT Dephosphorylation by Western Blot and Immunofluorescence</h3><div class="NLM_p last">Mouse splenocytes (2 × 10<sup>6</sup> cells/well) were cultured and treated with CsA or <b>25</b> for 20 h at 37 °C followed by another 4 h of stimulation with 1 μg/mL ionomycin (Calbiochem, La Jolla, CA, USA). After stimulation, the cells were washed once with sterile PBS, suspended in lysis buffer (Invitrogen, Carlsbad, CA, USA), and incubated on ice for 10 min followed by centrifugation at 19 000<i>g</i> for 15 min. The phosphorylation status of NFAT proteins in the supernatant was evaluated by Western blot using a monoclonal anti-NFATc1 antibody (Abcam, Cambridge, MA, USA). To identify the localization of NFAT1 by confocal microscope, the cells were washed and fixed using 3.7% formaldehyde for 20 min at rt after treatment. Thereafter, the cells were washed three times with PBS and were permeabilized using 0.5% Triton X-100 in PBS and were washed again three times with PBS prior to an overnight incubation (4 °C) with a primary antibody at a dilution of 1:100 in PBS containing 3% BSA. After incubation, the cells were again washed twice with PBS and were incubated with an Alexa 546-conjugated secondary antibody (Invitrogen, Carlsbad, CA, USA) diluted 1:200 in PBS containing 3% BSA for 2 h in the dark at rt. The cells were washed two more times in PBS and were counterstained with DAPI (4′,6′-diamidino-2-phenylindole) for 10 min. The cells were washed again with PBS and mounted on glass slides using a coverslip and mounting solution (VectaMount; Vector Laboratories, Inc., Burlingame, CA, USA). The images were captured using a Zeiss confocal laser scanning microscope (Zeiss, Oberkochen, Germany).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Determination of the IL-2 Concentration by ELISA</h3><div class="NLM_p last">Spleen cells (2 × 10<sup>6</sup> cells/well) were seeded in a 24-well plate and were stimulated with ionomycin (1 μg/mL) followed by CsA or <b>25</b> treatment in a dose-dependent manner for 24 h at 37 °C. After incubation, the culture media from triplicate wells were pooled and were assayed to determine the IL-2 concentration by ELISA according to a protocol from Enzo Life Sciences (Plymouth Meeting, PA). The IL-2 concentrations were calculated based on IL-2 standards and solutions.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Preparation of the Membrane Fraction</h3><div class="NLM_p last">Cells at a confluence of ∼80% in a 10 cm diameter culture dish were scraped using PBS. The cells were pelleted by centrifugation at 220<i>g</i> for 10 min. The pellet was resuspended in 1 mL of hypotonic buffer (10 mM Tris-HCl (pH 7.5), 10 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), and 2 μg/mL leupeptin) and was incubated for 10 min at 4 °C. The suspension was homogenized with 75 strokes using a glass dounce homogenizer and a tight-fitting pestle (Sigma-Aldrich, St. Louis, MO, USA). The nuclei and nondisrupted cells were removed by centrifugation at 220<i>g</i> for 10 min at 4 °C. The intracellular membranes in the resulting supernatant were centrifuged immediately at 68 000<i>g</i> in a microultracentrifuge (Hitachi, Japan) for 1 h at 4 °C. After centrifugation, the crude replication complex fraction was recovered and used for Western blot analysis.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Real-Time Image Analysis</h3><div class="NLM_p last">Huh7 replicon cells expressing a NS5A-GFP fusion protein were plated at 2 × 10<sup>3</sup> cells/well in 40 μL of culture media in 384-well plates (Greiner Bio-One, μClear black). After incubation overnight, serially diluted compounds in 20 μL of culture media were added. At 72 h postinfection, the plates were fixed with 2% paraformaldehyde (PFA) and the nuclei were stained with 10 μg/mL Hoechst 33342 (Sigma-Aldrich, St. Louis, MO, USA). The cells were visualized by fully automated confocal microscopy (Opera, PerkinElmer) and were analyzed with an in-house written software program. The infected cells were measured by their GFP expression, and cytotoxicity was measured by counting the nuclei. The EC<sub>50</sub> and CC<sub>50</sub> were calculated by nonlinear regression using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Real-Time Quantitative Reverse Transcriptase PCR Analysis</h3><div class="NLM_p last">Real-time quantitative reverse transcriptase PCR (qRT-PCR) was performed using the SYBR Green PCR Master Mix (Invitrogen/Applied Biosystems, Carlsbad, CA, USA) and the ABI Prism 7300 real-time PCR system (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer’s instructions. Calculations based on the 2<sup>–ΔΔ<i>C</i><sub>T</sub></sup> method were performed using the following equation: <i>R</i> (ratio) = 2<sup>–[Δ<i>C</i><sub>T</sub>(sample)−Δ<i>C</i><sub>T</sub>(control)]</sup>. The data were expressed as the fold change in the treatment groups relative to that in the controls and were normalized to GAPDH.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Determination of IL-8 and IFN-α Concentrations in the Cell Culture Media Using ELISA</h3><div class="NLM_p last">HCV replicon Con1b cells (2 × 10<sup>6</sup> cells/well) were plated in 6-well plates followed by treatment with 2 μM CsA or <b>25</b> in a time-dependent manner for up to 4 days at 37 °C. After incubation, the culture media were pooled and assayed for IL-8 and IFN-α concentrations using ELISA (eBioscience, San Diego, CA, USA) per the manufacturer’s instructions.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Synergy Analysis</h3><div class="NLM_p last">To determine whether the effects of the combination of <b>25</b> with IFN-α, ribavirin, or telaprevir were synergistic, additive, or antagonistic, the calcuSyn software (Biosoft, Cambridge, U.K.) was used to calculate the combination index (CI) value. Additivity, synergy, and antagonism were indicated by CI = 1.0, <1.0, and >1.0, respectively.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> HCV Mouse Model</h3><div class="NLM_p last">Immunodeficient, 5- to 6-week-old NOD/SCID female mice (Charles River Laboratories, USA) were used in the in vivo experiments. Animal use and the experimental protocol (KHUASP (SE)-11-045) were approved by the Institutional Animal Care and Use Committee of Kyung Hee University (Seoul, Korea). The mice were engrafted with control Huh7 cells or Huh7 cells containing the HCV-Con1b replicon (1 × 10<sup>6</sup> cells in 200 μL of PBS) by intrasplenic injection.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The cell transplantation and surgical procedures were performed under anesthesia with prophylactic antibiotics. Intraperitoneal administration of CsA and <b>25</b> (50 mg/kg) was started 6 weeks after the cell transplantation and was continued for 14 days. Each treatment group consisted of five animals. After treatment completion, the mice were euthanized and the liver tissue was dissected for analysis.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Histology and Fluorescence Immunohistochemistry</h3><div class="NLM_p last">The liver tissue of each mouse was dissected and cryoprotected in 30% sucrose for the subsequent preparation of paraffin-embedded tissue sections. The paraffin tissue sections were prepared for H&E staining. The deparaffinized and rehydrated sections were incubated overnight at 4 °C with a monoclonal antibody against human hepatocytes (Hep par 1) and HCV NS5A (Santa Cruz Biotechnologies, Inc., Santa Cruz, CA, USA) at a 1:50 dilution. After three washes, the sections were incubated with an Alexa Fluor 488- or Alexa Fluor 546-conjugated anti-rabbit or anti-mouse IgG antibody (Invitrogen, Carlsbad, CA, USA) at a dilution of 1:100 for 2 h. The nuclei were labeled with DAPI for 5 min. Images were acquired using confocal microscopy.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Western Blot Analysis</h3><div class="NLM_p last">The cell extracts were separated by SDS–PAGE and were transferred onto a nitrocellulose membrane. After blocking, the membranes were incubated with primary antibodies followed by incubation with a secondary antibody. The protein samples were detected with enhanced chemiluminescence reagents (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01064">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32045" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32045" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01064" class="ext-link">10.1021/acs.jmedchem.5b01064</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Synthesis and characterization of the compounds, molecular docking, and details of the biological assays (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_001.csv">jm5b01064_si_001.csv (1.76 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_002.pdf">jm5b01064_si_002.pdf (3.19 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01064" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31887" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31887" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sung Soo Kim</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 130-701, Republic
of Korea</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#13607460787a7e53787b663d72703d7861"><span class="__cf_email__" data-cfemail="384b5f4b5351557853504d16595b16534a">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Won-Jea Cho</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 500-757, Republic of Korea</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#97e0fdf4fff8d7fdf9e2b9f6f4b9fce5"><span class="__cf_email__" data-cfemail="5a2d303932351a30342f743b39743128">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suhui Yang</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 500-757, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jyothi K.R.</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 130-701, Republic
of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sangbin Lim</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 130-701, Republic
of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tae Gyu Choi</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 130-701, Republic
of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jin-Hwan Kim</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 130-701, Republic
of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Salima Akter</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 130-701, Republic
of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Miran Jang</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 130-701, Republic
of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hyun-Jong Ahn</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology, School of Medicine, Kyung
Hee University, Seoul 130-701, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hee-Young Kim</span> - <span class="hlFld-Affiliation affiliation">Applied
Molecular Virology, Institute Pasteur Korea, Gyeonggi-do 463-400, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marc P. Windisch</span> - <span class="hlFld-Affiliation affiliation">Applied
Molecular Virology, Institute Pasteur Korea, Gyeonggi-do 463-400, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daulat B. Khadka</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 500-757, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chao Zhao</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 500-757, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yifeng Jin</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 500-757, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Insug Kang</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 130-701, Republic
of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joohun Ha</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul 130-701, Republic
of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Byung-Chul Oh</span> - <span class="hlFld-Affiliation affiliation">Lee
Gil Ya Cancer and Diabetes Institute, Gachon
University of Medicine and Science, Incheon 406-840, Republic
of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meehyein Kim</span> - <span class="hlFld-Affiliation affiliation">Virus Research
and Testing Group, Korea Research Institute
of Chemical Technology, Daejeon 305-600, Republic of Korea</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>S.Y. and J.K.R. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d3054e3794-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86453" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86453" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by a grant from the National Research Foundation of Korea (NRF) funded by the Korean government (MEST) (Grant 2011-0030072) and Korea Health Industry Development Institute (KHIDI) (Grant HI12C1640).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i47" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i47"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i48" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i48"> Abbreviations Used</h2><tr><td class="NLM_term">DAA</td><td class="NLM_def"><p class="first last">direct-acting antiviral</p></td></tr><tr><td class="NLM_term">IFN-α</td><td class="NLM_def"><p class="first last">interferon α</p></td></tr><tr><td class="NLM_term">CypA</td><td class="NLM_def"><p class="first last">cyclophilin A</p></td></tr><tr><td class="NLM_term">CsA</td><td class="NLM_def"><p class="first last">cyclosporin A</p></td></tr><tr><td class="NLM_term">PPIase</td><td class="NLM_def"><p class="first last">peptidylprolyl cis–trans isomerase</p></td></tr><tr><td class="NLM_term">NFAT</td><td class="NLM_def"><p class="first last">nuclear factor of activated T cell</p></td></tr><tr><td class="NLM_term">TFE</td><td class="NLM_def"><p class="first last">2,2,2-trifluoroethanol</p></td></tr><tr><td class="NLM_term">IL-2</td><td class="NLM_def"><p class="first last">interleukin 2</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>D</sub></td><td class="NLM_def"><p class="first last">dissociation constant</p></td></tr><tr><td class="NLM_term">ITC</td><td class="NLM_def"><p class="first last">isothermal titration calorimetry</p></td></tr><tr><td class="NLM_term">Janus kinase-signal transducer and activator of transcription (JAK-STAT)</td><td class="NLM_def"></td></tr><tr><td class="NLM_term">ISG</td><td class="NLM_def"><p class="first last">IFN-stimulated gene</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70268" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70268" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 49 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Seeff, L. B.</span><span> </span><span class="NLM_article-title">Natural history of hepatitis C</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">21S</span><span class="NLM_x">–</span> <span class="NLM_lpage">28S</span><span class="refDoi"> DOI: 10.1002/hep.510260704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fhep.510260704" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1997&pages=21S-28S&author=L.+B.+Seeff&title=Natural+history+of+hepatitis+C&doi=10.1002%2Fhep.510260704"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fhep.510260704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.510260704%26sid%3Dliteratum%253Aachs%26aulast%3DSeeff%26aufirst%3DL.%2BB.%26atitle%3DNatural%2520history%2520of%2520hepatitis%2520C%26jtitle%3DHepatology%26date%3D1997%26volume%3D26%26spage%3D21S%26epage%3D28S%26doi%3D10.1002%2Fhep.510260704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Kowdley, K. V.</span><span> </span><span class="NLM_article-title">Hematologic side effects of interferon and ribavirin therapy</span> <span class="citation_source-journal">J. Clin. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">S3</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.1097/01.mcg.0000145494.76305.11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1097%2F01.mcg.0000145494.76305.11" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2005&pages=S3-8&author=K.+V.+Kowdley&title=Hematologic+side+effects+of+interferon+and+ribavirin+therapy&doi=10.1097%2F01.mcg.0000145494.76305.11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1097%2F01.mcg.0000145494.76305.11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.mcg.0000145494.76305.11%26sid%3Dliteratum%253Aachs%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26atitle%3DHematologic%2520side%2520effects%2520of%2520interferon%2520and%2520ribavirin%2520therapy%26jtitle%3DJ.%2520Clin.%2520Gastroenterol.%26date%3D2005%26volume%3D39%26spage%3DS3%26epage%3D8%26doi%3D10.1097%2F01.mcg.0000145494.76305.11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Strader, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeff, L. B.</span><span> </span><span class="NLM_article-title">A brief history of the treatment of viral hepatitis C</span> <span class="citation_source-journal">Clin. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">6</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span><span class="refDoi"> DOI: 10.1002/cld.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fcld.1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=6-11&author=D.+B.+Straderauthor=L.+B.+Seeff&title=A+brief+history+of+the+treatment+of+viral+hepatitis+C&doi=10.1002%2Fcld.1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fcld.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcld.1%26sid%3Dliteratum%253Aachs%26aulast%3DStrader%26aufirst%3DD.%2BB.%26aulast%3DSeeff%26aufirst%3DL.%2BB.%26atitle%3DA%2520brief%2520history%2520of%2520the%2520treatment%2520of%2520viral%2520hepatitis%2520C%26jtitle%3DClin.%2520Liver%2520Dis.%26date%3D2012%26volume%3D1%26spage%3D6%26epage%3D11%26doi%3D10.1002%2Fcld.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Heim, M. H.</span><span> </span><span class="NLM_article-title">25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">535</span><span class="NLM_x">–</span> <span class="NLM_lpage">542</span><span class="refDoi"> DOI: 10.1038/nri3463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1038%2Fnri3463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=23743475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovFamurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=535-542&author=M.+H.+Heim&title=25+years+of+interferon-based+treatment+of+chronic+hepatitis+C%3A+an+epoch+coming+to+an+end&doi=10.1038%2Fnri3463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end</span></div><div class="casAuthors">Heim, Markus H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">535-542</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chronic hepatitis caused by infection with hepatitis C virus C (HCV) (therefore known as chronic hepatitis C (CHC)) is a leading cause of liver disease worldwide.  For the past 25 years, recombinant interferon-α (IFNα) has been the main component of treatments for HCV infection.  Treatment efficacy has shown a stepwise improvement following the pegylation of IFNα and its use in combination with other antiviral drugs.  However, viral escape mechanisms, refractory IFNα signalling in the liver and substantial drug toxicity still limit the efficacy of this treatment.  A new generation of HCV-specific antiviral drugs will probably improve response rates and might replace IFNs in CHC treatment in the next few years.  This Timeline article summarizes the history of CHC treatment using recombinant IFNα with an emphasis on the mechanisms of action and the causes of non-response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKQQMKuR1xXLVg90H21EOLACvtfcHk0lhRG31MMJK4aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovFamurc%253D&md5=29af7191c765714e2020f354979e0e50</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnri3463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3463%26sid%3Dliteratum%253Aachs%26aulast%3DHeim%26aufirst%3DM.%2BH.%26atitle%3D25%2520years%2520of%2520interferon-based%2520treatment%2520of%2520chronic%2520hepatitis%2520C%253A%2520an%2520epoch%2520coming%2520to%2520an%2520end%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D13%26spage%3D535%26epage%3D542%26doi%3D10.1038%2Fnri3463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Liang, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghany, M. G.</span><span> </span><span class="NLM_article-title">Current and future therapies for hepatitis C virus infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">1907</span><span class="NLM_x">–</span> <span class="NLM_lpage">1917</span><span class="refDoi"> DOI: 10.1056/NEJMra1213651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1056%2FNEJMra1213651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=23675659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsl2gs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=1907-1917&author=T.+J.+Liangauthor=M.+G.+Ghany&title=Current+and+future+therapies+for+hepatitis+C+virus+infection&doi=10.1056%2FNEJMra1213651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Current and future therapies for hepatitis C virus infection</span></div><div class="casAuthors">Liang, T. Jake; Ghany, Marc G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1907-1917</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The recent approval of two direct-acting antiviral agents for hepatitis C viral (HCV) infection that specifically inhibit viral replication has dramatically increased the viral clearance rate.  It is anticipated that in the course of such a screening process, a large no. of persons will be found to be infected with HCV; this article reviews the current therapy for HCV infection and the landscape of drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4zjjmKeKrZrVg90H21EOLACvtfcHk0lhRG31MMJK4aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsl2gs78%253D&md5=6be058d0298a4441a180ac076d7293aa</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1213651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1213651%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DT.%2BJ.%26aulast%3DGhany%26aufirst%3DM.%2BG.%26atitle%3DCurrent%2520and%2520future%2520therapies%2520for%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D1907%26epage%3D1917%26doi%3D10.1056%2FNEJMra1213651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Manns, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Hahn, T.</span><span> </span><span class="NLM_article-title">Novel therapies for hepatitis C - one pill fits all?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">595</span><span class="NLM_x">–</span> <span class="NLM_lpage">610</span><span class="refDoi"> DOI: 10.1038/nrd4050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1038%2Fnrd4050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=595-610&author=M.+P.+Mannsauthor=T.+von+Hahn&title=Novel+therapies+for+hepatitis+C+-+one+pill+fits+all%3F&doi=10.1038%2Fnrd4050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd4050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4050%26sid%3Dliteratum%253Aachs%26aulast%3DManns%26aufirst%3DM.%2BP.%26aulast%3Dvon%2BHahn%26aufirst%3DT.%26atitle%3DNovel%2520therapies%2520for%2520hepatitis%2520C%2520-%2520one%2520pill%2520fits%2520all%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D595%26epage%3D610%26doi%3D10.1038%2Fnrd4050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Sherman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flamm, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afdhal, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reesink, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sankoh, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poordad, F.</span><span> </span><span class="NLM_article-title">Response-guided telaprevir combination treatment for hepatitis C virus infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">1014</span><span class="NLM_x">–</span> <span class="NLM_lpage">1024</span><span class="refDoi"> DOI: 10.1056/NEJMoa1014463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1056%2FNEJMoa1014463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=21916639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2mtrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1014-1024&author=K.+E.+Shermanauthor=S.+L.+Flammauthor=N.+H.+Afdhalauthor=D.+R.+Nelsonauthor=M.+S.+Sulkowskiauthor=G.+T.+Eversonauthor=M.+W.+Friedauthor=M.+Adlerauthor=H.+W.+Reesinkauthor=M.+Martinauthor=A.+J.+Sankohauthor=N.+Addaauthor=R.+S.+Kauffmanauthor=S.+Georgeauthor=C.+I.+Wrightauthor=F.+Poordad&title=Response-guided+telaprevir+combination+treatment+for+hepatitis+C+virus+infection&doi=10.1056%2FNEJMoa1014463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Response-guided telaprevir combination treatment for hepatitis C virus infection</span></div><div class="casAuthors">Sherman, Kenneth E.; Flamm, Steven L.; Afdhal, Nezam H.; Nelson, David R.; Sulkowski, Mark S.; Everson, Gregory T.; Fried, Michael W.; Adler, Michael; Reesink, Hendrik W.; Martin, Marie; Sankoh, Abdul J.; Adda, Nathalie; Kauffman, Robert S.; George, Shelley; Wright, Christopher I.; Poordad, Fred</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1014-1024</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Patients with chronic infection with hepatitis C virus (HCV) genotype 1 often need 48 wk of peginterferon-ribavirin treatment for a sustained virol. response.  We designed a noninferiority trial (noninferiority margin, -10.5%) to compare rates of sustained virol. response among patients receiving two treatment durations.  Methods: We enrolled patients with chronic infection with HCV genotype 1 who had not previously received treatment.  All patients received telaprevir at a dose of 750 mg every 8 h, peginterferon alfa-2a at a dose of 180 μg per wk, and ribavirin at a dose of 1000 to 1200 mg per day, for 12 wk (T12PR12), followed by peginterferon-ribavirin.  Patients who had an extended rapid virol. response (undetectable HCV RNA levels at weeks 4 and 12) were randomly assigned after week 20 to receive the dual therapy for 4 more weeks (T12PR24) or 28 more weeks (T12PR48).  Patients without an extended rapid virol. response were assigned to T12PR48.  Results: Of the 540 patients, a total of 352 (65%) had an extended rapid virol. response.  The overall rate of sustained virol. response was 72%.  Among the 322 patients with an extended rapid virol. response who were randomly assigned to a study group, 149 (92%) in the T12PR24 group and 140 (88%) in the T12PR48 group had a sustained virol. response (abs. difference, 4 percentage points; 95% confidence interval, -2 to 11), establishing noninferiority.  Adverse events included rash (in 37% of patients, severe in 5%) and anemia (in 39%, severe in 60%).  Discontinuation of all the study drugs was based on adverse events in 18% of patients overall, as well as in 1%0/ of patients (all of whom were randomly assigned) in the T12PR24 group and 12% of the patients randomly assigned to the T12PR48 group (P < 0.001).  Conclusions: In this study, among patients with chronic HCV infection who had not received treatment previously, a regimen of peginterferon-ribavirin for 24 wk, with telaprevir for the first 12 wk, was noninferior to the same regimen for 48 wk in patients with undetectable HCV RNA at weeks 4 and 12, with an extended rapid virol. response achieved in nearly two thirds of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_7m3eqLwOibVg90H21EOLACvtfcHk0lhRG31MMJK4aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2mtrrI&md5=338e575a354c4e51d0471dda3949847f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1014463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1014463%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DK.%2BE.%26aulast%3DFlamm%26aufirst%3DS.%2BL.%26aulast%3DAfdhal%26aufirst%3DN.%2BH.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DFried%26aufirst%3DM.%2BW.%26aulast%3DAdler%26aufirst%3DM.%26aulast%3DReesink%26aufirst%3DH.%2BW.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DSankoh%26aufirst%3DA.%2BJ.%26aulast%3DAdda%26aufirst%3DN.%26aulast%3DKauffman%26aufirst%3DR.%2BS.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DWright%26aufirst%3DC.%2BI.%26aulast%3DPoordad%26aufirst%3DF.%26atitle%3DResponse-guided%2520telaprevir%2520combination%2520treatment%2520for%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D1014%26epage%3D1024%26doi%3D10.1056%2FNEJMoa1014463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Bacon, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vierling, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, Z. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sings, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boparai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burroughs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brass, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteban, R.</span><span> </span><span class="NLM_article-title">Boceprevir for previously treated chronic HCV genotype 1 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1207</span><span class="NLM_x">–</span> <span class="NLM_lpage">1217</span><span class="refDoi"> DOI: 10.1056/NEJMoa1009482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1056%2FNEJMoa1009482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=21449784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1Cht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1207-1217&author=B.+R.+Baconauthor=S.+C.+Gordonauthor=E.+Lawitzauthor=P.+Marcellinauthor=J.+M.+Vierlingauthor=S.+Zeuzemauthor=F.+Poordadauthor=Z.+D.+Goodmanauthor=H.+L.+Singsauthor=N.+Boparaiauthor=M.+Burroughsauthor=C.+A.+Brassauthor=J.+K.+Albrechtauthor=R.+Esteban&title=Boceprevir+for+previously+treated+chronic+HCV+genotype+1+infection&doi=10.1056%2FNEJMoa1009482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Boceprevir for previously treated chronic HCV genotype 1 infection</span></div><div class="casAuthors">Bacon, Bruce R.; Gordon, Stuart C.; Lawitz, Eric; Marcellin, Patrick; Vierling, John M.; Zeuzem, Stefan; Poordad, Fred; Goodman, Zachary D.; Sings, Heather L.; Boparai, Navdeep; Burroughs, Margaret; Brass, Clifford A.; Albrecht, Janice K.; Esteban, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1207-1217</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are suboptimal.  Boceprevir, a protease inhibitor that binds to the HCV nonstructural 3 (NS3) active site, has been suggested as an addnl. treatment.  To assess the effect of the combination of boceprevir and peginterferon-ribavirin for retreatment of patients with chronic HCV genotype 1 infection, we randomly assigned patients (in a 1:2:2 ratio) to one of three groups.  In all three groups, peginterferon alfa-2b and ribavirin were administered for 4 wk (the lead-in period).  Subsequently, group 1 (control group) received placebo plus peginterferon-ribavirin for 44 wk; group 2 received boceprevir plus peginterferon-ribavirin for 32 wk, and patients with a detectable HCV RNA level at week 8 received placebo plus peginterferon-ribavirin for an addnl. 12 wk; and group 3 received boceprevir plus peginterferon-ribavirin for 44 wk.  A total of 403 patients were treated.  The rate of sustained virol. response was significantly higher in the two boceprevir groups (group 2, 59%; group 3, 66%) than in the control group (21%, P < 0.001).  Among patients with an undetectable HCV RNA level at week 8, the rate of sustained virol. response was 86% after 32 wk of triple therapy and 88% after 44 wk of triple therapy.  Among the 102 patients with a decrease in the HCV RNA level of less than 1 log10 IU per mL at treatment week 4, the rates of sustained virol. response were 0%, 33%, and 34% in groups 1, 2, and 3, resp.  Anemia was significantly more common in the boceprevir groups than in the control group, and erythropoietin was administered in 41 to 46% of boceprevir-treated patients and 21% of controls.  The addn. of boceprevir to peginterferon-ribavirin resulted in significantly higher rates of sustained virol. response in previously treated patients with chronic HCV genotype 1 infection, as compared with peginterferon-ribavirin alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjykaE3KIqArVg90H21EOLACvtfcHk0lg3AObC-kChwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1Cht7k%253D&md5=402802777ab3a369c71332a84a8b40e3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1009482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1009482%26sid%3Dliteratum%253Aachs%26aulast%3DBacon%26aufirst%3DB.%2BR.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DVierling%26aufirst%3DJ.%2BM.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DGoodman%26aufirst%3DZ.%2BD.%26aulast%3DSings%26aufirst%3DH.%2BL.%26aulast%3DBoparai%26aufirst%3DN.%26aulast%3DBurroughs%26aufirst%3DM.%26aulast%3DBrass%26aufirst%3DC.%2BA.%26aulast%3DAlbrecht%26aufirst%3DJ.%2BK.%26aulast%3DEsteban%26aufirst%3DR.%26atitle%3DBoceprevir%2520for%2520previously%2520treated%2520chronic%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1207%26epage%3D1217%26doi%3D10.1056%2FNEJMoa1009482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Yau, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, E. M.</span><span> </span><span class="NLM_article-title">Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review</span> <span class="citation_source-journal">Can. J. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">445</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=25229466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A280%3ADC%252BC2M7itlymsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=445-451&author=A.+H.+Yauauthor=E.+M.+Yoshida&title=Hepatitis+C+drugs%3A+the+end+of+the+pegylated+interferon+era+and+the+emergence+of+all-oral+interferon-free+antiviral+regimens%3A+a+concise+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review</span></div><div class="casAuthors">Yau Alan Hoi Lun; Yoshida Eric M</div><div class="citationInfo"><span class="NLM_cas:title">Canadian journal of gastroenterology & hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">445-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Between 2001 and 2011, the standard of care for chronic hepatitis C virus (HCV) infection was a combination of pegylated interferon (PEG-IFN) and ribavirin (RBV).  In May 2011, boceprevir and telaprevir, two first-generation NS3/4A protease inhibitors, were approved in combination with PEG-IFN and RBV for 24 to 48 weeks in hepatitis C virus genotype 1 infections.  In December 2013, simeprevir, a second-generation NS3/4A protease inhibitor, was approved for use with PEG-IFN and RBV for 12 weeks in genotype 1, while sofosbuvir, a NS5B nucleotide polymerase inhibitor, was approved for use with PEG-IFN and RBV for 12 weeks in genotypes 1 and 4, as well as with RBV alone for 12 weeks in genotype 2 and for 24 weeks in genotype 3.  Sofosbuvir combined with simeprevir or an NS5A replication complex inhibitor (ledipasvir or daclatasvir) with or without RBV for 12 weeks in genotype 1 resulted in a sustained virological response >90%, irrespective of previous treatment history or presence of cirrhosis.  Similarly impressive sustained virological response rates have been shown with ABT-450/r (ritonavir-boosted NS3/4A protease inhibitor)-based regimens in combination with other direct-acting antiviral agent(s) with or without RBV for 12 weeks in genotype 1.  The optimal all-oral interferon-free antiviral regimen likely entails a combination of an NS5B nucleotide polymerase inhibitor with either a second-generation NS3/4A protease inhibitor or an NS5A replication complex inhibitor with or without RBV.  Further research is needed to determine the role of resistance testing, clarify the optimal follow-up duration post-treatment, and evaluate the antiviral efficacy and safety in difficult-to-cure patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtIKrjnj9vbC-bLEOO4dYpfW6udTcc2eZZw8hNDHExrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7itlymsg%253D%253D&md5=6158273c12e24d51cca8e7e85749dd1b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYau%26aufirst%3DA.%2BH.%26aulast%3DYoshida%26aufirst%3DE.%2BM.%26atitle%3DHepatitis%2520C%2520drugs%253A%2520the%2520end%2520of%2520the%2520pegylated%2520interferon%2520era%2520and%2520the%2520emergence%2520of%2520all-oral%2520interferon-free%2520antiviral%2520regimens%253A%2520a%2520concise%2520review%26jtitle%3DCan.%2520J.%2520Gastroenterol.%2520Hepatol.%26date%3D2014%26volume%3D28%26spage%3D445%26epage%3D451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Wyles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svarovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flamm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span> </span><span class="NLM_article-title">Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1793</span><span class="NLM_x">–</span> <span class="NLM_lpage">1797</span><span class="refDoi"> DOI: 10.1002/hep.27814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fhep.27814" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=1793-1797&author=D.+Wylesauthor=P.+Pockrosauthor=G.+Morelliauthor=Z.+Younesauthor=E.+Svarovskaiaauthor=J.+C.+Yangauthor=P.+S.+Pangauthor=Y.+Zhuauthor=J.+G.+McHutchisonauthor=S.+Flammauthor=E.+Lawitz&title=Ledipasvir-sofosbuvir+plus+ribavirin+for+patients+with+genotype+1+hepatitis+C+virus+previously+treated+in+clinical+trials+of+sofosbuvir+regimens&doi=10.1002%2Fhep.27814"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fhep.27814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27814%26sid%3Dliteratum%253Aachs%26aulast%3DWyles%26aufirst%3DD.%26aulast%3DPockros%26aufirst%3DP.%26aulast%3DMorelli%26aufirst%3DG.%26aulast%3DYounes%26aufirst%3DZ.%26aulast%3DSvarovskaia%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DFlamm%26aufirst%3DS.%26aulast%3DLawitz%26aufirst%3DE.%26atitle%3DLedipasvir-sofosbuvir%2520plus%2520ribavirin%2520for%2520patients%2520with%2520genotype%25201%2520hepatitis%2520C%2520virus%2520previously%2520treated%2520in%2520clinical%2520trials%2520of%2520sofosbuvir%2520regimens%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D1793%26epage%3D1797%26doi%3D10.1002%2Fhep.27814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varunok, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguilar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felizarta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGovern, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polepally, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D. E.</span><span> </span><span class="NLM_article-title">Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">364</span><span class="NLM_x">–</span> <span class="NLM_lpage">369</span><span class="refDoi"> DOI: 10.1016/j.jhep.2015.03.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1016%2Fj.jhep.2015.03.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=25839406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslCntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=364-369&author=J.+Lalezariauthor=J.+G.+Sullivanauthor=P.+Varunokauthor=E.+Galenauthor=K.+V.+Kowdleyauthor=V.+Rustgiauthor=H.+Aguilarauthor=F.+Felizartaauthor=B.+McGovernauthor=M.+Kingauthor=A.+R.+Polepallyauthor=D.+E.+Cohen&title=Ombitasvir%2Fparitaprevir%2Fr+and+dasabuvir+plus+ribavirin+in+HCV+genotype+1-infected+patients+on+methadone+or+buprenorphine&doi=10.1016%2Fj.jhep.2015.03.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine</span></div><div class="casAuthors">Lalezari, Jacob; Sullivan, J. Greg; Varunok, Peter; Galen, Edward; Kowdley, Kris V.; Rustgi, Vinod; Aguilar, Humberto; Felizarta, Franco; McGovern, Barbara; King, Martin; Polepally, Akshanth R.; Cohen, Daniel E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">364-369</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV)-infected patients with a history of injection drug use have low rates of initiation and completion of interferon-based therapies.  This study evaluated efficacy, safety, and pharmacokinetics of a 12-wk all-oral regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir + ribavirin in HCV genotype 1-infected patients on stable opioid replacement therapy.This was a phase II, multicenter, open-label, single-arm study in treatment-na.ovrddot.ive or peginterferon/ribavirin treatment-experienced HCV genotype 1-infected patients on methadone or buprenorphine ± naloxone.  Patients received 12 wk of co-formulated ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) and dasabuvir (250 mg twice daily) + wt.-based ribavirin.  The primary efficacy endpoint was sustained virol. response 12 wk post-treatment.Thirty-eight non-cirrhotic patients on chronic methadone (n = 19) or buprenorphine (n = 19) were enrolled.  A total of 37 patients (97.4%) had a sustained virol. response 12 wk post-treatment.  No patient had a viral breakthrough or relapse.  One patient discontinued due to serious adverse events unrelated to study drug (cerebrovascular accident and sarcoma).  The most frequent adverse events were nausea, fatigue, and headache.  Eight patients had on-treatment Hb concns. <10 g/dL.  Pharmacokinetic analyses indicated no clin. meaningful impact of methadone or buprenorphine on ombitasvir, paritaprevir, ritonavir, dasabuvir, or dasabuvir M1 metabolite exposures.  No dose adjustments of methadone or buprenorphine were required.The interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir + ribavirin for 12 wk was well tolerated and achieved sustained virol. response in 97.4% of patients on opioid substitution therapy in this study.  This all-oral regimen may provide an effective alternative to interferon-based therapies for HCV-infected patients with a history of injection drug use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuco6UpiasarVg90H21EOLACvtfcHk0lgm6JqkJKN05w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslCntbs%253D&md5=a8dd009dd2f639c0c71b35cdc3aa8fe9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2015.03.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2015.03.029%26sid%3Dliteratum%253Aachs%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DSullivan%26aufirst%3DJ.%2BG.%26aulast%3DVarunok%26aufirst%3DP.%26aulast%3DGalen%26aufirst%3DE.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DAguilar%26aufirst%3DH.%26aulast%3DFelizarta%26aufirst%3DF.%26aulast%3DMcGovern%26aufirst%3DB.%26aulast%3DKing%26aufirst%3DM.%26aulast%3DPolepally%26aufirst%3DA.%2BR.%26aulast%3DCohen%26aufirst%3DD.%2BE.%26atitle%3DOmbitasvir%252Fparitaprevir%252Fr%2520and%2520dasabuvir%2520plus%2520ribavirin%2520in%2520HCV%2520genotype%25201-infected%2520patients%2520on%2520methadone%2520or%2520buprenorphine%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D63%26spage%3D364%26epage%3D369%26doi%3D10.1016%2Fj.jhep.2015.03.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notsumata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurosaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setze, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilot-Matias, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilchez, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1523</span><span class="NLM_x">–</span> <span class="NLM_lpage">1532</span><span class="refDoi"> DOI: 10.1002/hep.27705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fhep.27705" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=1523-1532&author=K.+Chayamaauthor=K.+Notsumataauthor=M.+Kurosakiauthor=K.+Satoauthor=L.+Rodriguesauthor=C.+Setzeauthor=P.+Badriauthor=T.+Pilot-Matiasauthor=R.+A.+Vilchezauthor=H.+Kumada&title=Randomized+trial+of+interferon-+and+ribavirin-free+ombitasvir%2Fparitaprevir%2Fritonavir+in+treatment-experienced+hepatitis+C+virus-infected+patients&doi=10.1002%2Fhep.27705"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fhep.27705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27705%26sid%3Dliteratum%253Aachs%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DNotsumata%26aufirst%3DK.%26aulast%3DKurosaki%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DRodrigues%26aufirst%3DL.%26aulast%3DSetze%26aufirst%3DC.%26aulast%3DBadri%26aufirst%3DP.%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DVilchez%26aufirst%3DR.%2BA.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DRandomized%2520trial%2520of%2520interferon-%2520and%2520ribavirin-free%2520ombitasvir%252Fparitaprevir%252Fritonavir%2520in%2520treatment-experienced%2520hepatitis%2520C%2520virus-infected%2520patients%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D1523%26epage%3D1532%26doi%3D10.1002%2Fhep.27705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiffman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Assi, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNally, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feld, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pianko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. R.</span><span> </span><span class="NLM_article-title">Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">1867</span><span class="NLM_x">–</span> <span class="NLM_lpage">1877</span><span class="refDoi"> DOI: 10.1056/NEJMoa1214854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1056%2FNEJMoa1214854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=23607593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsl2gsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=1867-1877&author=I.+M.+Jacobsonauthor=S.+C.+Gordonauthor=K.+V.+Kowdleyauthor=E.+M.+Yoshidaauthor=M.+Rodriguez-Torresauthor=M.+S.+Sulkowskiauthor=M.+L.+Shiffmanauthor=E.+Lawitzauthor=G.+Eversonauthor=M.+Bennettauthor=E.+Schiffauthor=M.+T.+Al-Assiauthor=G.+M.+Subramanianauthor=D.+Anauthor=M.+Linauthor=J.+McNallyauthor=D.+Brainardauthor=W.+T.+Symondsauthor=J.+G.+McHutchisonauthor=K.+Patelauthor=J.+Feldauthor=S.+Piankoauthor=D.+R.+Nelson&title=Sofosbuvir+for+hepatitis+C+genotype+2+or+3+in+patients+without+treatment+options&doi=10.1056%2FNEJMoa1214854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options</span></div><div class="casAuthors">Jacobson, Ira M.; Gordon, Stuart C.; Kowdley, Kris V.; Yoshida, Eric M.; Rodriguez-Torres, Maribel; Sulkowski, Mark S.; Shiffman, Mitchell L.; Lawitz, Eric; Everson, Gregory; Bennett, Michael; Schiff, Eugene; Al-Assi, M. Tarek; Subramanian, G. Mani; Lin, Ming; McNally, John; Brainard, Diana; Symonds, William T.; McHutchison, John G.; Patel, Keyur; Feld, Jordan; Pianko, Stephen; Nelson, David R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1867-1877</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for whom treatment with peginterferon is not an option, or who have not had a response to prior interferon treatment, currently have no approved treatment options.  In phase 2 trials, regimens including the oral nucleotide polymerase inhibitor sofosbuvir have shown efficacy in patients, with HCV genotype 2 or 3 infection.  We conducted two randomized, phase 3 studies involving patients with chronic HCV genotype 2 or 3 infection.  In one trial, patients for whom treatment with peginterferon was not an option received oral sofosbuvir and ribavirin (207 patients) or matching placebo (71) for 12 wk.  In a second trial, patients who had not had a response to prior interferon therapy received sofosbuvir and ribavirin for 12 wk (103 patients) or 16 wk (98).  The primary end point was a sustained virol. response at 12 wk after therapy.  Among patients for whom treatment with peginterferon was not an option, the rate of a sustained virol. response was 78% (95% confidence interval [CI], 72 to 83) with sofosbuvir and ribavirin, as compared with 0% with placebo (P<0.001).  Among previously treated patients, the rate of response was 50% with 12 wk of treatment, as compared with 73% with 16 wk of treatment (difference, -23 percentage points; 95% CI, -35 to -11; P<0.001).  In both studies, response rates were lower among patients with genotype 3 infection than among those with genotype 2 infection and, among patients with genotype 3 infection, lower among those with cirrhosis than among those without cirrhosis.  The most common adverse events were headache, fatigue, nausea, and insomnia; the overall rate of discontinuation of sofosbuvir was low (1 to 2%).  In patients with HCV genotype 2 or 3 infection for whom treatment with peginterferon and ribavirin was not an option, 12 or 16 wk of treatment with sofosbuvir and ribavirin was effective.  Efficacy was increased among patients with HCV genotype 2 infection and those without cirrhosis.  In previously treated patients with genotype 3 infection, 16 wk of therapy was significantly more effective than 12 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobO40R_56pvbVg90H21EOLACvtfcHk0lgm6JqkJKN05w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsl2gsrk%253D&md5=d12d834921319bec54f6bc725ba58c51</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1214854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1214854%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DYoshida%26aufirst%3DE.%2BM.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DShiffman%26aufirst%3DM.%2BL.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DEverson%26aufirst%3DG.%26aulast%3DBennett%26aufirst%3DM.%26aulast%3DSchiff%26aufirst%3DE.%26aulast%3DAl-Assi%26aufirst%3DM.%2BT.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DAn%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DBrainard%26aufirst%3DD.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DFeld%26aufirst%3DJ.%26aulast%3DPianko%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26atitle%3DSofosbuvir%2520for%2520hepatitis%2520C%2520genotype%25202%2520or%25203%2520in%2520patients%2520without%2520treatment%2520options%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D1867%26epage%3D1877%26doi%3D10.1056%2FNEJMoa1214854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Nelson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harlan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oguchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz-Lasanta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinovitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravendhran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheikh, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varunok, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennicken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rana, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span> </span><span class="NLM_article-title">All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1127</span><span class="NLM_x">–</span> <span class="NLM_lpage">1135</span><span class="refDoi"> DOI: 10.1002/hep.27726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fhep.27726" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=1127-1135&author=D.+R.+Nelsonauthor=J.+N.+Cooperauthor=J.+P.+Lalezariauthor=E.+Lawitzauthor=P.+J.+Pockrosauthor=N.+Gitlinauthor=B.+F.+Freilichauthor=Z.+H.+Younesauthor=W.+Harlanauthor=R.+Ghalibauthor=G.+Oguchiauthor=P.+J.+Thuluvathauthor=G.+Ortiz-Lasantaauthor=M.+Rabinovitzauthor=D.+Bernsteinauthor=M.+Bennettauthor=T.+Hawkinsauthor=N.+Ravendhranauthor=A.+M.+Sheikhauthor=P.+Varunokauthor=K.+V.+Kowdleyauthor=D.+Hennickenauthor=F.+McPheeauthor=K.+Ranaauthor=E.+A.+Hughes&title=All-oral+12-week+treatment+with+daclatasvir+plus+sofosbuvir+in+patients+with+hepatitis+C+virus+genotype+3+infection%3A+ALLY-3+phase+III+study&doi=10.1002%2Fhep.27726"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fhep.27726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27726%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DCooper%26aufirst%3DJ.%2BN.%26aulast%3DLalezari%26aufirst%3DJ.%2BP.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DGitlin%26aufirst%3DN.%26aulast%3DFreilich%26aufirst%3DB.%2BF.%26aulast%3DYounes%26aufirst%3DZ.%2BH.%26aulast%3DHarlan%26aufirst%3DW.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DOguchi%26aufirst%3DG.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DOrtiz-Lasanta%26aufirst%3DG.%26aulast%3DRabinovitz%26aufirst%3DM.%26aulast%3DBernstein%26aufirst%3DD.%26aulast%3DBennett%26aufirst%3DM.%26aulast%3DHawkins%26aufirst%3DT.%26aulast%3DRavendhran%26aufirst%3DN.%26aulast%3DSheikh%26aufirst%3DA.%2BM.%26aulast%3DVarunok%26aufirst%3DP.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DHennicken%26aufirst%3DD.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DRana%26aufirst%3DK.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26atitle%3DAll-oral%252012-week%2520treatment%2520with%2520daclatasvir%2520plus%2520sofosbuvir%2520in%2520patients%2520with%2520hepatitis%2520C%2520virus%2520genotype%25203%2520infection%253A%2520ALLY-3%2520phase%2520III%2520study%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D1127%26epage%3D1135%26doi%3D10.1002%2Fhep.27726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Ruane, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ain, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stryker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meshrekey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soliman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfe, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riad, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikhail, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kersey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massetto, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doehle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knox, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span> </span><span class="NLM_article-title">Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1040</span><span class="NLM_x">–</span> <span class="NLM_lpage">1046</span><span class="refDoi"> DOI: 10.1016/j.jhep.2014.10.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1016%2Fj.jhep.2014.10.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=25450208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFWksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=1040-1046&author=P.+J.+Ruaneauthor=D.+Ainauthor=R.+Strykerauthor=R.+Meshrekeyauthor=M.+Solimanauthor=P.+R.+Wolfeauthor=J.+Riadauthor=S.+Mikhailauthor=K.+Kerseyauthor=D.+Jiangauthor=B.+Massettoauthor=B.+Doehleauthor=B.+J.+Kirbyauthor=S.+J.+Knoxauthor=J.+G.+McHutchisonauthor=W.+T.+Symonds&title=Sofosbuvir+plus+ribavirin+for+the+treatment+of+chronic+genotype+4+hepatitis+C+virus+infection+in+patients+of+Egyptian+ancestry&doi=10.1016%2Fj.jhep.2014.10.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry</span></div><div class="casAuthors">Ruane, Peter J.; Ain, Dani; Stryker, Richard; Meshrekey, Raymond; Soliman, Mina; Wolfe, Peter R.; Riad, Joseph; Mikhail, Sameh; Kersey, Kathryn; Jiang, Deyuan; Massetto, Benedetta; Doehle, Brian; Kirby, Brian J.; Knox, Steven J.; McHutchison, John G.; Symonds, William T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1040-1046</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We conducted an open-label phase 2 study to assess the efficacy and safety of the oral nucleotide polymerase inhibitor sofosbuvir in combination with ribavirin in patients of Egyptian ancestry, chronically infected with genotype 4 hepatitis C virus (HCV).Treatment-naive and previously treated patients with genotype 4 HCV were randomly allocated in a 1:1 ratio to receive sofosbuvir 400 mg and wt.-based ribavirin, for 12 or 24 wk.  The primary efficacy endpoint was the proportion of patients with sustained virol. response (HCV RNA <25 IU/mL) 12 wk after cessation of therapy (SVR12).Thirty treatment-naive and thirty previously treated patients were enrolled and treated for 12 wk (n = 31) or 24 wk (n = 29).  Overall, 23% of patients had cirrhosis and 38% had diabetes. 14% of treatment-naive patients were interferon ineligible and 63% of treatment-experienced patients had prior non-response.  SVR12 was achieved by 68% of patients (95% CI, 49-83%) in the 12-wk group, and by 93% of patients (95% CI, 77-99%) in the 24-wk group.  The most common adverse events were headache, insomnia, and fatigue.  No patient discontinued treatment due to an adverse event.The findings from the present study suggest that 24 wk of sofosbuvir plus ribavirin is an efficacious and well tolerated treatment in patients with HCV genotype 4 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3HNYO9MOtoLVg90H21EOLACvtfcHk0ljAQflmwzI0hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFWksro%253D&md5=d4259fb4087ac943e11d16c88594c77a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.10.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.10.044%26sid%3Dliteratum%253Aachs%26aulast%3DRuane%26aufirst%3DP.%2BJ.%26aulast%3DAin%26aufirst%3DD.%26aulast%3DStryker%26aufirst%3DR.%26aulast%3DMeshrekey%26aufirst%3DR.%26aulast%3DSoliman%26aufirst%3DM.%26aulast%3DWolfe%26aufirst%3DP.%2BR.%26aulast%3DRiad%26aufirst%3DJ.%26aulast%3DMikhail%26aufirst%3DS.%26aulast%3DKersey%26aufirst%3DK.%26aulast%3DJiang%26aufirst%3DD.%26aulast%3DMassetto%26aufirst%3DB.%26aulast%3DDoehle%26aufirst%3DB.%26aulast%3DKirby%26aufirst%3DB.%2BJ.%26aulast%3DKnox%26aufirst%3DS.%2BJ.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26atitle%3DSofosbuvir%2520plus%2520ribavirin%2520for%2520the%2520treatment%2520of%2520chronic%2520genotype%25204%2520hepatitis%2520C%2520virus%2520infection%2520in%2520patients%2520of%2520Egyptian%2520ancestry%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26spage%3D1040%26epage%3D1046%26doi%3D10.1016%2Fj.jhep.2014.10.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">European Association for the Study of Liver.</span><span> </span><span class="NLM_article-title">EASL Recommendations on Treatment of Hepatitis C 2015</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">236</span><span class="refDoi"> DOI: 10.1016/j.jhep.2015.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1016%2Fj.jhep.2015.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=25911336" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=199-236&author=European+Association+for+the+Study+of+Liver.&title=EASL+Recommendations+on+Treatment+of+Hepatitis+C+2015&doi=10.1016%2Fj.jhep.2015.03.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2015.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2015.03.025%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DEASL%2520Recommendations%2520on%2520Treatment%2520of%2520Hepatitis%2520C%25202015%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D63%26spage%3D199%26epage%3D236%26doi%3D10.1016%2Fj.jhep.2015.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Poveda, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyles, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedreira, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro-Iglesias, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cachay, E.</span><span> </span><span class="NLM_article-title">Update on hepatitis C virus resistance to direct-acting antiviral agents</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">191</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2014.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1016%2Fj.antiviral.2014.05.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2014&pages=181-191&author=E.+Povedaauthor=D.+L.+Wylesauthor=A.+Menaauthor=J.+D.+Pedreiraauthor=A.+Castro-Iglesiasauthor=E.+Cachay&title=Update+on+hepatitis+C+virus+resistance+to+direct-acting+antiviral+agents&doi=10.1016%2Fj.antiviral.2014.05.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DPoveda%26aufirst%3DE.%26aulast%3DWyles%26aufirst%3DD.%2BL.%26aulast%3DMena%26aufirst%3DA.%26aulast%3DPedreira%26aufirst%3DJ.%2BD.%26aulast%3DCastro-Iglesias%26aufirst%3DA.%26aulast%3DCachay%26aufirst%3DE.%26atitle%3DUpdate%2520on%2520hepatitis%2520C%2520virus%2520resistance%2520to%2520direct-acting%2520antiviral%2520agents%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D108%26spage%3D181%26epage%3D191%26doi%3D10.1016%2Fj.antiviral.2014.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Wyles, D. L.</span><span> </span><span class="NLM_article-title">Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection</span> <span class="citation_source-journal">Top. Antiviral Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=23154254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A280%3ADC%252BC3s7js1Wrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=139-145&author=D.+L.+Wyles&title=Beyond+telaprevir+and+boceprevir%3A+resistance+and+new+agents+for+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection</span></div><div class="casAuthors">Wyles David L</div><div class="citationInfo"><span class="NLM_cas:title">Topics in antiviral medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">139-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The addition of the hepatitis C virus (HCV) protease inhibitors telaprevir and boceprevir to peginterferon alfa with ribavirin therapy has increased cure rates in HCV infection.  Numerous other direct-acting antivirals (DAAs) are in advanced stages of development, including next-generation protease inhibitors, nonstructural protein (NS) 5A inhibitors, and nonnucleoside and nucleos(t)ide NS5B polymerase inhibitors.  The classes have different potencies, different resistance mutation profiles, and different barriers to the emergence of resistance.  A comprehensive table of resistance mutations for classes of DAAs is presented.  Numerous combinations of DAAs with or without ribavirin have been evaluated in early studies of interferon alfa-free regimens, with results indicating that cure is indeed possible with such therapy and suggesting that identification of regimens that could produce cure in the majority of patients may occur within the foreseeable future.  This article summarizes a presentation by David L.  Wyles, MD, at the IAS-USA live continuing medical education activity held in New York in June 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0UHQu1DLNKQpJitSxOdIlfW6udTcc2eZc6hotqoMXVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7js1Wrtw%253D%253D&md5=6316bc6277cce8b176c313bb8d23c65b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWyles%26aufirst%3DD.%2BL.%26atitle%3DBeyond%2520telaprevir%2520and%2520boceprevir%253A%2520resistance%2520and%2520new%2520agents%2520for%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DTop.%2520Antiviral%2520Med.%26date%3D2012%26volume%3D20%26spage%3D139%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Pawlotsky, J. M.</span><span> </span><span class="NLM_article-title">Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1742</span><span class="NLM_x">–</span> <span class="NLM_lpage">1751</span><span class="refDoi"> DOI: 10.1002/hep.24262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fhep.24262" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2011&pages=1742-1751&author=J.+M.+Pawlotsky&title=Treatment+failure+and+resistance+with+direct-acting+antiviral+drugs+against+hepatitis+C+virus&doi=10.1002%2Fhep.24262"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fhep.24262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24262%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.%2BM.%26atitle%3DTreatment%2520failure%2520and%2520resistance%2520with%2520direct-acting%2520antiviral%2520drugs%2520against%2520hepatitis%2520C%2520virus%26jtitle%3DHepatology%26date%3D2011%26volume%3D53%26spage%3D1742%26epage%3D1751%26doi%3D10.1002%2Fhep.24262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Xiao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fofana, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heydmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soulier, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habersetzer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doffoel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeisel, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumert, T. F.</span><span> </span><span class="NLM_article-title">Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1004128</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1004128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1371%2Fjournal.ppat.1004128" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=e1004128&author=F.+Xiaoauthor=I.+Fofanaauthor=L.+Heydmannauthor=H.+Barthauthor=E.+Soulierauthor=F.+Habersetzerauthor=M.+Doffoelauthor=J.+Bukhauthor=A.+H.+Patelauthor=M.+B.+Zeiselauthor=T.+F.+Baumert&title=Hepatitis+C+virus+cell-cell+transmission+and+resistance+to+direct-acting+antiviral+agents&doi=10.1371%2Fjournal.ppat.1004128"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1004128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1004128%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DFofana%26aufirst%3DI.%26aulast%3DHeydmann%26aufirst%3DL.%26aulast%3DBarth%26aufirst%3DH.%26aulast%3DSoulier%26aufirst%3DE.%26aulast%3DHabersetzer%26aufirst%3DF.%26aulast%3DDoffoel%26aufirst%3DM.%26aulast%3DBukh%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DA.%2BH.%26aulast%3DZeisel%26aufirst%3DM.%2BB.%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26atitle%3DHepatitis%2520C%2520virus%2520cell-cell%2520transmission%2520and%2520resistance%2520to%2520direct-acting%2520antiviral%2520agents%26jtitle%3DPLoS%2520Pathog.%26date%3D2014%26volume%3D10%26spage%3De1004128%26doi%3D10.1371%2Fjournal.ppat.1004128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Aissa Larousse, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trimoulet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recordon Pinson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tauzin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzouz, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben Mami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheikh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Triki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleury, H.</span><span> </span><span class="NLM_article-title">Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naive patients infected with HCV genotype 1 in Tunisia</span> <span class="citation_source-journal">Virol. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="refDoi"> DOI: 10.1186/s12985-015-0318-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1186%2Fs12985-015-0318-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=26047611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A280%3ADC%252BC2MbgslOisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=84&author=J.+Aissa+Larousseauthor=P.+Trimouletauthor=P.+Recordon+Pinsonauthor=B.+Tauzinauthor=M.+M.+Azzouzauthor=N.+Ben+Mamiauthor=I.+Cheikhauthor=H.+Trikiauthor=H.+Fleury&title=Prevalence+of+hepatitis+C+virus+%28HCV%29+variants+resistant+to+NS5A+inhibitors+in+naive+patients+infected+with+HCV+genotype+1+in+Tunisia&doi=10.1186%2Fs12985-015-0318-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naive patients infected with HCV genotype 1 in Tunisia</span></div><div class="casAuthors">Aissa Larousse Jameleddine; Triki Henda; Aissa Larousse Jameleddine; Trimoulet Pascale; Recordon Pinson Patricia; Fleury Herve; Aissa Larousse Jameleddine; Trimoulet Pascale; Recordon Pinson Patricia; Tauzin Brigitte; Fleury Herve; Azzouz Mohamed Mssadak; Ben Mami Nabyl; Cheikh Imed</div><div class="citationInfo"><span class="NLM_cas:title">Virology journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Hepatitis C virus (HCV) non-structural protein 5A (NS5A) inhibitors have been recently developed to inhibit NS5A activities and have been approved for the treatment of HCV infection.  However the drawback of these direct acting antivirals (DAAs) is the emergence of resistance mutations.  The prevalence of such mutations conferring resistance to HCV-NS5A inhibitors before treatment has not been investigated so far in the Tunisian population.  The aim of this study was to detect HCV variants resistant to HCV-NS5A inhibitors in hepatitis C patients infected with HCV genotype 1 before any treatment with NS5A inhibitors.  METHODS:  Amplification and direct sequencing of the HCV NS5A region was carried out on 112 samples from 149 untreated patients.  RESULTS:  In genotype 1a strains, amino acid substitutions conferring resistance to NS5A inhibitors (M28V) were detected in 1/7 (14.2 %) HCV NS5A sequences analyzed.  In genotype 1b, resistance mutations in the NS5A region (R30Q; L31M; P58S and Y93H) were observed in 17/105 (16.2 %) HCV NS5A sequences analyzed.  R30Q and Y93H (n = 6; 5.7 %) predominated over P58S (n = 4; 3.8 %) and L31M (n = 3; 2.8 %).  CONCLUSIONS:  Mutations conferring resistance to HCV NS5A inhibitors are frequent in treatment-naive Tunisian patients infected with HCV genotype 1b.  Their influence in the context of DAA therapies has not been fully investigated and should be taken into consideration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ5jx6gB5Y60X6CEoQgWY10fW6udTcc2eZnS596Rjx0aLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbgslOisg%253D%253D&md5=f5f24d39f50817a3cacb1b0f68073895</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2Fs12985-015-0318-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12985-015-0318-0%26sid%3Dliteratum%253Aachs%26aulast%3DAissa%2BLarousse%26aufirst%3DJ.%26aulast%3DTrimoulet%26aufirst%3DP.%26aulast%3DRecordon%2BPinson%26aufirst%3DP.%26aulast%3DTauzin%26aufirst%3DB.%26aulast%3DAzzouz%26aufirst%3DM.%2BM.%26aulast%3DBen%2BMami%26aufirst%3DN.%26aulast%3DCheikh%26aufirst%3DI.%26aulast%3DTriki%26aufirst%3DH.%26aulast%3DFleury%26aufirst%3DH.%26atitle%3DPrevalence%2520of%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%2520variants%2520resistant%2520to%2520NS5A%2520inhibitors%2520in%2520naive%2520patients%2520infected%2520with%2520HCV%2520genotype%25201%2520in%2520Tunisia%26jtitle%3DVirol.%2520J.%26date%3D2015%26volume%3D12%26spage%3D84%26doi%3D10.1186%2Fs12985-015-0318-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Tong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Pogam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piso, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baronas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">So, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klumpp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Najera, I.</span><span> </span><span class="NLM_article-title">In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir</span> <span class="citation_source-journal">J. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">209</span><span class="NLM_x">, </span> <span class="NLM_fpage">668</span><span class="NLM_x">–</span> <span class="NLM_lpage">675</span><span class="refDoi"> DOI: 10.1093/infdis/jit562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1093%2Finfdis%2Fjit562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=24154738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC2cXis1Cjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2014&pages=668-675&author=X.+Tongauthor=S.+Le+Pogamauthor=L.+Liauthor=K.+Hainesauthor=K.+Pisoauthor=V.+Baronasauthor=J.+M.+Yanauthor=S.+S.+Soauthor=K.+Klumppauthor=I.+Najera&title=In+vivo+emergence+of+a+novel+mutant+L159F%2FL320F+in+the+NS5B+polymerase+confers+low-level+resistance+to+the+HCV+polymerase+inhibitors+mericitabine+and+sofosbuvir&doi=10.1093%2Finfdis%2Fjit562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir</span></div><div class="casAuthors">Tong, Xiao; Le Pogam, Sophie; Li, Lewyn; Haines, Kristin; Piso, Katherine; Baronas, Victoria; Yan, Jun-Mei; So, Sung-Sau; Klumpp, Klaus; Najera, Isabel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">668-675</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background. Resistance to mericitabine (prodrug of HCV NS5B polymerase inhibitor PSI-6130) is rare and conferred by the NS5B S282T mutation.  Methods. Serum HCV RNA from patients who experienced viral breakthrough, partial response, or nonresponse in 2 clin. trials in which patients received mericitabine plus peginterferon alfa-2a (40KD)/ribavirin were analyzed by population and clonal sequence anal. as well as phenotypic assay for assessment of in vivo mericitabine resistance.  Results. Among 405 patients treated with mericitabine plus peginterferon alfa-2a/ribavirin in PROPEL and JUMP-C, virol. breakthrough or nonresponse were not obsd.; 12 patients experienced a partial response.  The NS5B S282T resistance mutation was not obsd. in any patient.  A no. of treatment-assocd. NS5B changes were obsd. and characterized.  A novel double mutant (L159F/L320F) with impaired replication capacity was detected in one HCV genotype 1b-infected patient.  Introduction of double mutant L159F/L320F into genotype 1a (H77) and 1b (Con-1) replicons, resp., increased the EC50 for mericitabine by 3.1- and 5.5-fold and the EC90 by 3.1- and 8.9-fold.  The double mutant also decreased susceptibility to sofosbuvir (GS-7977) and GS-938 but not setrobuvir, relative to wild-type.  Conclusions. A novel and replication-deficient double mutation (L159F/L320F) confers low-level resistance to mericitabine and cross-resistance to both sofosbuvir and GS-938.  Clin. Trials Registration NCT00869661, NCT01057667.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreimBZ-G2tC7Vg90H21EOLACvtfcHk0lj-18ehnN0NTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXis1Cjsrg%253D&md5=f652e8cb6c86966a37573245e66793fd</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjit562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjit562%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DX.%26aulast%3DLe%2BPogam%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DHaines%26aufirst%3DK.%26aulast%3DPiso%26aufirst%3DK.%26aulast%3DBaronas%26aufirst%3DV.%26aulast%3DYan%26aufirst%3DJ.%2BM.%26aulast%3DSo%26aufirst%3DS.%2BS.%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DNajera%26aufirst%3DI.%26atitle%3DIn%2520vivo%2520emergence%2520of%2520a%2520novel%2520mutant%2520L159F%252FL320F%2520in%2520the%2520NS5B%2520polymerase%2520confers%2520low-level%2520resistance%2520to%2520the%2520HCV%2520polymerase%2520inhibitors%2520mericitabine%2520and%2520sofosbuvir%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2014%26volume%3D209%26spage%3D668%26epage%3D675%26doi%3D10.1093%2Finfdis%2Fjit562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Shi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiraga, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aikata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tateno-Mukaidani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshizato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inaba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span> </span><span class="NLM_article-title">Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1055</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1136/gutjnl-2012-302600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1136%2Fgutjnl-2012-302600" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=1055-1061&author=N.+Shiauthor=N.+Hiragaauthor=M.+Imamuraauthor=C.+N.+Hayesauthor=Y.+Zhangauthor=K.+Kosakaauthor=A.+Okazakiauthor=E.+Murakamiauthor=M.+Tsugeauthor=H.+Abeauthor=H.+Aikataauthor=S.+Takahashiauthor=H.+Ochiauthor=C.+Tateno-Mukaidaniauthor=K.+Yoshizatoauthor=H.+Matsuiauthor=A.+Kanaiauthor=T.+Inabaauthor=F.+McPheeauthor=M.+Gaoauthor=K.+Chayama&title=Combination+therapies+with+NS5A%2C+NS3+and+NS5B+inhibitors+on+different+genotypes+of+hepatitis+C+virus+in+human+hepatocyte+chimeric+mice&doi=10.1136%2Fgutjnl-2012-302600"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2012-302600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2012-302600%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DN.%26aulast%3DHiraga%26aufirst%3DN.%26aulast%3DImamura%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DC.%2BN.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKosaka%26aufirst%3DK.%26aulast%3DOkazaki%26aufirst%3DA.%26aulast%3DMurakami%26aufirst%3DE.%26aulast%3DTsuge%26aufirst%3DM.%26aulast%3DAbe%26aufirst%3DH.%26aulast%3DAikata%26aufirst%3DH.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DOchi%26aufirst%3DH.%26aulast%3DTateno-Mukaidani%26aufirst%3DC.%26aulast%3DYoshizato%26aufirst%3DK.%26aulast%3DMatsui%26aufirst%3DH.%26aulast%3DKanai%26aufirst%3DA.%26aulast%3DInaba%26aufirst%3DT.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DChayama%26aufirst%3DK.%26atitle%3DCombination%2520therapies%2520with%2520NS5A%252C%2520NS3%2520and%2520NS5B%2520inhibitors%2520on%2520different%2520genotypes%2520of%2520hepatitis%2520C%2520virus%2520in%2520human%2520hepatocyte%2520chimeric%2520mice%26jtitle%3DGut%26date%3D2013%26volume%3D62%26spage%3D1055%26epage%3D1061%26doi%3D10.1136%2Fgutjnl-2012-302600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Watashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hijikata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosaka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaji, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimotohno, K.</span><span> </span><span class="NLM_article-title">Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1282</span><span class="NLM_x">–</span> <span class="NLM_lpage">1288</span><span class="refDoi"> DOI: 10.1053/jhep.2003.50449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1053%2Fjhep.2003.50449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=14578868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsVOnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=1282-1288&author=K.+Watashiauthor=M.+Hijikataauthor=M.+Hosakaauthor=M.+Yamajiauthor=K.+Shimotohno&title=Cyclosporin+A+suppresses+replication+of+hepatitis+C+virus+genome+in+cultured+hepatocytes&doi=10.1053%2Fjhep.2003.50449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes</span></div><div class="casAuthors">Watashi, Koichi; Hijikata, Makoto; Hosaka, Masahiro; Yamaji, Masashi; Shimotohno, Kunitada</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1282-1288</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">Persistent infection of hepatitis C virus (HCV) is a major cause of liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.  Searching for a substance with anti-HCV potential, we examd. the effects of a variety of compds. on HCV replication using a HCV subgenomic replicon cell culture system.  Consequently, the immunosuppressant cyclosporin A (CsA) was found to have a suppressive effect on the HCV replicon RNA level and HCV protein expression in these cells.  CsA also inhibited multiplication of the HCV genome in a cultured human hepatocyte cell line infected with HCV using HCV-pos. plasma.  This anti-HCV activity of CsA appeared to be independent of its immunosuppressive function.  In conclusion, our results suggest that CsA may represent a new approach for the development of anti-HCV therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB9pezI0G0OLVg90H21EOLACvtfcHk0lg68Y2fsECh7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsVOnt7o%253D&md5=5c83a94dccdc2cb357d8d7d573a37b0f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1053%2Fjhep.2003.50449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fjhep.2003.50449%26sid%3Dliteratum%253Aachs%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DHijikata%26aufirst%3DM.%26aulast%3DHosaka%26aufirst%3DM.%26aulast%3DYamaji%26aufirst%3DM.%26aulast%3DShimotohno%26aufirst%3DK.%26atitle%3DCyclosporin%2520A%2520suppresses%2520replication%2520of%2520hepatitis%2520C%2520virus%2520genome%2520in%2520cultured%2520hepatocytes%26jtitle%3DHepatology%26date%3D2003%26volume%3D38%26spage%3D1282%26epage%3D1288%26doi%3D10.1053%2Fjhep.2003.50449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Chatterji, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobardt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selvarajah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vuagniaux, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallay, P.</span><span> </span><span class="NLM_article-title">The isomerase active site of cyclophilin A is critical for hepatitis C virus replication</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">16998</span><span class="NLM_x">–</span> <span class="NLM_lpage">17005</span><span class="refDoi"> DOI: 10.1074/jbc.M109.007625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1074%2Fjbc.M109.007625" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=16998-17005&author=U.+Chatterjiauthor=M.+Bobardtauthor=S.+Selvarajahauthor=F.+Yangauthor=H.+Tangauthor=N.+Sakamotoauthor=G.+Vuagniauxauthor=T.+Parkinsonauthor=P.+Gallay&title=The+isomerase+active+site+of+cyclophilin+A+is+critical+for+hepatitis+C+virus+replication&doi=10.1074%2Fjbc.M109.007625"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.007625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.007625%26sid%3Dliteratum%253Aachs%26aulast%3DChatterji%26aufirst%3DU.%26aulast%3DBobardt%26aufirst%3DM.%26aulast%3DSelvarajah%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DSakamoto%26aufirst%3DN.%26aulast%3DVuagniaux%26aufirst%3DG.%26aulast%3DParkinson%26aufirst%3DT.%26aulast%3DGallay%26aufirst%3DP.%26atitle%3DThe%2520isomerase%2520active%2520site%2520of%2520cyclophilin%2520A%2520is%2520critical%2520for%2520hepatitis%2520C%2520virus%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D16998%26epage%3D17005%26doi%3D10.1074%2Fjbc.M109.007625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Kaul, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pertel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zayas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luban, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1000546</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1000546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1371%2Fjournal.ppat.1000546" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=e1000546&author=A.+Kaulauthor=S.+Staufferauthor=C.+Bergerauthor=T.+Pertelauthor=J.+Schmittauthor=S.+Kallisauthor=M.+Zayasauthor=V.+Lohmannauthor=J.+Lubanauthor=R.+Bartenschlager&title=Essential+role+of+cyclophilin+A+for+hepatitis+C+virus+replication+and+virus+production+and+possible+link+to+polyprotein+cleavage+kinetics&doi=10.1371%2Fjournal.ppat.1000546"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1000546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1000546%26sid%3Dliteratum%253Aachs%26aulast%3DKaul%26aufirst%3DA.%26aulast%3DStauffer%26aufirst%3DS.%26aulast%3DBerger%26aufirst%3DC.%26aulast%3DPertel%26aufirst%3DT.%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DKallis%26aufirst%3DS.%26aulast%3DZayas%26aufirst%3DM.%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DLuban%26aufirst%3DJ.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DEssential%2520role%2520of%2520cyclophilin%2520A%2520for%2520hepatitis%2520C%2520virus%2520replication%2520and%2520virus%2520production%2520and%2520possible%2520link%2520to%2520polyprotein%2520cleavage%2520kinetics%26jtitle%3DPLoS%2520Pathog.%26date%3D2009%26volume%3D5%26spage%3De1000546%26doi%3D10.1371%2Fjournal.ppat.1000546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Liu, J. O.</span><span> </span><span class="NLM_article-title">Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">198</span><span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00756.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1111%2Fj.1600-065X.2008.00756.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=19290928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=184-198&author=J.+O.+Liu&title=Calmodulin-dependent+phosphatase%2C+kinases%2C+and+transcriptional+corepressors+involved+in+T-cell+activation&doi=10.1111%2Fj.1600-065X.2008.00756.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation</span></div><div class="casAuthors">Liu, Jun O.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">184-198</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The second messenger calcium plays an essential role in mediating the T-cell receptor (TCR) signaling pathway leading to cytokine prodn. and T-cell clonal expansion.  The immunosuppressive drugs cyclosporine A and FK506 have served both as therapeutic agents and as mol. probes for unraveling the protein phosphatase calcineurin as a rate-limiting enzyme involved in the transmission of calcium signal from the cytosol into the nucleus to reprogram gene expression.  The use of mouse knockout models has helped to verify and further elucidate the functions of different isoforms of calcineurin in both helper T-cell activation and thymocyte development.  In addn. to calcineurin, three other classes of calmodulin-binding proteins have also been shown to play important roles in calcium signaling in T cells.  Thus, Cabin 1 and class II histone deacetylases have been found to constitute a novel calcium-signaling module in conjunction with the transcription factor myocyte enhance factor family and the transcriptional coactivator p300 to suppress and activate cytokine gene transcription in a calcium-dependent manner.  The calmodulin-dependent protein kinases II and IV were also shown to play neg. and pos. regulatory functions, resp., in TCR-mediated cytokine prodn.  The crosstalks among these and other signal transducers in T cells form an extensive nonlinear signaling network that dictates the final outcome of the TCR signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2geWtFLdom7Vg90H21EOLACvtfcHk0lg68Y2fsECh7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rF&md5=c2647ba7175f0e9d556b6902c96b4e04</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00756.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00756.x%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26atitle%3DCalmodulin-dependent%2520phosphatase%252C%2520kinases%252C%2520and%2520transcriptional%2520corepressors%2520involved%2520in%2520T-cell%2520activation%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D184%26epage%3D198%26doi%3D10.1111%2Fj.1600-065X.2008.00756.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Goto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hishiki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hijikata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimotohno, K.</span><span> </span><span class="NLM_article-title">Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">884</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2006.03.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1016%2Fj.bbrc.2006.03.059" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2006&pages=879-884&author=K.+Gotoauthor=K.+Watashiauthor=T.+Murataauthor=T.+Hishikiauthor=M.+Hijikataauthor=K.+Shimotohno&title=Evaluation+of+the+anti-hepatitis+C+virus+effects+of+cyclophilin+inhibitors%2C+cyclosporin+A%2C+and+NIM811&doi=10.1016%2Fj.bbrc.2006.03.059"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2006.03.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2006.03.059%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DMurata%26aufirst%3DT.%26aulast%3DHishiki%26aufirst%3DT.%26aulast%3DHijikata%26aufirst%3DM.%26aulast%3DShimotohno%26aufirst%3DK.%26atitle%3DEvaluation%2520of%2520the%2520anti-hepatitis%2520C%2520virus%2520effects%2520of%2520cyclophilin%2520inhibitors%252C%2520cyclosporin%2520A%252C%2520and%2520NIM811%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2006%26volume%3D343%26spage%3D879%26epage%3D884%26doi%3D10.1016%2Fj.bbrc.2006.03.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Hopkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scorneaux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wring, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeill, Y.</span><span> </span><span class="NLM_article-title">SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">672</span><span class="refDoi"> DOI: 10.1128/AAC.00660-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1128%2FAAC.00660-09" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=660-672&author=S.+Hopkinsauthor=B.+Scorneauxauthor=Z.+Huangauthor=M.+G.+Murrayauthor=S.+Wringauthor=C.+Smitleyauthor=R.+Harrisauthor=F.+Erdmannauthor=G.+Fischerauthor=Y.+Ribeill&title=SCY-635%2C+a+novel+nonimmunosuppressive+analog+of+cyclosporine+that+exhibits+potent+inhibition+of+hepatitis+C+virus+RNA+replication+in+vitro&doi=10.1128%2FAAC.00660-09"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1128%2FAAC.00660-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00660-09%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DS.%26aulast%3DScorneaux%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DMurray%26aufirst%3DM.%2BG.%26aulast%3DWring%26aufirst%3DS.%26aulast%3DSmitley%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DR.%26aulast%3DErdmann%26aufirst%3DF.%26aulast%3DFischer%26aufirst%3DG.%26aulast%3DRibeill%26aufirst%3DY.%26atitle%3DSCY-635%252C%2520a%2520novel%2520nonimmunosuppressive%2520analog%2520of%2520cyclosporine%2520that%2520exhibits%2520potent%2520inhibition%2520of%2520hepatitis%2520C%2520virus%2520RNA%2520replication%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D660%26epage%3D672%26doi%3D10.1128%2FAAC.00660-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Paeshuyse, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaul, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Clercq, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenwirth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumont, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scalfaro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neyts, J.</span><span> </span><span class="NLM_article-title">The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">770</span><span class="refDoi"> DOI: 10.1002/hep.21102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fhep.21102" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2006&pages=761-770&author=J.+Paeshuyseauthor=A.+Kaulauthor=E.+De+Clercqauthor=B.+Rosenwirthauthor=J.+M.+Dumontauthor=P.+Scalfaroauthor=R.+Bartenschlagerauthor=J.+Neyts&title=The+non-immunosuppressive+cyclosporin+DEBIO-025+is+a+potent+inhibitor+of+hepatitis+C+virus+replication+in+vitro&doi=10.1002%2Fhep.21102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fhep.21102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.21102%26sid%3Dliteratum%253Aachs%26aulast%3DPaeshuyse%26aufirst%3DJ.%26aulast%3DKaul%26aufirst%3DA.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DRosenwirth%26aufirst%3DB.%26aulast%3DDumont%26aufirst%3DJ.%2BM.%26aulast%3DScalfaro%26aufirst%3DP.%26aulast%3DBartenschlager%26aufirst%3DR.%26aulast%3DNeyts%26aufirst%3DJ.%26atitle%3DThe%2520non-immunosuppressive%2520cyclosporin%2520DEBIO-025%2520is%2520a%2520potent%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520replication%2520in%2520vitro%26jtitle%3DHepatology%26date%3D2006%26volume%3D43%26spage%3D761%26epage%3D770%26doi%3D10.1002%2Fhep.21102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Zydowsky, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etzkorn, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stolz, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, C. T.</span><span> </span><span class="NLM_article-title">Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1092</span><span class="NLM_x">–</span> <span class="NLM_lpage">1099</span><span class="refDoi"> DOI: 10.1002/pro.5560010903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fpro.5560010903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1338979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADyaK3sXhs1Cisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1992&pages=1092-1099&author=L.+D.+Zydowskyauthor=F.+A.+Etzkornauthor=H.+Y.+Changauthor=S.+B.+Fergusonauthor=L.+A.+Stolzauthor=S.+I.+Hoauthor=C.+T.+Walsh&title=Active+site+mutants+of+human+cyclophilin+A+separate+peptidyl-prolyl+isomerase+activity+from+cyclosporin+A+binding+and+calcineurin+inhibition&doi=10.1002%2Fpro.5560010903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition</span></div><div class="casAuthors">Zydowsky, Lynne D.; Etzkorn, Felicia A.; Chang, Howard Y.; Ferguson, Stephen B.; Stolz, Lesley A.; Ho, Susanna I.; Walsh, Christopher T.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1092-9</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    </div><div class="casAbstract">Based on recent x-ray structural information, 6 site-directed mutants of human cyclophilin A (hCyPA) involving residues in the putative active site (His-54, Arg-55, Phe-60, Gln-111, Phe-113, and His-126) were constructed, overexpressed, and purified from Escherichia coli to homogeneity.  Mutant proteins W121A, H54Q, R55A, F60A, Q111A, F113A, and H126Q were assayed for peptidylprolyl cis-trans-isomerase (PPIase) activity, their ability to bind the immunosuppressive drug, cyclosporin A (CsA), and phosphoprotein phosphatase 2B (calcineurin) inhibition in the presence of CsA.  The results indicated that H54Q, Q111A, F113A, and W121A retained 3-15% of the catalytic efficiency (kcat/Km) of wild-type recombinant hCyPA.  The remaining 3 mutants (R55A, F60A, and H126Q) each retained <1% of the wild-type catalytic efficiency, indicating the participation of these residues in PPIase catalysis.  Each of the mutants bound to a CsA affinity matrix.  Mutants R55A, F60A, F113A, and H126Q inhibited calcineurin in the presence of CsA, whereas W121A did not.  Although CsA is a competitive inhibitor of PPIase activity, was able to complex with enzymically inactive cyclophilins and inhibit the phosphatase activity of calcineurin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm1wQYRf-R9rVg90H21EOLACvtfcHk0lgWxkMa8xK4Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhs1Cisrc%253D&md5=a68ce94f777c5aec962caefc083d7b8c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fpro.5560010903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.5560010903%26sid%3Dliteratum%253Aachs%26aulast%3DZydowsky%26aufirst%3DL.%2BD.%26aulast%3DEtzkorn%26aufirst%3DF.%2BA.%26aulast%3DChang%26aufirst%3DH.%2BY.%26aulast%3DFerguson%26aufirst%3DS.%2BB.%26aulast%3DStolz%26aufirst%3DL.%2BA.%26aulast%3DHo%26aufirst%3DS.%2BI.%26aulast%3DWalsh%26aufirst%3DC.%2BT.%26atitle%3DActive%2520site%2520mutants%2520of%2520human%2520cyclophilin%2520A%2520separate%2520peptidyl-prolyl%2520isomerase%2520activity%2520from%2520cyclosporin%2520A%2520binding%2520and%2520calcineurin%2520inhibition%26jtitle%3DProtein%2520Sci.%26date%3D1992%26volume%3D1%26spage%3D1092%26epage%3D1099%26doi%3D10.1002%2Fpro.5560010903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Davis, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campagna-Slater, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finerty, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paramanathan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tempel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouyang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenmesser, E. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhe-Paganon, S.</span><span> </span><span class="NLM_article-title">Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases</span> <span class="citation_source-journal">PLoS Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1000439</span><span class="refDoi"> DOI: 10.1371/journal.pbio.1000439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1371%2Fjournal.pbio.1000439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=20676357" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=e1000439&author=T.+L.+Davisauthor=J.+R.+Walkerauthor=V.+Campagna-Slaterauthor=P.+J.+Finertyauthor=R.+Paramanathanauthor=G.+Bernsteinauthor=F.+MacKenzieauthor=W.+Tempelauthor=H.+Ouyangauthor=W.+H.+Leeauthor=E.+Z.+Eisenmesserauthor=S.+Dhe-Paganon&title=Structural+and+biochemical+characterization+of+the+human+cyclophilin+family+of+peptidyl-prolyl+isomerases&doi=10.1371%2Fjournal.pbio.1000439"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1000439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1000439%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DT.%2BL.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DCampagna-Slater%26aufirst%3DV.%26aulast%3DFinerty%26aufirst%3DP.%2BJ.%26aulast%3DParamanathan%26aufirst%3DR.%26aulast%3DBernstein%26aufirst%3DG.%26aulast%3DMacKenzie%26aufirst%3DF.%26aulast%3DTempel%26aufirst%3DW.%26aulast%3DOuyang%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DW.%2BH.%26aulast%3DEisenmesser%26aufirst%3DE.%2BZ.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26atitle%3DStructural%2520and%2520biochemical%2520characterization%2520of%2520the%2520human%2520cyclophilin%2520family%2520of%2520peptidyl-prolyl%2520isomerases%26jtitle%3DPLoS%2520Biol.%26date%3D2010%26volume%3D8%26spage%3De1000439%26doi%3D10.1371%2Fjournal.pbio.1000439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Mikol, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pflugl, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walkinshaw, M. D.</span><span> </span><span class="NLM_article-title">X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex at 2.1 A resolution</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">234</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">–</span> <span class="NLM_lpage">1130</span><span class="refDoi"> DOI: 10.1006/jmbi.1993.1664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1006%2Fjmbi.1993.1664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=8263916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADyaK2cXmvVyktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=1993&pages=1119-1130&author=V.+Mikolauthor=J.+Kallenauthor=G.+Pfluglauthor=M.+D.+Walkinshaw&title=X-ray+structure+of+a+monomeric+cyclophilin+A-cyclosporin+A+crystal+complex+at+2.1+A+resolution&doi=10.1006%2Fjmbi.1993.1664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex at 2.1 Å resolution</span></div><div class="casAuthors">Mikol, Vincent; Kallen, Joerg; Pfluegl, Gaston; Walkinshaw, Malcolm D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1119-30</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    </div><div class="casAbstract">The crystal structure of a complex between recombinant human cyclophilin A (Cyp) and cyclosporin A (CsA) has been detd. from a novel orthorhombic crystal form that contains only one monomer of complex per asym. unit rather than five in the previously detd. tetragonal structure.  The structure has been refined at 2.1 Å resoln. to a crystallog. R-factor of 16.7%.  The conformation of Cyp is practically unchanged with respect to the tetragonal form.  A certain no. of previously undefined side-chains have been located in the electron d. and a very detailed picture of the ordered solvent structure has been obtained.  The interactions between CsA and Cyp are conserved.  A network of the possibly conserved, water-mediated contacts is described.  The structure of CsA in the monomeric complex is similar to that of the decameric complex, but shows a few small differences in the so-called effector domain of CsA, probably due to differences in crystal environment.  The fact that this monomeric crystal form can be obtained shows that the formation of pentamer or decamer complexes is not a generally obsd. phenomenon and is not a prerequisite for biol. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqShxtMu0I3LLVg90H21EOLACvtfcHk0lhFxxwd7Z5a1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvVyktw%253D%253D&md5=fd63ff4984fd51b3b45c97a07ca80b75</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1993.1664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1993.1664%26sid%3Dliteratum%253Aachs%26aulast%3DMikol%26aufirst%3DV.%26aulast%3DKallen%26aufirst%3DJ.%26aulast%3DPflugl%26aufirst%3DG.%26aulast%3DWalkinshaw%26aufirst%3DM.%2BD.%26atitle%3DX-ray%2520structure%2520of%2520a%2520monomeric%2520cyclophilin%2520A-cyclosporin%2520A%2520crystal%2520complex%2520at%25202.1%2520A%2520resolution%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1993%26volume%3D234%26spage%3D1119%26epage%3D1130%26doi%3D10.1006%2Fjmbi.1993.1664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Ngouansavanh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span> </span><span class="NLM_article-title">Alcohols in isonitrile-based multicomponent reaction: Passerini reaction of alcohols in the presence of o-iodoxybenzoic acid</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3495</span><span class="NLM_x">–</span> <span class="NLM_lpage">3497</span><span class="refDoi"> DOI: 10.1002/anie.200600588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fanie.200600588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsVKjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=3495-3497&author=T.+Ngouansavanhauthor=J.+Zhu&title=Alcohols+in+isonitrile-based+multicomponent+reaction%3A+Passerini+reaction+of+alcohols+in+the+presence+of+o-iodoxybenzoic+acid&doi=10.1002%2Fanie.200600588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Alcohols in isonitrile-based multicomponent reaction: Passerini reaction of alcohols in the presence of o-iodoxybenzoic acid</span></div><div class="casAuthors">Ngouansavanh, Tifelle; Zhu, Jieping</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3495-3497</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An alc. instead of an aldehyde was found to be an effective reaction partner in the three-component Passerini reaction (P-3CR) in the presence of o-iodoxybenzoic acid (IBX).  Thus, by simply heating a soln. of an alc. R1CH2OH [R1 = n-Pr, Ph, PhCH2, AcO(CH2)5, PhCH2OCONHCH2, (R)-AcNHCH(CH2Ph), etc.], a carboxylic acid R2CO2H [R2 = Me, Ph, (S)-MeOCHPh, etc.], an isonitrile R3NC (R3 = Me3C, MeO2CCH2, cyclohexyl, PhCH2), and IBX at 40°C, an oxidn./P-3CR sequence occurred smoothly to afford the corresponding α-acyloxy carboxamides R2CO2CHR1CONHR3 in good to excellent yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3YQSdopRvPLVg90H21EOLACvtfcHk0lhFxxwd7Z5a1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsVKjsbg%253D&md5=980ba4cd01faccb27f9d385253c1eb1c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fanie.200600588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200600588%26sid%3Dliteratum%253Aachs%26aulast%3DNgouansavanh%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DJ.%26atitle%3DAlcohols%2520in%2520isonitrile-based%2520multicomponent%2520reaction%253A%2520Passerini%2520reaction%2520of%2520alcohols%2520in%2520the%2520presence%2520of%2520o-iodoxybenzoic%2520acid%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2006%26volume%3D45%26spage%3D3495%26epage%3D3497%26doi%3D10.1002%2Fanie.200600588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Domling, A.</span><span> </span><span class="NLM_article-title">Recent developments in isocyanide based multicomponent reactions in applied chemistry</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span><span class="refDoi"> DOI: 10.1021/cr0505728</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0505728" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FhslyntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2006&pages=17-89&author=A.+Domling&title=Recent+developments+in+isocyanide+based+multicomponent+reactions+in+applied+chemistry&doi=10.1021%2Fcr0505728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in isocyanide based multicomponent reactions in applied chemistry</span></div><div class="casAuthors">Domling Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Chemical reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-89</span>
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtCMEx7SbgjiM8MEzWGjS9fW6udTcc2eYhGWzYGzUVeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FhslyntA%253D%253D&md5=33b233fa9ca718d7e0e6db6fee49e5fd</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fcr0505728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0505728%26sid%3Dliteratum%253Aachs%26aulast%3DDomling%26aufirst%3DA.%26atitle%3DRecent%2520developments%2520in%2520isocyanide%2520based%2520multicomponent%2520reactions%2520in%2520applied%2520chemistry%26jtitle%3DChem.%2520Rev.%26date%3D2006%26volume%3D106%26spage%3D17%26epage%3D89%26doi%3D10.1021%2Fcr0505728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Borawski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troke, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puyang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibaja, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mickanin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighton-Davies, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornellataracido, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baryza, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tallarico, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joberty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bantscheff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouwmeester, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathy, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Compton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiedmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaither, L. A.</span><span> </span><span class="NLM_article-title">Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">10058</span><span class="NLM_x">–</span> <span class="NLM_lpage">10074</span><span class="refDoi"> DOI: 10.1128/JVI.02418-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1128%2FJVI.02418-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=19605471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFyrurjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2009&pages=10058-10074&author=J.+Borawskiauthor=P.+Trokeauthor=X.+Puyangauthor=V.+Gibajaauthor=S.+Zhaoauthor=C.+Mickaninauthor=J.+Leighton-Daviesauthor=C.+J.+Wilsonauthor=V.+Myerauthor=I.+Cornellataracidoauthor=J.+Baryzaauthor=J.+Tallaricoauthor=G.+Jobertyauthor=M.+Bantscheffauthor=M.+Schirleauthor=T.+Bouwmeesterauthor=J.+E.+Mathyauthor=K.+Linauthor=T.+Comptonauthor=M.+Labowauthor=B.+Wiedmannauthor=L.+A.+Gaither&title=Class+III+phosphatidylinositol+4-kinase+alpha+and+beta+are+novel+host+factor+regulators+of+hepatitis+C+virus+replication&doi=10.1128%2FJVI.02418-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication</span></div><div class="casAuthors">Borawski, Jason; Troke, Philip; Puyang, Xiaoling; Gibaja, Veronica; Zhao, ShanChaun; Mickanin, Craig; Leighton-Davies, Juliet; Wilson, Christopher J.; Myer, Vic; Taracido, Ivan Cornella; Baryza, Jeremy; Tallarico, John; Joberty, Gerard; Bantscheff, Marcus; Schirle, Markus; Bouwmeester, Tewis; Mathy, Joanna E.; Lin, Kai; Compton, Teresa; Labow, Mark; Wiedmann, Brigitte; Gaither, L. Alex</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10058-10074</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Host factor pathways are known to be essential for hepatitis C virus (HCV) infection and replication in human liver cells.  To search for novel host factor proteins required for HCV replication, we screened a subgenomic genotype 1b replicon cell line (Luc-1b) with a kinome and druggable collection of 20,779 siRNAs.  We identified and validated several enzymes required for HCV replication, including class III phosphatidylinositol 4-kinases (PI4KA and PI4KB), carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), and mevalonate (diphospho) decarboxylase.  Knockdown of PI4KA could inhibit the replication and/or HCV RNA levels of the two subgenomic genotype 1b clones (SG-1b and Luc-1b), two subgenomic genotype 1a clones (SG-1a and Luc-1a), JFH-1 genotype 2a infectious virus (JFH1-2a), and the genomic genotype 1a (FL-1a) replicon.  In contrast, PI4KB knockdown inhibited replication and/or HCV RNA levels of Luc-1b, SG-1b, and Luc-1a replicons.  The small mol. inhibitor, PIK93, was found to block subgenomic genotype 1b (Luc-1b), subgenomic genotype 1a (Luc-1a), and genomic genotype 2a (JFH1-2a) infectious virus replication in the nanomolar range.  PIK93 was characterized by using quant. chem. proteomics and in vitro biochem. assays to demonstrate PIK93 is a bone fide PI4KA and PI4KB inhibitor.  Our data demonstrate that genetic or pharmacol. modulation of PI4KA and PI4KB inhibits multiple genotypes of HCV and represents a novel druggable class of therapeutic targets for HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Zjz0O33L9bVg90H21EOLACvtfcHk0lhZ4UyX2iUwag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFyrurjN&md5=f823b4ac8a9efd864fced393cf487c94</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1128%2FJVI.02418-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02418-08%26sid%3Dliteratum%253Aachs%26aulast%3DBorawski%26aufirst%3DJ.%26aulast%3DTroke%26aufirst%3DP.%26aulast%3DPuyang%26aufirst%3DX.%26aulast%3DGibaja%26aufirst%3DV.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DMickanin%26aufirst%3DC.%26aulast%3DLeighton-Davies%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DMyer%26aufirst%3DV.%26aulast%3DCornellataracido%26aufirst%3DI.%26aulast%3DBaryza%26aufirst%3DJ.%26aulast%3DTallarico%26aufirst%3DJ.%26aulast%3DJoberty%26aufirst%3DG.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DSchirle%26aufirst%3DM.%26aulast%3DBouwmeester%26aufirst%3DT.%26aulast%3DMathy%26aufirst%3DJ.%2BE.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DCompton%26aufirst%3DT.%26aulast%3DLabow%26aufirst%3DM.%26aulast%3DWiedmann%26aufirst%3DB.%26aulast%3DGaither%26aufirst%3DL.%2BA.%26atitle%3DClass%2520III%2520phosphatidylinositol%25204-kinase%2520alpha%2520and%2520beta%2520are%2520novel%2520host%2520factor%2520regulators%2520of%2520hepatitis%2520C%2520virus%2520replication%26jtitle%3DJ.%2520Virol.%26date%3D2009%26volume%3D83%26spage%3D10058%26epage%3D10074%26doi%3D10.1128%2FJVI.02418-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span> </span><span class="NLM_article-title">A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication</span> <span class="citation_source-journal">Virus Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">155</span><span class="NLM_x">, </span> <span class="NLM_fpage">406</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span><span class="refDoi"> DOI: 10.1016/j.virusres.2010.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1016%2Fj.virusres.2010.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=21144873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVygug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2011&pages=406-414&author=Y.+Wuauthor=Q.+Liaoauthor=R.+Yangauthor=X.+Chen&title=A+novel+luciferase+and+GFP+dual+reporter+virus+for+rapid+and+convenient+evaluation+of+hepatitis+C+virus+replication&doi=10.1016%2Fj.virusres.2010.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication</span></div><div class="casAuthors">Wu, Yang; Liao, Qingjiao; Yang, Rongge; Chen, Xinwen; Chen, Xulin</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">406-414</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein, we describe the development of a monocistronic dual reporter virus for monitoring hepatitis C virus (HCV) replication.  The recombinant construct encodes for the humanized Renilla luciferase (hRLuc) reporter gene inserted upstream of the viral open reading frame and a green fluorescent protein (GFP) gene inserted into the C-terminus of non-structural protein 5A (NS5A) of the JFH1 viral genome.  The viral RNA replicated efficiently in transfected cells and infectious virions could be produced without obvious attenuation of viral replication.  The viral titer of the dual reporter virus was comparable to that of single reporter viruses.  The expression levels of these two reporter genes correlated well with HCV replication in the presence or absence of antiviral agents.  Moreover, because of the direct visibility of GFP fluorescence and the correlation between GFP pos. cell nos. and hRLuc activity, the optimal time for measuring hRLuc activity was detd.  This novel infectious system is a time saving and cost effective method for studying the interaction between viruses and host cells as well as for screening anti-HCV drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9qp1EawGtcLVg90H21EOLACvtfcHk0lhZ4UyX2iUwag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVygug%253D%253D&md5=4e720e693e9f83adc0433547bf5d3689</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2010.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2010.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLiao%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DA%2520novel%2520luciferase%2520and%2520GFP%2520dual%2520reporter%2520virus%2520for%2520rapid%2520and%2520convenient%2520evaluation%2520of%2520hepatitis%2520C%2520virus%2520replication%26jtitle%3DVirus%2520Res.%26date%3D2011%26volume%3D155%26spage%3D406%26epage%3D414%26doi%3D10.1016%2Fj.virusres.2010.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Jang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Achary, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.</span><span> </span><span class="NLM_article-title">Synthesis and anti-influenza virus activity of 4-oxo- or thioxo-4,5-dihydrofuro[3,4-c]pyridin-3(1H)-ones</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">66</span><span class="NLM_x">–</span> <span class="NLM_lpage">75</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2014.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1016%2Fj.antiviral.2014.04.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2014&pages=66-75&author=Y.+J.+Jangauthor=R.+Acharyauthor=H.+W.+Leeauthor=H.+J.+Leeauthor=C.+K.+Leeauthor=S.+B.+Hanauthor=Y.+S.+Jungauthor=N.+S.+Kangauthor=P.+Kimauthor=M.+Kim&title=Synthesis+and+anti-influenza+virus+activity+of+4-oxo-+or+thioxo-4%2C5-dihydrofuro%5B3%2C4-c%5Dpyridin-3%281H%29-ones&doi=10.1016%2Fj.antiviral.2014.04.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DY.%2BJ.%26aulast%3DAchary%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DH.%2BW.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DC.%2BK.%26aulast%3DHan%26aufirst%3DS.%2BB.%26aulast%3DJung%26aufirst%3DY.%2BS.%26aulast%3DKang%26aufirst%3DN.%2BS.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520anti-influenza%2520virus%2520activity%2520of%25204-oxo-%2520or%2520thioxo-4%252C5-dihydrofuro%255B3%252C4-c%255Dpyridin-3%25281H%2529-ones%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D107%26spage%3D66%26epage%3D75%26doi%3D10.1016%2Fj.antiviral.2014.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Kim, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auh, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, B. C.</span><span> </span><span class="NLM_article-title">beta-propeller phytase hydrolyzes insoluble Ca(2+)-phytate salts and completely abrogates the ability of phytate to chelate metal ions</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">10216</span><span class="NLM_x">–</span> <span class="NLM_lpage">10227</span><span class="refDoi"> DOI: 10.1021/bi1010249</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi1010249" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=10216-10227&author=O.+H.+Kimauthor=Y.+O.+Kimauthor=J.+H.+Shimauthor=Y.+S.+Jungauthor=W.+J.+Jungauthor=W.+C.+Choiauthor=H.+Leeauthor=S.+J.+Leeauthor=K.+K.+Kimauthor=J.+H.+Auhauthor=H.+Kimauthor=J.+W.+Kimauthor=T.+K.+Ohauthor=B.+C.+Oh&title=beta-propeller+phytase+hydrolyzes+insoluble+Ca%282%2B%29-phytate+salts+and+completely+abrogates+the+ability+of+phytate+to+chelate+metal+ions&doi=10.1021%2Fbi1010249"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fbi1010249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1010249%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DO.%2BH.%26aulast%3DKim%26aufirst%3DY.%2BO.%26aulast%3DShim%26aufirst%3DJ.%2BH.%26aulast%3DJung%26aufirst%3DY.%2BS.%26aulast%3DJung%26aufirst%3DW.%2BJ.%26aulast%3DChoi%26aufirst%3DW.%2BC.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DKim%26aufirst%3DK.%2BK.%26aulast%3DAuh%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DJ.%2BW.%26aulast%3DOh%26aufirst%3DT.%2BK.%26aulast%3DOh%26aufirst%3DB.%2BC.%26atitle%3Dbeta-propeller%2520phytase%2520hydrolyzes%2520insoluble%2520Ca%25282%252B%2529-phytate%2520salts%2520and%2520completely%2520abrogates%2520the%2520ability%2520of%2520phytate%2520to%2520chelate%2520metal%2520ions%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D10216%26epage%3D10227%26doi%3D10.1021%2Fbi1010249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Chow, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rincon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. J.</span><span> </span><span class="NLM_article-title">Requirement for transcription factor NFAT in interleukin-2 expression</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2300</span><span class="NLM_x">–</span> <span class="NLM_lpage">2307</span><span class="refDoi"> DOI: 10.1128/MCB.19.3.2300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1128%2FMCB.19.3.2300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10022916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADyaK1MXhsFCjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=2300-2307&author=C.+W.+Chowauthor=M.+Rinconauthor=R.+J.+Davis&title=Requirement+for+transcription+factor+NFAT+in+interleukin-2+expression&doi=10.1128%2FMCB.19.3.2300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement for transcription factor NFAT in interleukin-2 expression</span></div><div class="casAuthors">Chow, Chi-Wing; Rincon, Mercedes; Davis, Roger J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2300-2307</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The nuclear factor of activated T cells (NFAT) transcription factor is implicated in expression of the cytokine interleukin-2 (IL-2).  Binding sites for NFAT are located in the IL-2 promoter.  Furthermore, pharmacol. studies demonstrate that the drug cyclosporin A inhibits both NFAT activation and IL-2 expression.  However, targeted disruption of the NFAT1 and NFAT2 genes in mice does not cause decreased IL-2 secretion.  The role of NFAT in IL-2 gene expression is therefore unclear.  Here the authors report the construction of a dominant-neg. NFAT mutant (dnNFAT) that selectively inhibits NFAT-mediated gene expression.  The inhibitory effect of dnNFAT is mediated by suppression of activation-induced nuclear translocation of NFAT.  Expression of dnNFAT in cultured T cells caused inhibition of IL-2 promoter activity and decreased expression of IL-2 protein.  Similarly, expression of dnNFAT in transgenic mice also caused decreased IL-2 gene expression.  These data demonstrate that NFAT is a crit. component of the signaling pathway that regulates IL-2 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu9KAT181x5rVg90H21EOLACvtfcHk0lhBeBJXgQBQ0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsFCjsrg%253D&md5=5221377e3a321c531aeade22a4dd0109</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1128%2FMCB.19.3.2300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.19.3.2300%26sid%3Dliteratum%253Aachs%26aulast%3DChow%26aufirst%3DC.%2BW.%26aulast%3DRincon%26aufirst%3DM.%26aulast%3DDavis%26aufirst%3DR.%2BJ.%26atitle%3DRequirement%2520for%2520transcription%2520factor%2520NFAT%2520in%2520interleukin-2%2520expression%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1999%26volume%3D19%26spage%3D2300%26epage%3D2307%26doi%3D10.1128%2FMCB.19.3.2300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Hopkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallay, P.</span><span> </span><span class="NLM_article-title">Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection</span> <span class="citation_source-journal">Viruses</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">2558</span><span class="NLM_x">–</span> <span class="NLM_lpage">2577</span><span class="refDoi"> DOI: 10.3390/v4112558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.3390%2Fv4112558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=23202494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSrtrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=2558-2577&author=S.+Hopkinsauthor=P.+Gallay&title=Cyclophilin+inhibitors%3A+an+emerging+class+of+therapeutics+for+the+treatment+of+chronic+hepatitis+C+infection&doi=10.3390%2Fv4112558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection</span></div><div class="casAuthors">Hopkins, Sam; Gallay, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2558-2577</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The advent of the replicon system together with advances in cell culture have contributed significantly to our understanding of the function of virally-encoded structural and nonstructural proteins in the replication cycle of the hepatitis C virus.  In addn., in vitro systems have been used to identify several host proteins whose expression is crit. for supporting such diverse activities as viral entry, RNA replication, particle assembly and the release of infectious virions.  Among all known host proteins that participate in the HCV replication cycle, cyclophilins are unique because they constitute the only host target that has formed the basis of pharmaceutical drug discovery and drug development programs.  The introduction of the nonimmunosuppressive cyclophilin inhibitors into clin. testing has confirmed the clin. utility of CsA-based inhibitors for the treatment of individuals with chronic hepatitis C infection and has yielded new insights into their mechanism(s) of action.  This review describes the biochem. evidence for the potential roles played by cyclophilins in supporting HCV RNA replication and summarizes clin. trial results obtained with the first generation of nonimmunosuppressive cyclophilin inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZzgAJ1L1MN7Vg90H21EOLACvtfcHk0lhBeBJXgQBQ0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSrtrrE&md5=ec08cd3fcb01f3d38ee8a04e98c9195a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3390%2Fv4112558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv4112558%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DS.%26aulast%3DGallay%26aufirst%3DP.%26atitle%3DCyclophilin%2520inhibitors%253A%2520an%2520emerging%2520class%2520of%2520therapeutics%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520infection%26jtitle%3DViruses%26date%3D2012%26volume%3D4%26spage%3D2558%26epage%3D2577%26doi%3D10.3390%2Fv4112558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Kaufmann, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robb, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. A.</span><span> </span><span class="NLM_article-title">Mechanism of action of cyclosporin A: inhibition of lymphokine secretion studied with antigen-stimulated T cell hybridomas</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">3107</span><span class="NLM_x">–</span> <span class="NLM_lpage">3111</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=1984&pages=3107-3111&author=Y.+Kaufmannauthor=A.+E.+Changauthor=R.+J.+Robbauthor=S.+A.+Rosenberg&title=Mechanism+of+action+of+cyclosporin+A%3A+inhibition+of+lymphokine+secretion+studied+with+antigen-stimulated+T+cell+hybridomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaufmann%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DA.%2BE.%26aulast%3DRobb%26aufirst%3DR.%2BJ.%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26atitle%3DMechanism%2520of%2520action%2520of%2520cyclosporin%2520A%253A%2520inhibition%2520of%2520lymphokine%2520secretion%2520studied%2520with%2520antigen-stimulated%2520T%2520cell%2520hybridomas%26jtitle%3DJ.%2520Immunol.%26date%3D1984%26volume%3D133%26spage%3D3107%26epage%3D3111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Hopkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobardt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterji, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Rivera, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallay, P. A.</span><span> </span><span class="NLM_article-title">The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">3888</span><span class="NLM_x">–</span> <span class="NLM_lpage">3897</span><span class="refDoi"> DOI: 10.1128/AAC.00693-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1128%2FAAC.00693-12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=3888-3897&author=S.+Hopkinsauthor=M.+Bobardtauthor=U.+Chatterjiauthor=J.+A.+Garcia-Riveraauthor=P.+Limauthor=P.+A.+Gallay&title=The+cyclophilin+inhibitor+SCY-635+disrupts+hepatitis+C+virus+NS5A-cyclophilin+A+complexes&doi=10.1128%2FAAC.00693-12"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1128%2FAAC.00693-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00693-12%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DS.%26aulast%3DBobardt%26aufirst%3DM.%26aulast%3DChatterji%26aufirst%3DU.%26aulast%3DGarcia-Rivera%26aufirst%3DJ.%2BA.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DGallay%26aufirst%3DP.%2BA.%26atitle%3DThe%2520cyclophilin%2520inhibitor%2520SCY-635%2520disrupts%2520hepatitis%2520C%2520virus%2520NS5A-cyclophilin%2520A%2520complexes%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D3888%26epage%3D3897%26doi%3D10.1128%2FAAC.00693-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Foster, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stonehouse, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, M.</span><span> </span><span class="NLM_article-title">Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">7460</span><span class="NLM_x">–</span> <span class="NLM_lpage">7464</span><span class="refDoi"> DOI: 10.1128/JVI.00393-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1128%2FJVI.00393-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=21593166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslCisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=7460-7464&author=T.+L.+Fosterauthor=P.+Gallayauthor=N.+J.+Stonehouseauthor=M.+Harris&title=Cyclophilin+A+interacts+with+domain+II+of+hepatitis+C+virus+NS5A+and+stimulates+RNA+binding+in+an+isomerase-dependent+manner&doi=10.1128%2FJVI.00393-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner</span></div><div class="casAuthors">Foster, Toshana L.; Gallay, Philippe; Stonehouse, Nicola J.; Harris, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7460-7464</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">NS5A plays a crit., yet poorly defined, role in hepatitis C virus genome replication.  The protein consists of 3 domains, each of which is able to bind independently to the 3' untranslated region (UTR) of the viral pos. strand genomic RNA.  The peptidyl-prolyl isomerase cyclophilin A (CypA) binds to domain II, catalyzing cis-trans isomerization.  CypA inhibitors such as cyclosporine (CsA) were shown to inhibit hepatitis C virus (HCV) replication.  We show here that CypA stimulated domain II RNA binding activity, and this stimulation was abrogated by CsA.  An isomerase mutant of CypA (H126Q) failed to bind to domain II and did not stimulate RNA binding.  Finally, we demonstrate that the RNA binding of 2 domain II mutants, the D316E and D316E/Y317N mutants, previously shown to exhibit CypA independence for RNA replication, was unaffected by CypA.  This study provides an insight into the mol. mechanism of CypA activity during HCV replication and further validates the use of CypA inhibitors in HCV therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ-kLl4Y8V4rVg90H21EOLACvtfcHk0liSkch1QocguA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslCisr4%253D&md5=2dfe5029d201ae08880f75e860df60fc</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1128%2FJVI.00393-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00393-11%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DT.%2BL.%26aulast%3DGallay%26aufirst%3DP.%26aulast%3DStonehouse%26aufirst%3DN.%2BJ.%26aulast%3DHarris%26aufirst%3DM.%26atitle%3DCyclophilin%2520A%2520interacts%2520with%2520domain%2520II%2520of%2520hepatitis%2520C%2520virus%2520NS5A%2520and%2520stimulates%2520RNA%2520binding%2520in%2520an%2520isomerase-dependent%2520manner%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D7460%26epage%3D7464%26doi%3D10.1128%2FJVI.00393-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Blight, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolykhalov, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">Efficient initiation of HCV RNA replication in cell culture</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">1972</span><span class="NLM_x">–</span> <span class="NLM_lpage">1974</span><span class="refDoi"> DOI: 10.1126/science.290.5498.1972</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1126%2Fscience.290.5498.1972" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=11110665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BD3cXoslKgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2000&pages=1972-1974&author=K.+J.+Blightauthor=A.+A.+Kolykhalovauthor=C.+M.+Rice&title=Efficient+initiation+of+HCV+RNA+replication+in+cell+culture&doi=10.1126%2Fscience.290.5498.1972"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient initiation of HCV RNA replication in cell culture</span></div><div class="casAuthors">Blight, Keril J.; Kolykhalov, Alexander A.; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">5498</span>),
    <span class="NLM_cas:pages">1972-1974</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a global health problem affecting an estd. 170 million individuals worldwide.  We report the identification of multiple independent adaptive mutations that cluster in the HCV nonstructural protein NS5A and confer increased replicative ability in vitro.  Among these adaptive mutations were a single amino acid substitution that allowed HCV RNA replication in 10% of transfected hepatoma cells and a deletion of 47 amino acids encompassing the interferon (IFN) sensitivity detg. region (ISDR).  Independent of the ISDR, IFN-α rapidly inhibited HCV RNA replication in vitro.  This work establishes a robust, cell-based system for genetic and functional analyses of HCV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPYOuqOjy-ZbVg90H21EOLACvtfcHk0liSkch1QocguA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXoslKgsL4%253D&md5=67eb65d15efc36854faf3940db9a5d91</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1126%2Fscience.290.5498.1972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.290.5498.1972%26sid%3Dliteratum%253Aachs%26aulast%3DBlight%26aufirst%3DK.%2BJ.%26aulast%3DKolykhalov%26aufirst%3DA.%2BA.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DEfficient%2520initiation%2520of%2520HCV%2520RNA%2520replication%2520in%2520cell%2520culture%26jtitle%3DScience%26date%3D2000%26volume%3D290%26spage%3D1972%26epage%3D1974%26doi%3D10.1126%2Fscience.290.5498.1972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Kumthip, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chusri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jilg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fusco, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantip, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongsawat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maneekarn, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">8581</span><span class="NLM_x">–</span> <span class="NLM_lpage">8591</span><span class="refDoi"> DOI: 10.1128/JVI.00533-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1128%2FJVI.00533-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=22674974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtF2jtLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=8581-8591&author=K.+Kumthipauthor=P.+Chusriauthor=N.+Jilgauthor=L.+Zhaoauthor=D.+N.+Fuscoauthor=H.+Zhaoauthor=K.+Gotoauthor=D.+Chengauthor=E.+A.+Schaeferauthor=L.+Zhangauthor=C.+Pantipauthor=S.+Thongsawatauthor=A.+O%E2%80%99Brienauthor=L.+F.+Pengauthor=N.+Maneekarnauthor=R.+T.+Chungauthor=W.+Lin&title=Hepatitis+C+virus+NS5A+disrupts+STAT1+phosphorylation+and+suppresses+type+I+interferon+signaling&doi=10.1128%2FJVI.00533-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling</span></div><div class="casAuthors">Kumthip, Kattareeya; Chusri, Pattranuch; Jilg, Nikolaus; Zhao, Lei; Fusco, Dahlene N.; Zhao, Hong; Goto, Kaku; Cheng, Du; Schaefer, Esperance A.; Zhang, Leiliang; Pantip, Chansom; Thongsawat, Satawat; O'Brien, Amornrat; Peng, Lee F.; Maneekarn, Niwat; Chung, Raymond T.; Lin, Wenyu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8581-8591</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Responses to alpha interferon (IFN-α)-based treatment are dependent on both host and viral factors and vary markedly among patients infected with different hepatitis C virus (HCV) genotypes (GTs).  Patients infected with GT3 viruses consistently respond better to IFN treatment than do patients infected with GT1 viruses.  The mechanisms underlying this difference are not well understood.  In this study, we sought to det. the effects of HCV NS5A proteins from different genotypes on IFN signaling.  We found that the overexpression of either GT1 or GT3 NS5A proteins significantly inhibited IFN-induced IFN-stimulated response element (ISRE) signaling, phosphorylated STAT1 (P-STAT1) levels, and IFN-stimulated gene (ISG) expression compared to controls.  GT1 NS5A protein expression exhibited stronger inhibitory effects on IFN signaling than did GT3 NS5A protein expression.  Furthermore, GT1 NS5A bound to STAT1 with a higher affinity than did GT3 NS5A.  Domain mapping revealed that the C-terminal region of NS5A conferred these inhibitory effects on IFN signaling.  The overexpression of HCV NS5A increased HCV replication levels in JFH1-infected cells through the further redn. of levels of P-STAT1, ISRE signaling, and downstream ISG responses.  We demonstrated that the overexpression of GT1 NS5A proteins resulted in less IFN responsiveness than did the expression of GT3 NS5A proteins through stronger binding to STAT1.  We confirmed that GT1 NS5A proteins exerted stronger IFN signaling inhibition than did GT3 NS5A proteins in an infectious recombinant JFH1 virus.  The potent antiviral NS5A inhibitor BMS-790052 did not block NS5A-mediated IFN signaling suppression in an overexpression model, suggesting that NS5A's contributions to replication are independent of its subversive action on IFN.  We propose a model in which the binding of the C-terminal region of NS5A to STAT1 leads to decreased levels of P-STAT1, ISRE signaling, and ISG transcription and, ultimately, to preferential GT1 resistance to IFN treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg79F_jnivs7Vg90H21EOLACvtfcHk0liSkch1QocguA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtF2jtLjP&md5=c3eff494e9a562ff514e2650469b0996</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1128%2FJVI.00533-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00533-12%26sid%3Dliteratum%253Aachs%26aulast%3DKumthip%26aufirst%3DK.%26aulast%3DChusri%26aufirst%3DP.%26aulast%3DJilg%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DFusco%26aufirst%3DD.%2BN.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DD.%26aulast%3DSchaefer%26aufirst%3DE.%2BA.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DPantip%26aufirst%3DC.%26aulast%3DThongsawat%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DA.%26aulast%3DPeng%26aufirst%3DL.%2BF.%26aulast%3DManeekarn%26aufirst%3DN.%26aulast%3DChung%26aufirst%3DR.%2BT.%26aulast%3DLin%26aufirst%3DW.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520disrupts%2520STAT1%2520phosphorylation%2520and%2520suppresses%2520type%2520I%2520interferon%2520signaling%26jtitle%3DJ.%2520Virol.%26date%3D2012%26volume%3D86%26spage%3D8581%26epage%3D8591%26doi%3D10.1128%2FJVI.00533-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Zimmermann, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gassler, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nattermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luedde, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trautwein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tacke, F.</span><span> </span><span class="NLM_article-title">Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e21381</span><span class="refDoi"> DOI: 10.1371/journal.pone.0021381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1371%2Fjournal.pone.0021381" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e21381&author=H.+W.+Zimmermannauthor=S.+Seidlerauthor=N.+Gasslerauthor=J.+Nattermannauthor=T.+Lueddeauthor=C.+Trautweinauthor=F.+Tacke&title=Interleukin-8+is+activated+in+patients+with+chronic+liver+diseases+and+associated+with+hepatic+macrophage+accumulation+in+human+liver+fibrosis&doi=10.1371%2Fjournal.pone.0021381"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0021381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0021381%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DH.%2BW.%26aulast%3DSeidler%26aufirst%3DS.%26aulast%3DGassler%26aufirst%3DN.%26aulast%3DNattermann%26aufirst%3DJ.%26aulast%3DLuedde%26aufirst%3DT.%26aulast%3DTrautwein%26aufirst%3DC.%26aulast%3DTacke%26aufirst%3DF.%26atitle%3DInterleukin-8%2520is%2520activated%2520in%2520patients%2520with%2520chronic%2520liver%2520diseases%2520and%2520associated%2520with%2520hepatic%2520macrophage%2520accumulation%2520in%2520human%2520liver%2520fibrosis%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De21381%26doi%3D10.1371%2Fjournal.pone.0021381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Flisiak, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinman, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jablkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kryczka, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawlowska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heathcote, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolas-Metral, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosgurin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liz, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scalfaro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porchet, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crabbe, R.</span><span> </span><span class="NLM_article-title">The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1460</span><span class="NLM_x">–</span> <span class="NLM_lpage">1468</span><span class="refDoi"> DOI: 10.1002/hep.22835</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fhep.22835" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=1460-1468&author=R.+Flisiakauthor=S.+V.+Feinmanauthor=M.+Jablkowskiauthor=A.+Horbanauthor=W.+Kryczkaauthor=M.+Pawlowskaauthor=J.+E.+Heathcoteauthor=G.+Mazzellaauthor=C.+Vandelliauthor=V.+Nicolas-Metralauthor=P.+Grosgurinauthor=J.+S.+Lizauthor=P.+Scalfaroauthor=H.+Porchetauthor=R.+Crabbe&title=The+cyclophilin+inhibitor+Debio+025+combined+with+PEG+IFNalpha2a+significantly+reduces+viral+load+in+treatment-naive+hepatitis+C+patients&doi=10.1002%2Fhep.22835"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2Fhep.22835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22835%26sid%3Dliteratum%253Aachs%26aulast%3DFlisiak%26aufirst%3DR.%26aulast%3DFeinman%26aufirst%3DS.%2BV.%26aulast%3DJablkowski%26aufirst%3DM.%26aulast%3DHorban%26aufirst%3DA.%26aulast%3DKryczka%26aufirst%3DW.%26aulast%3DPawlowska%26aufirst%3DM.%26aulast%3DHeathcote%26aufirst%3DJ.%2BE.%26aulast%3DMazzella%26aufirst%3DG.%26aulast%3DVandelli%26aufirst%3DC.%26aulast%3DNicolas-Metral%26aufirst%3DV.%26aulast%3DGrosgurin%26aufirst%3DP.%26aulast%3DLiz%26aufirst%3DJ.%2BS.%26aulast%3DScalfaro%26aufirst%3DP.%26aulast%3DPorchet%26aufirst%3DH.%26aulast%3DCrabbe%26aufirst%3DR.%26atitle%3DThe%2520cyclophilin%2520inhibitor%2520Debio%2520025%2520combined%2520with%2520PEG%2520IFNalpha2a%2520significantly%2520reduces%2520viral%2520load%2520in%2520treatment-naive%2520hepatitis%2520C%2520patients%26jtitle%3DHepatology%26date%3D2009%26volume%3D49%26spage%3D1460%26epage%3D1468%26doi%3D10.1002%2Fhep.22835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Pan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramakrishnaiah, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fouraschen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Ruiter, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwekkeboom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tilanus, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Laan, L. J.</span><span> </span><span class="NLM_article-title">Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi)</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1330</span><span class="NLM_x">–</span> <span class="NLM_lpage">1339</span><span class="refDoi"> DOI: 10.1136/gutjnl-2011-300449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1136%2Fgutjnl-2011-300449" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=1330-1339&author=Q.+Panauthor=V.+Ramakrishnaiahauthor=S.+Henryauthor=S.+Fouraschenauthor=P.+E.+de+Ruiterauthor=J.+Kwekkeboomauthor=H.+W.+Tilanusauthor=H.+L.+Janssenauthor=L.+J.+van+der+Laan&title=Hepatic+cell-to-cell+transmission+of+small+silencing+RNA+can+extend+the+therapeutic+reach+of+RNA+interference+%28RNAi%29&doi=10.1136%2Fgutjnl-2011-300449"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2011-300449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2011-300449%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DQ.%26aulast%3DRamakrishnaiah%26aufirst%3DV.%26aulast%3DHenry%26aufirst%3DS.%26aulast%3DFouraschen%26aufirst%3DS.%26aulast%3Dde%2BRuiter%26aufirst%3DP.%2BE.%26aulast%3DKwekkeboom%26aufirst%3DJ.%26aulast%3DTilanus%26aufirst%3DH.%2BW.%26aulast%3DJanssen%26aufirst%3DH.%2BL.%26aulast%3Dvan%2Bder%2BLaan%26aufirst%3DL.%2BJ.%26atitle%3DHepatic%2520cell-to-cell%2520transmission%2520of%2520small%2520silencing%2520RNA%2520can%2520extend%2520the%2520therapeutic%2520reach%2520of%2520RNA%2520interference%2520%2528RNAi%2529%26jtitle%3DGut%26date%3D2012%26volume%3D61%26spage%3D1330%26epage%3D1339%26doi%3D10.1136%2Fgutjnl-2011-300449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 9 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessandra  Vidotto</span>, <span class="hlFld-ContribAuthor ">Ana T. S.  Morais</span>, <span class="hlFld-ContribAuthor ">Milene R.  Ribeiro</span>, <span class="hlFld-ContribAuthor ">Carolina C.  Pacca</span>, <span class="hlFld-ContribAuthor ">Ana C. B.  Terzian</span>, <span class="hlFld-ContribAuthor ">Laura H. V. G.  Gil</span>, <span class="hlFld-ContribAuthor ">Ronaldo  Mohana-Borges</span>, <span class="hlFld-ContribAuthor ">Philippe  Gallay</span>, and <span class="hlFld-ContribAuthor ">Mauricio L.  Nogueira</span>  . </span><span class="cited-content_cbyCitation_article-title">Systems Biology Reveals NS4B-Cyclophilin A Interaction: A New Target to Inhibit YFV Replication. </span><span class="cited-content_cbyCitation_journal-name">Journal of Proteome Research</span><span> <strong>2017,</strong> <em>16 </em>
                                    (4)
                                     , 1542-1555. <a href="https://doi.org/10.1021/acs.jproteome.6b00933" title="DOI URL">https://doi.org/10.1021/acs.jproteome.6b00933</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jproteome.6b00933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jproteome.6b00933%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Proteome%2520Research%26atitle%3DSystems%252BBiology%252BReveals%252BNS4B-Cyclophilin%252BA%252BInteraction%25253A%252BA%252BNew%252BTarget%252Bto%252BInhibit%252BYFV%252BReplication%26aulast%3DVidotto%26aufirst%3DAlessandra%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D27102016%26date%3D27032017%26date%3D07042017%26date%3D20032017%26volume%3D16%26issue%3D4%26spage%3D1542%26epage%3D1555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoli  Li</span>, <span class="hlFld-ContribAuthor ">Jinhe  Han</span>, <span class="hlFld-ContribAuthor ">Hye Won  Lee</span>, <span class="hlFld-ContribAuthor ">Yi-Seul  Yoon</span>, <span class="hlFld-ContribAuthor ">Yifeng  Jin</span>, <span class="hlFld-ContribAuthor ">Daulat B.  Khadka</span>, <span class="hlFld-ContribAuthor ">Suhui  Yang</span>, <span class="hlFld-ContribAuthor ">Meehyein  Kim</span>, <span class="hlFld-ContribAuthor ">Won-Jea  Cho</span>. </span><span class="cited-content_cbyCitation_article-title">SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (19)
                                     , 115679. <a href="https://doi.org/10.1016/j.bmc.2020.115679" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115679</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115679%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSAR%252Bstudy%252Bof%252Bbisamides%252Bas%252Bcyclophilin%252Ba%252Binhibitors%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bhost-targeting%252Btherapy%252Bfor%252Bhepatitis%252BC%252Bvirus%252Binfection%26aulast%3DLi%26aufirst%3DXiaoli%26date%3D2020%26volume%3D28%26issue%3D19%26spage%3D115679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinhe  Han</span>, <span class="hlFld-ContribAuthor ">Hye Won  Lee</span>, <span class="hlFld-ContribAuthor ">Yifeng  Jin</span>, <span class="hlFld-ContribAuthor ">Daulat B.  Khadka</span>, <span class="hlFld-ContribAuthor ">Suhui  Yang</span>, <span class="hlFld-ContribAuthor ">Xiaoli  Li</span>, <span class="hlFld-ContribAuthor ">Meehyein  Kim</span>, <span class="hlFld-ContribAuthor ">Won-Jea  Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>188 </em>, 112031. <a href="https://doi.org/10.1016/j.ejmech.2019.112031" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.112031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.112031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.112031%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMolecular%252Bdesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bbisamide%252Bderivatives%252Bas%252Bcyclophilin%252BA%252Binhibitors%252Bfor%252BHCV%252Btreatment%26aulast%3DHan%26aufirst%3DJinhe%26date%3D2020%26volume%3D188%26spage%3D112031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maryna V  Murlykina</span>, <span class="hlFld-ContribAuthor ">Oleksandr V  Kolomiets</span>, <span class="hlFld-ContribAuthor ">Maryna M  Kornet</span>, <span class="hlFld-ContribAuthor ">Yana I  Sakhno</span>, <span class="hlFld-ContribAuthor ">Sergey M  Desenko</span>, <span class="hlFld-ContribAuthor ">Victoriya V  Dyakonenko</span>, <span class="hlFld-ContribAuthor ">Svetlana V  Shishkina</span>, <span class="hlFld-ContribAuthor ">Oleksandr A  Brazhko</span>, <span class="hlFld-ContribAuthor ">Vladimir I  Musatov</span>, <span class="hlFld-ContribAuthor ">Alexander V  Tsygankov</span>, <span class="hlFld-ContribAuthor ">Erik V  Van der Eycken</span>, <span class="hlFld-ContribAuthor ">Valentyn A  Chebanov</span>. </span><span class="cited-content_cbyCitation_article-title">Doebner-type pyrazolopyridine carboxylic acids in an Ugi four-component reaction. </span><span class="cited-content_cbyCitation_journal-name">Beilstein Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>15 </em>, 1281-1288. <a href="https://doi.org/10.3762/bjoc.15.126" title="DOI URL">https://doi.org/10.3762/bjoc.15.126</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3762/bjoc.15.126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3762%2Fbjoc.15.126%26sid%3Dliteratum%253Aachs%26jtitle%3DBeilstein%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDoebner-type%252Bpyrazolopyridine%252Bcarboxylic%252Bacids%252Bin%252Ban%252BUgi%252Bfour-component%252Breaction%26aulast%3DMurlykina%26aufirst%3DMaryna%2BV%26date%3D2019%26date%3D2019%26volume%3D15%26spage%3D1281%26epage%3D1288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guanghai  Jin</span>, <span class="hlFld-ContribAuthor ">Jisu  Lee</span>, <span class="hlFld-ContribAuthor ">Kyeong  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical genetics-based development of small molecules targeting hepatitis C virus. </span><span class="cited-content_cbyCitation_journal-name">Archives of Pharmacal Research</span><span> <strong>2017,</strong> <em>40 </em>
                                    (9)
                                     , 1021-1036. <a href="https://doi.org/10.1007/s12272-017-0949-3" title="DOI URL">https://doi.org/10.1007/s12272-017-0949-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12272-017-0949-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12272-017-0949-3%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Pharmacal%2520Research%26atitle%3DChemical%252Bgenetics-based%252Bdevelopment%252Bof%252Bsmall%252Bmolecules%252Btargeting%252Bhepatitis%252BC%252Bvirus%26aulast%3DJin%26aufirst%3DGuanghai%26date%3D2017%26date%3D2017%26volume%3D40%26issue%3D9%26spage%3D1021%26epage%3D1036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guangdi  Li</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>. </span><span class="cited-content_cbyCitation_article-title">Current therapy for chronic hepatitis C: The role of direct-acting antivirals. </span><span class="cited-content_cbyCitation_journal-name">Antiviral Research</span><span> <strong>2017,</strong> <em>142 </em>, 83-122. <a href="https://doi.org/10.1016/j.antiviral.2017.02.014" title="DOI URL">https://doi.org/10.1016/j.antiviral.2017.02.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.antiviral.2017.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.antiviral.2017.02.014%26sid%3Dliteratum%253Aachs%26jtitle%3DAntiviral%2520Research%26atitle%3DCurrent%252Btherapy%252Bfor%252Bchronic%252Bhepatitis%252BC%25253A%252BThe%252Brole%252Bof%252Bdirect-acting%252Bantivirals%26aulast%3DLi%26aufirst%3DGuangdi%26date%3D2017%26volume%3D142%26spage%3D83%26epage%3D122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aravindhan  Ganesan</span>, <span class="hlFld-ContribAuthor ">Khaled  Barakat</span>. </span><span class="cited-content_cbyCitation_article-title">Applications of computer-aided approaches in the development of hepatitis C antiviral agents. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2017,</strong> <em>12 </em>
                                    (4)
                                     , 407-425. <a href="https://doi.org/10.1080/17460441.2017.1291628" title="DOI URL">https://doi.org/10.1080/17460441.2017.1291628</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2017.1291628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2017.1291628%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DApplications%252Bof%252Bcomputer-aided%252Bapproaches%252Bin%252Bthe%252Bdevelopment%252Bof%252Bhepatitis%252BC%252Bantiviral%252Bagents%26aulast%3DGanesan%26aufirst%3DAravindhan%26date%3D2017%26date%3D2017%26volume%3D12%26issue%3D4%26spage%3D407%26epage%3D425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdelhakim  Ahmed-Belkacem</span>, <span class="hlFld-ContribAuthor ">Lionel  Colliandre</span>, <span class="hlFld-ContribAuthor ">Nazim  Ahnou</span>, <span class="hlFld-ContribAuthor ">Quentin  Nevers</span>, <span class="hlFld-ContribAuthor ">Muriel  Gelin</span>, <span class="hlFld-ContribAuthor ">Yannick  Bessin</span>, <span class="hlFld-ContribAuthor ">Rozenn  Brillet</span>, <span class="hlFld-ContribAuthor ">Olivier  Cala</span>, <span class="hlFld-ContribAuthor ">Dominique  Douguet</span>, <span class="hlFld-ContribAuthor ">William  Bourguet</span>, <span class="hlFld-ContribAuthor ">Isabelle  Krimm</span>, <span class="hlFld-ContribAuthor ">Jean-Michel  Pawlotsky</span>, <span class="hlFld-ContribAuthor ">Jean- François  Guichou</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2016,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/ncomms12777" title="DOI URL">https://doi.org/10.1038/ncomms12777</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/ncomms12777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fncomms12777%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DFragment-based%252Bdiscovery%252Bof%252Ba%252Bnew%252Bfamily%252Bof%252Bnon-peptidic%252Bsmall-molecule%252Bcyclophilin%252Binhibitors%252Bwith%252Bpotent%252Bantiviral%252Bactivities%26aulast%3DAhmed-Belkacem%26aufirst%3DAbdelhakim%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chih-Wei  Liu</span>, <span class="hlFld-ContribAuthor ">Mark A.  Atkinson</span>, <span class="hlFld-ContribAuthor ">Qibin  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Type 1 diabetes cadaveric human pancreata exhibit a unique exocrine tissue proteomic profile. </span><span class="cited-content_cbyCitation_journal-name">PROTEOMICS</span><span> <strong>2016,</strong> <em>16 </em>
                                    (9)
                                     , 1432-1446. <a href="https://doi.org/10.1002/pmic.201500333" title="DOI URL">https://doi.org/10.1002/pmic.201500333</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pmic.201500333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpmic.201500333%26sid%3Dliteratum%253Aachs%26jtitle%3DPROTEOMICS%26atitle%3DType%252B1%252Bdiabetes%252Bcadaveric%252Bhuman%252Bpancreata%252Bexhibit%252Ba%252Bunique%252Bexocrine%252Btissue%252Bproteomic%252Bprofile%26aulast%3DLiu%26aufirst%3DChih-Wei%26date%3D2016%26date%3D2016%26volume%3D16%26issue%3D9%26spage%3D1432%26epage%3D1446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of four CypA inhibitors: CsA, NIM-811, SCY-635, and alisporivir.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structure of <b>5</b> and its binding mode inside CypA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Bis-amides <b>5</b>–<b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Isocyanides <b>1</b>, aldehydes <b>2</b>, amines <b>3</b>, and carboxylic acids <b>4</b> are listed in <a href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_002.pdf" class="ext-link">Table S1</a>.</p></p></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Chemical structure of <b>25</b> and its binding mode. (B) Sensograms showing <b>25</b> and CsA binding to CypA and CypB (upper and lower panels, respectively). (C) Relative response in resonance units showing interactions of <b>25</b> with CypA and CypB (upper and lower panels, respectively) at the different concentrations indicated. The <i>K</i><sub>D</sub> values (±sd) were calculated from three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Nonimmunosuppressive activity of <b>25</b>: effects of CsA and <b>25</b> on (A) mouse splenocyte viability, (B) calcineurin phosphatase activity, (C) phosphorylation of NFAT1, (D) nuclear translocation of NFAT1, and (E) IL-2 production. All data are representative of at least three different experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of <b>25</b> in HCV replicon cells. (A) HCV RNA levels at increasing concentrations of CsA and <b>25</b>. (B) Western blot analysis. HCV replicon cells were treated with increasing concentrations of CsA or <b>25</b> and were analyzed for NS5A (upper panels) and NS5B (middle panels) expression. All data are representative of at least three different experiments. (C) HCV Con1b replicon cells were treated with 2 μM CsA or <b>25</b>, and the total lysates and subcellular fractionated membranes were used to analyze the replication complex. (D) Confocal microscopy images. The cells were stained with an Alexa red- and Alexa green-conjugated antibody against NS5A and NS5B, respectively, and with DAPI for nuclear staining. Colocalization of merged red and green colors are shown in yellow. The images are representative of at least three different experiments. (E) Real-time image analysis. The potency of <b>25</b> was determined by the percentage of fluorescent cells in each image using subgenotype 1b replicon cells. The EC<sub>50</sub> and CC<sub>50</sub> were calculated by nonlinear regression analysis using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA). Shown is quantification of the GFP expression levels (left panel). GFP images of replicon levels were acquired at increasing concentrations of <b>25</b> (right panel). (F) Same as part E except for the use of JFH1 genotype 2a replicon cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Lead <b>25</b> stimulates IFN signals and inhibits IL-8 production in HCV replicon cells. (A) Real time qRT-PCR analysis with 2 μM CsA or <b>25</b> at different time intervals. (B) Western blot analysis with the indicated antibodies. (C) Same as part A except that changes in the IL-8 mRNA expression were analyzed. (D) ELISA analysis of the IL-8 levels. (E) Real time qRT-PCR analysis of IFN-α. The results were normalized to human glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (F) ELISA analysis of IFN-α secretion in the culture media. All data are representative of three different experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Combination treatment consisting of <b>25</b> and IFN-α, ribavirin, or telaprevir enhances the antiviral effect. (A) Real-time qRT-PCR analysis for HCV replicon RNA levels: (∗∗) <i>P</i> < 0.001 vs the cells treated with IFN-α, ribavirin, or telaprevir. (B) ELISA analysis of the IL-8 levels: (∗∗) <i>P</i> < 0.01 vs the cells treated with IFN-α; (∗∗∗) <i>P</i> < 0.001 vs the cells treated with ribavirin or telaprevir. (C) MTT assay: (∗) <i>P</i> < 0.05 vs the cells treated with CsA combined with IFN-α, (∗∗) <i>P</i> < 0.01 vs the cells treated with CsA combined with ribavirin, (∗∗∗) <i>P</i> < 0.001 vs the cells treated with CsA combined with telaprevir.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/medium/jm-2015-01064w_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Lead <b>25</b> abolishes viral replication in an HCV mouse model. (A) Schematic representation of the in vivo experiments using NOD/SCID mice. (B) Hematoxylin and eosin staining: histological examination of control and HCV replicon cells transplanted in mouse liver tissue. (C) Body weight changes of the mice. (D) HCV RNA levels in the liver of the mice assessed by real time qRT-PCR analysis. (E) HCV NS5A expression level after treatment with CsA or <b>25</b>. (F) Confocal microscopy analysis of Huh7 cells or Huh7 cells containing the HCV-Con1b replicon for human hepatocytes (green) and HCV NS5A (red). The nuclei were stained with DAPI (blue). The colocalization of human hepatocytes with HCV NS5A is shown in yellow. All data are representative of three different experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01064/20151218/images/large/jm-2015-01064w_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01064&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i49">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75624" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75624" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 49 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Seeff, L. B.</span><span> </span><span class="NLM_article-title">Natural history of hepatitis C</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">21S</span><span class="NLM_x">–</span> <span class="NLM_lpage">28S</span><span class="refDoi"> DOI: 10.1002/hep.510260704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fhep.510260704" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1997&pages=21S-28S&author=L.+B.+Seeff&title=Natural+history+of+hepatitis+C&doi=10.1002%2Fhep.510260704"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fhep.510260704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.510260704%26sid%3Dliteratum%253Aachs%26aulast%3DSeeff%26aufirst%3DL.%2BB.%26atitle%3DNatural%2520history%2520of%2520hepatitis%2520C%26jtitle%3DHepatology%26date%3D1997%26volume%3D26%26spage%3D21S%26epage%3D28S%26doi%3D10.1002%2Fhep.510260704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Kowdley, K. V.</span><span> </span><span class="NLM_article-title">Hematologic side effects of interferon and ribavirin therapy</span> <span class="citation_source-journal">J. Clin. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">S3</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.1097/01.mcg.0000145494.76305.11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1097%2F01.mcg.0000145494.76305.11" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2005&pages=S3-8&author=K.+V.+Kowdley&title=Hematologic+side+effects+of+interferon+and+ribavirin+therapy&doi=10.1097%2F01.mcg.0000145494.76305.11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1097%2F01.mcg.0000145494.76305.11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.mcg.0000145494.76305.11%26sid%3Dliteratum%253Aachs%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26atitle%3DHematologic%2520side%2520effects%2520of%2520interferon%2520and%2520ribavirin%2520therapy%26jtitle%3DJ.%2520Clin.%2520Gastroenterol.%26date%3D2005%26volume%3D39%26spage%3DS3%26epage%3D8%26doi%3D10.1097%2F01.mcg.0000145494.76305.11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Strader, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeff, L. B.</span><span> </span><span class="NLM_article-title">A brief history of the treatment of viral hepatitis C</span> <span class="citation_source-journal">Clin. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">6</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span><span class="refDoi"> DOI: 10.1002/cld.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fcld.1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=6-11&author=D.+B.+Straderauthor=L.+B.+Seeff&title=A+brief+history+of+the+treatment+of+viral+hepatitis+C&doi=10.1002%2Fcld.1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fcld.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcld.1%26sid%3Dliteratum%253Aachs%26aulast%3DStrader%26aufirst%3DD.%2BB.%26aulast%3DSeeff%26aufirst%3DL.%2BB.%26atitle%3DA%2520brief%2520history%2520of%2520the%2520treatment%2520of%2520viral%2520hepatitis%2520C%26jtitle%3DClin.%2520Liver%2520Dis.%26date%3D2012%26volume%3D1%26spage%3D6%26epage%3D11%26doi%3D10.1002%2Fcld.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Heim, M. H.</span><span> </span><span class="NLM_article-title">25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">535</span><span class="NLM_x">–</span> <span class="NLM_lpage">542</span><span class="refDoi"> DOI: 10.1038/nri3463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1038%2Fnri3463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=23743475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovFamurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=535-542&author=M.+H.+Heim&title=25+years+of+interferon-based+treatment+of+chronic+hepatitis+C%3A+an+epoch+coming+to+an+end&doi=10.1038%2Fnri3463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end</span></div><div class="casAuthors">Heim, Markus H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">535-542</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chronic hepatitis caused by infection with hepatitis C virus C (HCV) (therefore known as chronic hepatitis C (CHC)) is a leading cause of liver disease worldwide.  For the past 25 years, recombinant interferon-α (IFNα) has been the main component of treatments for HCV infection.  Treatment efficacy has shown a stepwise improvement following the pegylation of IFNα and its use in combination with other antiviral drugs.  However, viral escape mechanisms, refractory IFNα signalling in the liver and substantial drug toxicity still limit the efficacy of this treatment.  A new generation of HCV-specific antiviral drugs will probably improve response rates and might replace IFNs in CHC treatment in the next few years.  This Timeline article summarizes the history of CHC treatment using recombinant IFNα with an emphasis on the mechanisms of action and the causes of non-response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKQQMKuR1xXLVg90H21EOLACvtfcHk0lj8k_AJTUlC7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovFamurc%253D&md5=29af7191c765714e2020f354979e0e50</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnri3463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3463%26sid%3Dliteratum%253Aachs%26aulast%3DHeim%26aufirst%3DM.%2BH.%26atitle%3D25%2520years%2520of%2520interferon-based%2520treatment%2520of%2520chronic%2520hepatitis%2520C%253A%2520an%2520epoch%2520coming%2520to%2520an%2520end%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D13%26spage%3D535%26epage%3D542%26doi%3D10.1038%2Fnri3463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Liang, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghany, M. G.</span><span> </span><span class="NLM_article-title">Current and future therapies for hepatitis C virus infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">1907</span><span class="NLM_x">–</span> <span class="NLM_lpage">1917</span><span class="refDoi"> DOI: 10.1056/NEJMra1213651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1056%2FNEJMra1213651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=23675659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsl2gs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=1907-1917&author=T.+J.+Liangauthor=M.+G.+Ghany&title=Current+and+future+therapies+for+hepatitis+C+virus+infection&doi=10.1056%2FNEJMra1213651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Current and future therapies for hepatitis C virus infection</span></div><div class="casAuthors">Liang, T. Jake; Ghany, Marc G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1907-1917</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The recent approval of two direct-acting antiviral agents for hepatitis C viral (HCV) infection that specifically inhibit viral replication has dramatically increased the viral clearance rate.  It is anticipated that in the course of such a screening process, a large no. of persons will be found to be infected with HCV; this article reviews the current therapy for HCV infection and the landscape of drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4zjjmKeKrZrVg90H21EOLACvtfcHk0lj8k_AJTUlC7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsl2gs78%253D&md5=6be058d0298a4441a180ac076d7293aa</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1213651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1213651%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DT.%2BJ.%26aulast%3DGhany%26aufirst%3DM.%2BG.%26atitle%3DCurrent%2520and%2520future%2520therapies%2520for%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D1907%26epage%3D1917%26doi%3D10.1056%2FNEJMra1213651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Manns, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Hahn, T.</span><span> </span><span class="NLM_article-title">Novel therapies for hepatitis C - one pill fits all?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">595</span><span class="NLM_x">–</span> <span class="NLM_lpage">610</span><span class="refDoi"> DOI: 10.1038/nrd4050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1038%2Fnrd4050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=595-610&author=M.+P.+Mannsauthor=T.+von+Hahn&title=Novel+therapies+for+hepatitis+C+-+one+pill+fits+all%3F&doi=10.1038%2Fnrd4050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd4050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4050%26sid%3Dliteratum%253Aachs%26aulast%3DManns%26aufirst%3DM.%2BP.%26aulast%3Dvon%2BHahn%26aufirst%3DT.%26atitle%3DNovel%2520therapies%2520for%2520hepatitis%2520C%2520-%2520one%2520pill%2520fits%2520all%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D595%26epage%3D610%26doi%3D10.1038%2Fnrd4050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Sherman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flamm, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afdhal, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reesink, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sankoh, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poordad, F.</span><span> </span><span class="NLM_article-title">Response-guided telaprevir combination treatment for hepatitis C virus infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">1014</span><span class="NLM_x">–</span> <span class="NLM_lpage">1024</span><span class="refDoi"> DOI: 10.1056/NEJMoa1014463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1056%2FNEJMoa1014463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=21916639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2mtrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1014-1024&author=K.+E.+Shermanauthor=S.+L.+Flammauthor=N.+H.+Afdhalauthor=D.+R.+Nelsonauthor=M.+S.+Sulkowskiauthor=G.+T.+Eversonauthor=M.+W.+Friedauthor=M.+Adlerauthor=H.+W.+Reesinkauthor=M.+Martinauthor=A.+J.+Sankohauthor=N.+Addaauthor=R.+S.+Kauffmanauthor=S.+Georgeauthor=C.+I.+Wrightauthor=F.+Poordad&title=Response-guided+telaprevir+combination+treatment+for+hepatitis+C+virus+infection&doi=10.1056%2FNEJMoa1014463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Response-guided telaprevir combination treatment for hepatitis C virus infection</span></div><div class="casAuthors">Sherman, Kenneth E.; Flamm, Steven L.; Afdhal, Nezam H.; Nelson, David R.; Sulkowski, Mark S.; Everson, Gregory T.; Fried, Michael W.; Adler, Michael; Reesink, Hendrik W.; Martin, Marie; Sankoh, Abdul J.; Adda, Nathalie; Kauffman, Robert S.; George, Shelley; Wright, Christopher I.; Poordad, Fred</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1014-1024</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Patients with chronic infection with hepatitis C virus (HCV) genotype 1 often need 48 wk of peginterferon-ribavirin treatment for a sustained virol. response.  We designed a noninferiority trial (noninferiority margin, -10.5%) to compare rates of sustained virol. response among patients receiving two treatment durations.  Methods: We enrolled patients with chronic infection with HCV genotype 1 who had not previously received treatment.  All patients received telaprevir at a dose of 750 mg every 8 h, peginterferon alfa-2a at a dose of 180 μg per wk, and ribavirin at a dose of 1000 to 1200 mg per day, for 12 wk (T12PR12), followed by peginterferon-ribavirin.  Patients who had an extended rapid virol. response (undetectable HCV RNA levels at weeks 4 and 12) were randomly assigned after week 20 to receive the dual therapy for 4 more weeks (T12PR24) or 28 more weeks (T12PR48).  Patients without an extended rapid virol. response were assigned to T12PR48.  Results: Of the 540 patients, a total of 352 (65%) had an extended rapid virol. response.  The overall rate of sustained virol. response was 72%.  Among the 322 patients with an extended rapid virol. response who were randomly assigned to a study group, 149 (92%) in the T12PR24 group and 140 (88%) in the T12PR48 group had a sustained virol. response (abs. difference, 4 percentage points; 95% confidence interval, -2 to 11), establishing noninferiority.  Adverse events included rash (in 37% of patients, severe in 5%) and anemia (in 39%, severe in 60%).  Discontinuation of all the study drugs was based on adverse events in 18% of patients overall, as well as in 1%0/ of patients (all of whom were randomly assigned) in the T12PR24 group and 12% of the patients randomly assigned to the T12PR48 group (P < 0.001).  Conclusions: In this study, among patients with chronic HCV infection who had not received treatment previously, a regimen of peginterferon-ribavirin for 24 wk, with telaprevir for the first 12 wk, was noninferior to the same regimen for 48 wk in patients with undetectable HCV RNA at weeks 4 and 12, with an extended rapid virol. response achieved in nearly two thirds of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_7m3eqLwOibVg90H21EOLACvtfcHk0li6Np9EJlFuig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2mtrrI&md5=338e575a354c4e51d0471dda3949847f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1014463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1014463%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DK.%2BE.%26aulast%3DFlamm%26aufirst%3DS.%2BL.%26aulast%3DAfdhal%26aufirst%3DN.%2BH.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DFried%26aufirst%3DM.%2BW.%26aulast%3DAdler%26aufirst%3DM.%26aulast%3DReesink%26aufirst%3DH.%2BW.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DSankoh%26aufirst%3DA.%2BJ.%26aulast%3DAdda%26aufirst%3DN.%26aulast%3DKauffman%26aufirst%3DR.%2BS.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DWright%26aufirst%3DC.%2BI.%26aulast%3DPoordad%26aufirst%3DF.%26atitle%3DResponse-guided%2520telaprevir%2520combination%2520treatment%2520for%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D1014%26epage%3D1024%26doi%3D10.1056%2FNEJMoa1014463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Bacon, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vierling, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, Z. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sings, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boparai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burroughs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brass, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteban, R.</span><span> </span><span class="NLM_article-title">Boceprevir for previously treated chronic HCV genotype 1 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1207</span><span class="NLM_x">–</span> <span class="NLM_lpage">1217</span><span class="refDoi"> DOI: 10.1056/NEJMoa1009482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1056%2FNEJMoa1009482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=21449784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1Cht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1207-1217&author=B.+R.+Baconauthor=S.+C.+Gordonauthor=E.+Lawitzauthor=P.+Marcellinauthor=J.+M.+Vierlingauthor=S.+Zeuzemauthor=F.+Poordadauthor=Z.+D.+Goodmanauthor=H.+L.+Singsauthor=N.+Boparaiauthor=M.+Burroughsauthor=C.+A.+Brassauthor=J.+K.+Albrechtauthor=R.+Esteban&title=Boceprevir+for+previously+treated+chronic+HCV+genotype+1+infection&doi=10.1056%2FNEJMoa1009482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Boceprevir for previously treated chronic HCV genotype 1 infection</span></div><div class="casAuthors">Bacon, Bruce R.; Gordon, Stuart C.; Lawitz, Eric; Marcellin, Patrick; Vierling, John M.; Zeuzem, Stefan; Poordad, Fred; Goodman, Zachary D.; Sings, Heather L.; Boparai, Navdeep; Burroughs, Margaret; Brass, Clifford A.; Albrecht, Janice K.; Esteban, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1207-1217</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are suboptimal.  Boceprevir, a protease inhibitor that binds to the HCV nonstructural 3 (NS3) active site, has been suggested as an addnl. treatment.  To assess the effect of the combination of boceprevir and peginterferon-ribavirin for retreatment of patients with chronic HCV genotype 1 infection, we randomly assigned patients (in a 1:2:2 ratio) to one of three groups.  In all three groups, peginterferon alfa-2b and ribavirin were administered for 4 wk (the lead-in period).  Subsequently, group 1 (control group) received placebo plus peginterferon-ribavirin for 44 wk; group 2 received boceprevir plus peginterferon-ribavirin for 32 wk, and patients with a detectable HCV RNA level at week 8 received placebo plus peginterferon-ribavirin for an addnl. 12 wk; and group 3 received boceprevir plus peginterferon-ribavirin for 44 wk.  A total of 403 patients were treated.  The rate of sustained virol. response was significantly higher in the two boceprevir groups (group 2, 59%; group 3, 66%) than in the control group (21%, P < 0.001).  Among patients with an undetectable HCV RNA level at week 8, the rate of sustained virol. response was 86% after 32 wk of triple therapy and 88% after 44 wk of triple therapy.  Among the 102 patients with a decrease in the HCV RNA level of less than 1 log10 IU per mL at treatment week 4, the rates of sustained virol. response were 0%, 33%, and 34% in groups 1, 2, and 3, resp.  Anemia was significantly more common in the boceprevir groups than in the control group, and erythropoietin was administered in 41 to 46% of boceprevir-treated patients and 21% of controls.  The addn. of boceprevir to peginterferon-ribavirin resulted in significantly higher rates of sustained virol. response in previously treated patients with chronic HCV genotype 1 infection, as compared with peginterferon-ribavirin alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjykaE3KIqArVg90H21EOLACvtfcHk0li6Np9EJlFuig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1Cht7k%253D&md5=402802777ab3a369c71332a84a8b40e3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1009482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1009482%26sid%3Dliteratum%253Aachs%26aulast%3DBacon%26aufirst%3DB.%2BR.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DVierling%26aufirst%3DJ.%2BM.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DGoodman%26aufirst%3DZ.%2BD.%26aulast%3DSings%26aufirst%3DH.%2BL.%26aulast%3DBoparai%26aufirst%3DN.%26aulast%3DBurroughs%26aufirst%3DM.%26aulast%3DBrass%26aufirst%3DC.%2BA.%26aulast%3DAlbrecht%26aufirst%3DJ.%2BK.%26aulast%3DEsteban%26aufirst%3DR.%26atitle%3DBoceprevir%2520for%2520previously%2520treated%2520chronic%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1207%26epage%3D1217%26doi%3D10.1056%2FNEJMoa1009482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Yau, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, E. M.</span><span> </span><span class="NLM_article-title">Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review</span> <span class="citation_source-journal">Can. J. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">445</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=25229466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A280%3ADC%252BC2M7itlymsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=445-451&author=A.+H.+Yauauthor=E.+M.+Yoshida&title=Hepatitis+C+drugs%3A+the+end+of+the+pegylated+interferon+era+and+the+emergence+of+all-oral+interferon-free+antiviral+regimens%3A+a+concise+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review</span></div><div class="casAuthors">Yau Alan Hoi Lun; Yoshida Eric M</div><div class="citationInfo"><span class="NLM_cas:title">Canadian journal of gastroenterology & hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">445-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Between 2001 and 2011, the standard of care for chronic hepatitis C virus (HCV) infection was a combination of pegylated interferon (PEG-IFN) and ribavirin (RBV).  In May 2011, boceprevir and telaprevir, two first-generation NS3/4A protease inhibitors, were approved in combination with PEG-IFN and RBV for 24 to 48 weeks in hepatitis C virus genotype 1 infections.  In December 2013, simeprevir, a second-generation NS3/4A protease inhibitor, was approved for use with PEG-IFN and RBV for 12 weeks in genotype 1, while sofosbuvir, a NS5B nucleotide polymerase inhibitor, was approved for use with PEG-IFN and RBV for 12 weeks in genotypes 1 and 4, as well as with RBV alone for 12 weeks in genotype 2 and for 24 weeks in genotype 3.  Sofosbuvir combined with simeprevir or an NS5A replication complex inhibitor (ledipasvir or daclatasvir) with or without RBV for 12 weeks in genotype 1 resulted in a sustained virological response >90%, irrespective of previous treatment history or presence of cirrhosis.  Similarly impressive sustained virological response rates have been shown with ABT-450/r (ritonavir-boosted NS3/4A protease inhibitor)-based regimens in combination with other direct-acting antiviral agent(s) with or without RBV for 12 weeks in genotype 1.  The optimal all-oral interferon-free antiviral regimen likely entails a combination of an NS5B nucleotide polymerase inhibitor with either a second-generation NS3/4A protease inhibitor or an NS5A replication complex inhibitor with or without RBV.  Further research is needed to determine the role of resistance testing, clarify the optimal follow-up duration post-treatment, and evaluate the antiviral efficacy and safety in difficult-to-cure patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtIKrjnj9vbC-bLEOO4dYpfW6udTcc2eZF4c68BKhZSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7itlymsg%253D%253D&md5=6158273c12e24d51cca8e7e85749dd1b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYau%26aufirst%3DA.%2BH.%26aulast%3DYoshida%26aufirst%3DE.%2BM.%26atitle%3DHepatitis%2520C%2520drugs%253A%2520the%2520end%2520of%2520the%2520pegylated%2520interferon%2520era%2520and%2520the%2520emergence%2520of%2520all-oral%2520interferon-free%2520antiviral%2520regimens%253A%2520a%2520concise%2520review%26jtitle%3DCan.%2520J.%2520Gastroenterol.%2520Hepatol.%26date%3D2014%26volume%3D28%26spage%3D445%26epage%3D451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Wyles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svarovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flamm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span> </span><span class="NLM_article-title">Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1793</span><span class="NLM_x">–</span> <span class="NLM_lpage">1797</span><span class="refDoi"> DOI: 10.1002/hep.27814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fhep.27814" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=1793-1797&author=D.+Wylesauthor=P.+Pockrosauthor=G.+Morelliauthor=Z.+Younesauthor=E.+Svarovskaiaauthor=J.+C.+Yangauthor=P.+S.+Pangauthor=Y.+Zhuauthor=J.+G.+McHutchisonauthor=S.+Flammauthor=E.+Lawitz&title=Ledipasvir-sofosbuvir+plus+ribavirin+for+patients+with+genotype+1+hepatitis+C+virus+previously+treated+in+clinical+trials+of+sofosbuvir+regimens&doi=10.1002%2Fhep.27814"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fhep.27814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27814%26sid%3Dliteratum%253Aachs%26aulast%3DWyles%26aufirst%3DD.%26aulast%3DPockros%26aufirst%3DP.%26aulast%3DMorelli%26aufirst%3DG.%26aulast%3DYounes%26aufirst%3DZ.%26aulast%3DSvarovskaia%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DFlamm%26aufirst%3DS.%26aulast%3DLawitz%26aufirst%3DE.%26atitle%3DLedipasvir-sofosbuvir%2520plus%2520ribavirin%2520for%2520patients%2520with%2520genotype%25201%2520hepatitis%2520C%2520virus%2520previously%2520treated%2520in%2520clinical%2520trials%2520of%2520sofosbuvir%2520regimens%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D1793%26epage%3D1797%26doi%3D10.1002%2Fhep.27814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varunok, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguilar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felizarta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGovern, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polepally, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D. E.</span><span> </span><span class="NLM_article-title">Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">364</span><span class="NLM_x">–</span> <span class="NLM_lpage">369</span><span class="refDoi"> DOI: 10.1016/j.jhep.2015.03.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1016%2Fj.jhep.2015.03.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=25839406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslCntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=364-369&author=J.+Lalezariauthor=J.+G.+Sullivanauthor=P.+Varunokauthor=E.+Galenauthor=K.+V.+Kowdleyauthor=V.+Rustgiauthor=H.+Aguilarauthor=F.+Felizartaauthor=B.+McGovernauthor=M.+Kingauthor=A.+R.+Polepallyauthor=D.+E.+Cohen&title=Ombitasvir%2Fparitaprevir%2Fr+and+dasabuvir+plus+ribavirin+in+HCV+genotype+1-infected+patients+on+methadone+or+buprenorphine&doi=10.1016%2Fj.jhep.2015.03.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine</span></div><div class="casAuthors">Lalezari, Jacob; Sullivan, J. Greg; Varunok, Peter; Galen, Edward; Kowdley, Kris V.; Rustgi, Vinod; Aguilar, Humberto; Felizarta, Franco; McGovern, Barbara; King, Martin; Polepally, Akshanth R.; Cohen, Daniel E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">364-369</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV)-infected patients with a history of injection drug use have low rates of initiation and completion of interferon-based therapies.  This study evaluated efficacy, safety, and pharmacokinetics of a 12-wk all-oral regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir + ribavirin in HCV genotype 1-infected patients on stable opioid replacement therapy.This was a phase II, multicenter, open-label, single-arm study in treatment-na.ovrddot.ive or peginterferon/ribavirin treatment-experienced HCV genotype 1-infected patients on methadone or buprenorphine ± naloxone.  Patients received 12 wk of co-formulated ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) and dasabuvir (250 mg twice daily) + wt.-based ribavirin.  The primary efficacy endpoint was sustained virol. response 12 wk post-treatment.Thirty-eight non-cirrhotic patients on chronic methadone (n = 19) or buprenorphine (n = 19) were enrolled.  A total of 37 patients (97.4%) had a sustained virol. response 12 wk post-treatment.  No patient had a viral breakthrough or relapse.  One patient discontinued due to serious adverse events unrelated to study drug (cerebrovascular accident and sarcoma).  The most frequent adverse events were nausea, fatigue, and headache.  Eight patients had on-treatment Hb concns. <10 g/dL.  Pharmacokinetic analyses indicated no clin. meaningful impact of methadone or buprenorphine on ombitasvir, paritaprevir, ritonavir, dasabuvir, or dasabuvir M1 metabolite exposures.  No dose adjustments of methadone or buprenorphine were required.The interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir + ribavirin for 12 wk was well tolerated and achieved sustained virol. response in 97.4% of patients on opioid substitution therapy in this study.  This all-oral regimen may provide an effective alternative to interferon-based therapies for HCV-infected patients with a history of injection drug use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuco6UpiasarVg90H21EOLACvtfcHk0liTyITUQ666VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslCntbs%253D&md5=a8dd009dd2f639c0c71b35cdc3aa8fe9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2015.03.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2015.03.029%26sid%3Dliteratum%253Aachs%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DSullivan%26aufirst%3DJ.%2BG.%26aulast%3DVarunok%26aufirst%3DP.%26aulast%3DGalen%26aufirst%3DE.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DAguilar%26aufirst%3DH.%26aulast%3DFelizarta%26aufirst%3DF.%26aulast%3DMcGovern%26aufirst%3DB.%26aulast%3DKing%26aufirst%3DM.%26aulast%3DPolepally%26aufirst%3DA.%2BR.%26aulast%3DCohen%26aufirst%3DD.%2BE.%26atitle%3DOmbitasvir%252Fparitaprevir%252Fr%2520and%2520dasabuvir%2520plus%2520ribavirin%2520in%2520HCV%2520genotype%25201-infected%2520patients%2520on%2520methadone%2520or%2520buprenorphine%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D63%26spage%3D364%26epage%3D369%26doi%3D10.1016%2Fj.jhep.2015.03.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notsumata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurosaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setze, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilot-Matias, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilchez, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1523</span><span class="NLM_x">–</span> <span class="NLM_lpage">1532</span><span class="refDoi"> DOI: 10.1002/hep.27705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fhep.27705" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=1523-1532&author=K.+Chayamaauthor=K.+Notsumataauthor=M.+Kurosakiauthor=K.+Satoauthor=L.+Rodriguesauthor=C.+Setzeauthor=P.+Badriauthor=T.+Pilot-Matiasauthor=R.+A.+Vilchezauthor=H.+Kumada&title=Randomized+trial+of+interferon-+and+ribavirin-free+ombitasvir%2Fparitaprevir%2Fritonavir+in+treatment-experienced+hepatitis+C+virus-infected+patients&doi=10.1002%2Fhep.27705"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fhep.27705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27705%26sid%3Dliteratum%253Aachs%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DNotsumata%26aufirst%3DK.%26aulast%3DKurosaki%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DRodrigues%26aufirst%3DL.%26aulast%3DSetze%26aufirst%3DC.%26aulast%3DBadri%26aufirst%3DP.%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DVilchez%26aufirst%3DR.%2BA.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DRandomized%2520trial%2520of%2520interferon-%2520and%2520ribavirin-free%2520ombitasvir%252Fparitaprevir%252Fritonavir%2520in%2520treatment-experienced%2520hepatitis%2520C%2520virus-infected%2520patients%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D1523%26epage%3D1532%26doi%3D10.1002%2Fhep.27705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiffman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Assi, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNally, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feld, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pianko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. R.</span><span> </span><span class="NLM_article-title">Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">1867</span><span class="NLM_x">–</span> <span class="NLM_lpage">1877</span><span class="refDoi"> DOI: 10.1056/NEJMoa1214854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1056%2FNEJMoa1214854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=23607593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsl2gsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=1867-1877&author=I.+M.+Jacobsonauthor=S.+C.+Gordonauthor=K.+V.+Kowdleyauthor=E.+M.+Yoshidaauthor=M.+Rodriguez-Torresauthor=M.+S.+Sulkowskiauthor=M.+L.+Shiffmanauthor=E.+Lawitzauthor=G.+Eversonauthor=M.+Bennettauthor=E.+Schiffauthor=M.+T.+Al-Assiauthor=G.+M.+Subramanianauthor=D.+Anauthor=M.+Linauthor=J.+McNallyauthor=D.+Brainardauthor=W.+T.+Symondsauthor=J.+G.+McHutchisonauthor=K.+Patelauthor=J.+Feldauthor=S.+Piankoauthor=D.+R.+Nelson&title=Sofosbuvir+for+hepatitis+C+genotype+2+or+3+in+patients+without+treatment+options&doi=10.1056%2FNEJMoa1214854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options</span></div><div class="casAuthors">Jacobson, Ira M.; Gordon, Stuart C.; Kowdley, Kris V.; Yoshida, Eric M.; Rodriguez-Torres, Maribel; Sulkowski, Mark S.; Shiffman, Mitchell L.; Lawitz, Eric; Everson, Gregory; Bennett, Michael; Schiff, Eugene; Al-Assi, M. Tarek; Subramanian, G. Mani; Lin, Ming; McNally, John; Brainard, Diana; Symonds, William T.; McHutchison, John G.; Patel, Keyur; Feld, Jordan; Pianko, Stephen; Nelson, David R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1867-1877</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for whom treatment with peginterferon is not an option, or who have not had a response to prior interferon treatment, currently have no approved treatment options.  In phase 2 trials, regimens including the oral nucleotide polymerase inhibitor sofosbuvir have shown efficacy in patients, with HCV genotype 2 or 3 infection.  We conducted two randomized, phase 3 studies involving patients with chronic HCV genotype 2 or 3 infection.  In one trial, patients for whom treatment with peginterferon was not an option received oral sofosbuvir and ribavirin (207 patients) or matching placebo (71) for 12 wk.  In a second trial, patients who had not had a response to prior interferon therapy received sofosbuvir and ribavirin for 12 wk (103 patients) or 16 wk (98).  The primary end point was a sustained virol. response at 12 wk after therapy.  Among patients for whom treatment with peginterferon was not an option, the rate of a sustained virol. response was 78% (95% confidence interval [CI], 72 to 83) with sofosbuvir and ribavirin, as compared with 0% with placebo (P<0.001).  Among previously treated patients, the rate of response was 50% with 12 wk of treatment, as compared with 73% with 16 wk of treatment (difference, -23 percentage points; 95% CI, -35 to -11; P<0.001).  In both studies, response rates were lower among patients with genotype 3 infection than among those with genotype 2 infection and, among patients with genotype 3 infection, lower among those with cirrhosis than among those without cirrhosis.  The most common adverse events were headache, fatigue, nausea, and insomnia; the overall rate of discontinuation of sofosbuvir was low (1 to 2%).  In patients with HCV genotype 2 or 3 infection for whom treatment with peginterferon and ribavirin was not an option, 12 or 16 wk of treatment with sofosbuvir and ribavirin was effective.  Efficacy was increased among patients with HCV genotype 2 infection and those without cirrhosis.  In previously treated patients with genotype 3 infection, 16 wk of therapy was significantly more effective than 12 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobO40R_56pvbVg90H21EOLACvtfcHk0liQPAGA3jMsuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsl2gsrk%253D&md5=d12d834921319bec54f6bc725ba58c51</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1214854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1214854%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DYoshida%26aufirst%3DE.%2BM.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DShiffman%26aufirst%3DM.%2BL.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DEverson%26aufirst%3DG.%26aulast%3DBennett%26aufirst%3DM.%26aulast%3DSchiff%26aufirst%3DE.%26aulast%3DAl-Assi%26aufirst%3DM.%2BT.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DAn%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DBrainard%26aufirst%3DD.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DFeld%26aufirst%3DJ.%26aulast%3DPianko%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26atitle%3DSofosbuvir%2520for%2520hepatitis%2520C%2520genotype%25202%2520or%25203%2520in%2520patients%2520without%2520treatment%2520options%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D1867%26epage%3D1877%26doi%3D10.1056%2FNEJMoa1214854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Nelson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harlan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oguchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz-Lasanta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinovitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravendhran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheikh, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varunok, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennicken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rana, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span> </span><span class="NLM_article-title">All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1127</span><span class="NLM_x">–</span> <span class="NLM_lpage">1135</span><span class="refDoi"> DOI: 10.1002/hep.27726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fhep.27726" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=1127-1135&author=D.+R.+Nelsonauthor=J.+N.+Cooperauthor=J.+P.+Lalezariauthor=E.+Lawitzauthor=P.+J.+Pockrosauthor=N.+Gitlinauthor=B.+F.+Freilichauthor=Z.+H.+Younesauthor=W.+Harlanauthor=R.+Ghalibauthor=G.+Oguchiauthor=P.+J.+Thuluvathauthor=G.+Ortiz-Lasantaauthor=M.+Rabinovitzauthor=D.+Bernsteinauthor=M.+Bennettauthor=T.+Hawkinsauthor=N.+Ravendhranauthor=A.+M.+Sheikhauthor=P.+Varunokauthor=K.+V.+Kowdleyauthor=D.+Hennickenauthor=F.+McPheeauthor=K.+Ranaauthor=E.+A.+Hughes&title=All-oral+12-week+treatment+with+daclatasvir+plus+sofosbuvir+in+patients+with+hepatitis+C+virus+genotype+3+infection%3A+ALLY-3+phase+III+study&doi=10.1002%2Fhep.27726"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fhep.27726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27726%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DCooper%26aufirst%3DJ.%2BN.%26aulast%3DLalezari%26aufirst%3DJ.%2BP.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DGitlin%26aufirst%3DN.%26aulast%3DFreilich%26aufirst%3DB.%2BF.%26aulast%3DYounes%26aufirst%3DZ.%2BH.%26aulast%3DHarlan%26aufirst%3DW.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DOguchi%26aufirst%3DG.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DOrtiz-Lasanta%26aufirst%3DG.%26aulast%3DRabinovitz%26aufirst%3DM.%26aulast%3DBernstein%26aufirst%3DD.%26aulast%3DBennett%26aufirst%3DM.%26aulast%3DHawkins%26aufirst%3DT.%26aulast%3DRavendhran%26aufirst%3DN.%26aulast%3DSheikh%26aufirst%3DA.%2BM.%26aulast%3DVarunok%26aufirst%3DP.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DHennicken%26aufirst%3DD.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DRana%26aufirst%3DK.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26atitle%3DAll-oral%252012-week%2520treatment%2520with%2520daclatasvir%2520plus%2520sofosbuvir%2520in%2520patients%2520with%2520hepatitis%2520C%2520virus%2520genotype%25203%2520infection%253A%2520ALLY-3%2520phase%2520III%2520study%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D1127%26epage%3D1135%26doi%3D10.1002%2Fhep.27726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Ruane, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ain, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stryker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meshrekey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soliman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfe, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riad, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikhail, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kersey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massetto, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doehle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knox, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span> </span><span class="NLM_article-title">Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1040</span><span class="NLM_x">–</span> <span class="NLM_lpage">1046</span><span class="refDoi"> DOI: 10.1016/j.jhep.2014.10.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1016%2Fj.jhep.2014.10.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=25450208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFWksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=1040-1046&author=P.+J.+Ruaneauthor=D.+Ainauthor=R.+Strykerauthor=R.+Meshrekeyauthor=M.+Solimanauthor=P.+R.+Wolfeauthor=J.+Riadauthor=S.+Mikhailauthor=K.+Kerseyauthor=D.+Jiangauthor=B.+Massettoauthor=B.+Doehleauthor=B.+J.+Kirbyauthor=S.+J.+Knoxauthor=J.+G.+McHutchisonauthor=W.+T.+Symonds&title=Sofosbuvir+plus+ribavirin+for+the+treatment+of+chronic+genotype+4+hepatitis+C+virus+infection+in+patients+of+Egyptian+ancestry&doi=10.1016%2Fj.jhep.2014.10.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry</span></div><div class="casAuthors">Ruane, Peter J.; Ain, Dani; Stryker, Richard; Meshrekey, Raymond; Soliman, Mina; Wolfe, Peter R.; Riad, Joseph; Mikhail, Sameh; Kersey, Kathryn; Jiang, Deyuan; Massetto, Benedetta; Doehle, Brian; Kirby, Brian J.; Knox, Steven J.; McHutchison, John G.; Symonds, William T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1040-1046</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We conducted an open-label phase 2 study to assess the efficacy and safety of the oral nucleotide polymerase inhibitor sofosbuvir in combination with ribavirin in patients of Egyptian ancestry, chronically infected with genotype 4 hepatitis C virus (HCV).Treatment-naive and previously treated patients with genotype 4 HCV were randomly allocated in a 1:1 ratio to receive sofosbuvir 400 mg and wt.-based ribavirin, for 12 or 24 wk.  The primary efficacy endpoint was the proportion of patients with sustained virol. response (HCV RNA <25 IU/mL) 12 wk after cessation of therapy (SVR12).Thirty treatment-naive and thirty previously treated patients were enrolled and treated for 12 wk (n = 31) or 24 wk (n = 29).  Overall, 23% of patients had cirrhosis and 38% had diabetes. 14% of treatment-naive patients were interferon ineligible and 63% of treatment-experienced patients had prior non-response.  SVR12 was achieved by 68% of patients (95% CI, 49-83%) in the 12-wk group, and by 93% of patients (95% CI, 77-99%) in the 24-wk group.  The most common adverse events were headache, insomnia, and fatigue.  No patient discontinued treatment due to an adverse event.The findings from the present study suggest that 24 wk of sofosbuvir plus ribavirin is an efficacious and well tolerated treatment in patients with HCV genotype 4 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3HNYO9MOtoLVg90H21EOLACvtfcHk0lgw7dDDtGjhdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFWksro%253D&md5=d4259fb4087ac943e11d16c88594c77a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.10.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.10.044%26sid%3Dliteratum%253Aachs%26aulast%3DRuane%26aufirst%3DP.%2BJ.%26aulast%3DAin%26aufirst%3DD.%26aulast%3DStryker%26aufirst%3DR.%26aulast%3DMeshrekey%26aufirst%3DR.%26aulast%3DSoliman%26aufirst%3DM.%26aulast%3DWolfe%26aufirst%3DP.%2BR.%26aulast%3DRiad%26aufirst%3DJ.%26aulast%3DMikhail%26aufirst%3DS.%26aulast%3DKersey%26aufirst%3DK.%26aulast%3DJiang%26aufirst%3DD.%26aulast%3DMassetto%26aufirst%3DB.%26aulast%3DDoehle%26aufirst%3DB.%26aulast%3DKirby%26aufirst%3DB.%2BJ.%26aulast%3DKnox%26aufirst%3DS.%2BJ.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26atitle%3DSofosbuvir%2520plus%2520ribavirin%2520for%2520the%2520treatment%2520of%2520chronic%2520genotype%25204%2520hepatitis%2520C%2520virus%2520infection%2520in%2520patients%2520of%2520Egyptian%2520ancestry%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26spage%3D1040%26epage%3D1046%26doi%3D10.1016%2Fj.jhep.2014.10.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">European Association for the Study of Liver.</span><span> </span><span class="NLM_article-title">EASL Recommendations on Treatment of Hepatitis C 2015</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">236</span><span class="refDoi"> DOI: 10.1016/j.jhep.2015.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1016%2Fj.jhep.2015.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=25911336" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=199-236&author=European+Association+for+the+Study+of+Liver.&title=EASL+Recommendations+on+Treatment+of+Hepatitis+C+2015&doi=10.1016%2Fj.jhep.2015.03.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2015.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2015.03.025%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DEASL%2520Recommendations%2520on%2520Treatment%2520of%2520Hepatitis%2520C%25202015%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D63%26spage%3D199%26epage%3D236%26doi%3D10.1016%2Fj.jhep.2015.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Poveda, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyles, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedreira, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro-Iglesias, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cachay, E.</span><span> </span><span class="NLM_article-title">Update on hepatitis C virus resistance to direct-acting antiviral agents</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">191</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2014.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1016%2Fj.antiviral.2014.05.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2014&pages=181-191&author=E.+Povedaauthor=D.+L.+Wylesauthor=A.+Menaauthor=J.+D.+Pedreiraauthor=A.+Castro-Iglesiasauthor=E.+Cachay&title=Update+on+hepatitis+C+virus+resistance+to+direct-acting+antiviral+agents&doi=10.1016%2Fj.antiviral.2014.05.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DPoveda%26aufirst%3DE.%26aulast%3DWyles%26aufirst%3DD.%2BL.%26aulast%3DMena%26aufirst%3DA.%26aulast%3DPedreira%26aufirst%3DJ.%2BD.%26aulast%3DCastro-Iglesias%26aufirst%3DA.%26aulast%3DCachay%26aufirst%3DE.%26atitle%3DUpdate%2520on%2520hepatitis%2520C%2520virus%2520resistance%2520to%2520direct-acting%2520antiviral%2520agents%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D108%26spage%3D181%26epage%3D191%26doi%3D10.1016%2Fj.antiviral.2014.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Wyles, D. L.</span><span> </span><span class="NLM_article-title">Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection</span> <span class="citation_source-journal">Top. Antiviral Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=23154254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A280%3ADC%252BC3s7js1Wrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=139-145&author=D.+L.+Wyles&title=Beyond+telaprevir+and+boceprevir%3A+resistance+and+new+agents+for+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection</span></div><div class="casAuthors">Wyles David L</div><div class="citationInfo"><span class="NLM_cas:title">Topics in antiviral medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">139-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The addition of the hepatitis C virus (HCV) protease inhibitors telaprevir and boceprevir to peginterferon alfa with ribavirin therapy has increased cure rates in HCV infection.  Numerous other direct-acting antivirals (DAAs) are in advanced stages of development, including next-generation protease inhibitors, nonstructural protein (NS) 5A inhibitors, and nonnucleoside and nucleos(t)ide NS5B polymerase inhibitors.  The classes have different potencies, different resistance mutation profiles, and different barriers to the emergence of resistance.  A comprehensive table of resistance mutations for classes of DAAs is presented.  Numerous combinations of DAAs with or without ribavirin have been evaluated in early studies of interferon alfa-free regimens, with results indicating that cure is indeed possible with such therapy and suggesting that identification of regimens that could produce cure in the majority of patients may occur within the foreseeable future.  This article summarizes a presentation by David L.  Wyles, MD, at the IAS-USA live continuing medical education activity held in New York in June 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0UHQu1DLNKQpJitSxOdIlfW6udTcc2eYvmpEIhpxMWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7js1Wrtw%253D%253D&md5=6316bc6277cce8b176c313bb8d23c65b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWyles%26aufirst%3DD.%2BL.%26atitle%3DBeyond%2520telaprevir%2520and%2520boceprevir%253A%2520resistance%2520and%2520new%2520agents%2520for%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DTop.%2520Antiviral%2520Med.%26date%3D2012%26volume%3D20%26spage%3D139%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Pawlotsky, J. M.</span><span> </span><span class="NLM_article-title">Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1742</span><span class="NLM_x">–</span> <span class="NLM_lpage">1751</span><span class="refDoi"> DOI: 10.1002/hep.24262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fhep.24262" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2011&pages=1742-1751&author=J.+M.+Pawlotsky&title=Treatment+failure+and+resistance+with+direct-acting+antiviral+drugs+against+hepatitis+C+virus&doi=10.1002%2Fhep.24262"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fhep.24262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24262%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.%2BM.%26atitle%3DTreatment%2520failure%2520and%2520resistance%2520with%2520direct-acting%2520antiviral%2520drugs%2520against%2520hepatitis%2520C%2520virus%26jtitle%3DHepatology%26date%3D2011%26volume%3D53%26spage%3D1742%26epage%3D1751%26doi%3D10.1002%2Fhep.24262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Xiao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fofana, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heydmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soulier, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habersetzer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doffoel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeisel, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumert, T. F.</span><span> </span><span class="NLM_article-title">Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1004128</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1004128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1371%2Fjournal.ppat.1004128" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=e1004128&author=F.+Xiaoauthor=I.+Fofanaauthor=L.+Heydmannauthor=H.+Barthauthor=E.+Soulierauthor=F.+Habersetzerauthor=M.+Doffoelauthor=J.+Bukhauthor=A.+H.+Patelauthor=M.+B.+Zeiselauthor=T.+F.+Baumert&title=Hepatitis+C+virus+cell-cell+transmission+and+resistance+to+direct-acting+antiviral+agents&doi=10.1371%2Fjournal.ppat.1004128"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1004128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1004128%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DFofana%26aufirst%3DI.%26aulast%3DHeydmann%26aufirst%3DL.%26aulast%3DBarth%26aufirst%3DH.%26aulast%3DSoulier%26aufirst%3DE.%26aulast%3DHabersetzer%26aufirst%3DF.%26aulast%3DDoffoel%26aufirst%3DM.%26aulast%3DBukh%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DA.%2BH.%26aulast%3DZeisel%26aufirst%3DM.%2BB.%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26atitle%3DHepatitis%2520C%2520virus%2520cell-cell%2520transmission%2520and%2520resistance%2520to%2520direct-acting%2520antiviral%2520agents%26jtitle%3DPLoS%2520Pathog.%26date%3D2014%26volume%3D10%26spage%3De1004128%26doi%3D10.1371%2Fjournal.ppat.1004128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Aissa Larousse, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trimoulet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recordon Pinson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tauzin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzouz, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben Mami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheikh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Triki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleury, H.</span><span> </span><span class="NLM_article-title">Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naive patients infected with HCV genotype 1 in Tunisia</span> <span class="citation_source-journal">Virol. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="refDoi"> DOI: 10.1186/s12985-015-0318-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1186%2Fs12985-015-0318-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=26047611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A280%3ADC%252BC2MbgslOisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=84&author=J.+Aissa+Larousseauthor=P.+Trimouletauthor=P.+Recordon+Pinsonauthor=B.+Tauzinauthor=M.+M.+Azzouzauthor=N.+Ben+Mamiauthor=I.+Cheikhauthor=H.+Trikiauthor=H.+Fleury&title=Prevalence+of+hepatitis+C+virus+%28HCV%29+variants+resistant+to+NS5A+inhibitors+in+naive+patients+infected+with+HCV+genotype+1+in+Tunisia&doi=10.1186%2Fs12985-015-0318-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naive patients infected with HCV genotype 1 in Tunisia</span></div><div class="casAuthors">Aissa Larousse Jameleddine; Triki Henda; Aissa Larousse Jameleddine; Trimoulet Pascale; Recordon Pinson Patricia; Fleury Herve; Aissa Larousse Jameleddine; Trimoulet Pascale; Recordon Pinson Patricia; Tauzin Brigitte; Fleury Herve; Azzouz Mohamed Mssadak; Ben Mami Nabyl; Cheikh Imed</div><div class="citationInfo"><span class="NLM_cas:title">Virology journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Hepatitis C virus (HCV) non-structural protein 5A (NS5A) inhibitors have been recently developed to inhibit NS5A activities and have been approved for the treatment of HCV infection.  However the drawback of these direct acting antivirals (DAAs) is the emergence of resistance mutations.  The prevalence of such mutations conferring resistance to HCV-NS5A inhibitors before treatment has not been investigated so far in the Tunisian population.  The aim of this study was to detect HCV variants resistant to HCV-NS5A inhibitors in hepatitis C patients infected with HCV genotype 1 before any treatment with NS5A inhibitors.  METHODS:  Amplification and direct sequencing of the HCV NS5A region was carried out on 112 samples from 149 untreated patients.  RESULTS:  In genotype 1a strains, amino acid substitutions conferring resistance to NS5A inhibitors (M28V) were detected in 1/7 (14.2 %) HCV NS5A sequences analyzed.  In genotype 1b, resistance mutations in the NS5A region (R30Q; L31M; P58S and Y93H) were observed in 17/105 (16.2 %) HCV NS5A sequences analyzed.  R30Q and Y93H (n = 6; 5.7 %) predominated over P58S (n = 4; 3.8 %) and L31M (n = 3; 2.8 %).  CONCLUSIONS:  Mutations conferring resistance to HCV NS5A inhibitors are frequent in treatment-naive Tunisian patients infected with HCV genotype 1b.  Their influence in the context of DAA therapies has not been fully investigated and should be taken into consideration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ5jx6gB5Y60X6CEoQgWY10fW6udTcc2eaAsT3H38petrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbgslOisg%253D%253D&md5=f5f24d39f50817a3cacb1b0f68073895</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2Fs12985-015-0318-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12985-015-0318-0%26sid%3Dliteratum%253Aachs%26aulast%3DAissa%2BLarousse%26aufirst%3DJ.%26aulast%3DTrimoulet%26aufirst%3DP.%26aulast%3DRecordon%2BPinson%26aufirst%3DP.%26aulast%3DTauzin%26aufirst%3DB.%26aulast%3DAzzouz%26aufirst%3DM.%2BM.%26aulast%3DBen%2BMami%26aufirst%3DN.%26aulast%3DCheikh%26aufirst%3DI.%26aulast%3DTriki%26aufirst%3DH.%26aulast%3DFleury%26aufirst%3DH.%26atitle%3DPrevalence%2520of%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%2520variants%2520resistant%2520to%2520NS5A%2520inhibitors%2520in%2520naive%2520patients%2520infected%2520with%2520HCV%2520genotype%25201%2520in%2520Tunisia%26jtitle%3DVirol.%2520J.%26date%3D2015%26volume%3D12%26spage%3D84%26doi%3D10.1186%2Fs12985-015-0318-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Tong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Pogam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piso, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baronas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">So, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klumpp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Najera, I.</span><span> </span><span class="NLM_article-title">In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir</span> <span class="citation_source-journal">J. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">209</span><span class="NLM_x">, </span> <span class="NLM_fpage">668</span><span class="NLM_x">–</span> <span class="NLM_lpage">675</span><span class="refDoi"> DOI: 10.1093/infdis/jit562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1093%2Finfdis%2Fjit562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=24154738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC2cXis1Cjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2014&pages=668-675&author=X.+Tongauthor=S.+Le+Pogamauthor=L.+Liauthor=K.+Hainesauthor=K.+Pisoauthor=V.+Baronasauthor=J.+M.+Yanauthor=S.+S.+Soauthor=K.+Klumppauthor=I.+Najera&title=In+vivo+emergence+of+a+novel+mutant+L159F%2FL320F+in+the+NS5B+polymerase+confers+low-level+resistance+to+the+HCV+polymerase+inhibitors+mericitabine+and+sofosbuvir&doi=10.1093%2Finfdis%2Fjit562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir</span></div><div class="casAuthors">Tong, Xiao; Le Pogam, Sophie; Li, Lewyn; Haines, Kristin; Piso, Katherine; Baronas, Victoria; Yan, Jun-Mei; So, Sung-Sau; Klumpp, Klaus; Najera, Isabel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">668-675</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background. Resistance to mericitabine (prodrug of HCV NS5B polymerase inhibitor PSI-6130) is rare and conferred by the NS5B S282T mutation.  Methods. Serum HCV RNA from patients who experienced viral breakthrough, partial response, or nonresponse in 2 clin. trials in which patients received mericitabine plus peginterferon alfa-2a (40KD)/ribavirin were analyzed by population and clonal sequence anal. as well as phenotypic assay for assessment of in vivo mericitabine resistance.  Results. Among 405 patients treated with mericitabine plus peginterferon alfa-2a/ribavirin in PROPEL and JUMP-C, virol. breakthrough or nonresponse were not obsd.; 12 patients experienced a partial response.  The NS5B S282T resistance mutation was not obsd. in any patient.  A no. of treatment-assocd. NS5B changes were obsd. and characterized.  A novel double mutant (L159F/L320F) with impaired replication capacity was detected in one HCV genotype 1b-infected patient.  Introduction of double mutant L159F/L320F into genotype 1a (H77) and 1b (Con-1) replicons, resp., increased the EC50 for mericitabine by 3.1- and 5.5-fold and the EC90 by 3.1- and 8.9-fold.  The double mutant also decreased susceptibility to sofosbuvir (GS-7977) and GS-938 but not setrobuvir, relative to wild-type.  Conclusions. A novel and replication-deficient double mutation (L159F/L320F) confers low-level resistance to mericitabine and cross-resistance to both sofosbuvir and GS-938.  Clin. Trials Registration NCT00869661, NCT01057667.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreimBZ-G2tC7Vg90H21EOLACvtfcHk0ljYQeVKWQRS7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXis1Cjsrg%253D&md5=f652e8cb6c86966a37573245e66793fd</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjit562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjit562%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DX.%26aulast%3DLe%2BPogam%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DHaines%26aufirst%3DK.%26aulast%3DPiso%26aufirst%3DK.%26aulast%3DBaronas%26aufirst%3DV.%26aulast%3DYan%26aufirst%3DJ.%2BM.%26aulast%3DSo%26aufirst%3DS.%2BS.%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DNajera%26aufirst%3DI.%26atitle%3DIn%2520vivo%2520emergence%2520of%2520a%2520novel%2520mutant%2520L159F%252FL320F%2520in%2520the%2520NS5B%2520polymerase%2520confers%2520low-level%2520resistance%2520to%2520the%2520HCV%2520polymerase%2520inhibitors%2520mericitabine%2520and%2520sofosbuvir%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2014%26volume%3D209%26spage%3D668%26epage%3D675%26doi%3D10.1093%2Finfdis%2Fjit562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Shi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiraga, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aikata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tateno-Mukaidani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshizato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inaba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span> </span><span class="NLM_article-title">Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1055</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1136/gutjnl-2012-302600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1136%2Fgutjnl-2012-302600" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=1055-1061&author=N.+Shiauthor=N.+Hiragaauthor=M.+Imamuraauthor=C.+N.+Hayesauthor=Y.+Zhangauthor=K.+Kosakaauthor=A.+Okazakiauthor=E.+Murakamiauthor=M.+Tsugeauthor=H.+Abeauthor=H.+Aikataauthor=S.+Takahashiauthor=H.+Ochiauthor=C.+Tateno-Mukaidaniauthor=K.+Yoshizatoauthor=H.+Matsuiauthor=A.+Kanaiauthor=T.+Inabaauthor=F.+McPheeauthor=M.+Gaoauthor=K.+Chayama&title=Combination+therapies+with+NS5A%2C+NS3+and+NS5B+inhibitors+on+different+genotypes+of+hepatitis+C+virus+in+human+hepatocyte+chimeric+mice&doi=10.1136%2Fgutjnl-2012-302600"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2012-302600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2012-302600%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DN.%26aulast%3DHiraga%26aufirst%3DN.%26aulast%3DImamura%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DC.%2BN.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKosaka%26aufirst%3DK.%26aulast%3DOkazaki%26aufirst%3DA.%26aulast%3DMurakami%26aufirst%3DE.%26aulast%3DTsuge%26aufirst%3DM.%26aulast%3DAbe%26aufirst%3DH.%26aulast%3DAikata%26aufirst%3DH.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DOchi%26aufirst%3DH.%26aulast%3DTateno-Mukaidani%26aufirst%3DC.%26aulast%3DYoshizato%26aufirst%3DK.%26aulast%3DMatsui%26aufirst%3DH.%26aulast%3DKanai%26aufirst%3DA.%26aulast%3DInaba%26aufirst%3DT.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DChayama%26aufirst%3DK.%26atitle%3DCombination%2520therapies%2520with%2520NS5A%252C%2520NS3%2520and%2520NS5B%2520inhibitors%2520on%2520different%2520genotypes%2520of%2520hepatitis%2520C%2520virus%2520in%2520human%2520hepatocyte%2520chimeric%2520mice%26jtitle%3DGut%26date%3D2013%26volume%3D62%26spage%3D1055%26epage%3D1061%26doi%3D10.1136%2Fgutjnl-2012-302600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Watashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hijikata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosaka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaji, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimotohno, K.</span><span> </span><span class="NLM_article-title">Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1282</span><span class="NLM_x">–</span> <span class="NLM_lpage">1288</span><span class="refDoi"> DOI: 10.1053/jhep.2003.50449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1053%2Fjhep.2003.50449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=14578868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsVOnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=1282-1288&author=K.+Watashiauthor=M.+Hijikataauthor=M.+Hosakaauthor=M.+Yamajiauthor=K.+Shimotohno&title=Cyclosporin+A+suppresses+replication+of+hepatitis+C+virus+genome+in+cultured+hepatocytes&doi=10.1053%2Fjhep.2003.50449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes</span></div><div class="casAuthors">Watashi, Koichi; Hijikata, Makoto; Hosaka, Masahiro; Yamaji, Masashi; Shimotohno, Kunitada</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1282-1288</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">Persistent infection of hepatitis C virus (HCV) is a major cause of liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.  Searching for a substance with anti-HCV potential, we examd. the effects of a variety of compds. on HCV replication using a HCV subgenomic replicon cell culture system.  Consequently, the immunosuppressant cyclosporin A (CsA) was found to have a suppressive effect on the HCV replicon RNA level and HCV protein expression in these cells.  CsA also inhibited multiplication of the HCV genome in a cultured human hepatocyte cell line infected with HCV using HCV-pos. plasma.  This anti-HCV activity of CsA appeared to be independent of its immunosuppressive function.  In conclusion, our results suggest that CsA may represent a new approach for the development of anti-HCV therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB9pezI0G0OLVg90H21EOLACvtfcHk0lhObn7DmHbLAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsVOnt7o%253D&md5=5c83a94dccdc2cb357d8d7d573a37b0f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1053%2Fjhep.2003.50449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fjhep.2003.50449%26sid%3Dliteratum%253Aachs%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DHijikata%26aufirst%3DM.%26aulast%3DHosaka%26aufirst%3DM.%26aulast%3DYamaji%26aufirst%3DM.%26aulast%3DShimotohno%26aufirst%3DK.%26atitle%3DCyclosporin%2520A%2520suppresses%2520replication%2520of%2520hepatitis%2520C%2520virus%2520genome%2520in%2520cultured%2520hepatocytes%26jtitle%3DHepatology%26date%3D2003%26volume%3D38%26spage%3D1282%26epage%3D1288%26doi%3D10.1053%2Fjhep.2003.50449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Chatterji, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobardt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selvarajah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vuagniaux, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallay, P.</span><span> </span><span class="NLM_article-title">The isomerase active site of cyclophilin A is critical for hepatitis C virus replication</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">16998</span><span class="NLM_x">–</span> <span class="NLM_lpage">17005</span><span class="refDoi"> DOI: 10.1074/jbc.M109.007625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1074%2Fjbc.M109.007625" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=16998-17005&author=U.+Chatterjiauthor=M.+Bobardtauthor=S.+Selvarajahauthor=F.+Yangauthor=H.+Tangauthor=N.+Sakamotoauthor=G.+Vuagniauxauthor=T.+Parkinsonauthor=P.+Gallay&title=The+isomerase+active+site+of+cyclophilin+A+is+critical+for+hepatitis+C+virus+replication&doi=10.1074%2Fjbc.M109.007625"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.007625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.007625%26sid%3Dliteratum%253Aachs%26aulast%3DChatterji%26aufirst%3DU.%26aulast%3DBobardt%26aufirst%3DM.%26aulast%3DSelvarajah%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DSakamoto%26aufirst%3DN.%26aulast%3DVuagniaux%26aufirst%3DG.%26aulast%3DParkinson%26aufirst%3DT.%26aulast%3DGallay%26aufirst%3DP.%26atitle%3DThe%2520isomerase%2520active%2520site%2520of%2520cyclophilin%2520A%2520is%2520critical%2520for%2520hepatitis%2520C%2520virus%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D16998%26epage%3D17005%26doi%3D10.1074%2Fjbc.M109.007625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Kaul, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pertel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zayas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luban, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1000546</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1000546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1371%2Fjournal.ppat.1000546" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=e1000546&author=A.+Kaulauthor=S.+Staufferauthor=C.+Bergerauthor=T.+Pertelauthor=J.+Schmittauthor=S.+Kallisauthor=M.+Zayasauthor=V.+Lohmannauthor=J.+Lubanauthor=R.+Bartenschlager&title=Essential+role+of+cyclophilin+A+for+hepatitis+C+virus+replication+and+virus+production+and+possible+link+to+polyprotein+cleavage+kinetics&doi=10.1371%2Fjournal.ppat.1000546"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1000546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1000546%26sid%3Dliteratum%253Aachs%26aulast%3DKaul%26aufirst%3DA.%26aulast%3DStauffer%26aufirst%3DS.%26aulast%3DBerger%26aufirst%3DC.%26aulast%3DPertel%26aufirst%3DT.%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DKallis%26aufirst%3DS.%26aulast%3DZayas%26aufirst%3DM.%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DLuban%26aufirst%3DJ.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DEssential%2520role%2520of%2520cyclophilin%2520A%2520for%2520hepatitis%2520C%2520virus%2520replication%2520and%2520virus%2520production%2520and%2520possible%2520link%2520to%2520polyprotein%2520cleavage%2520kinetics%26jtitle%3DPLoS%2520Pathog.%26date%3D2009%26volume%3D5%26spage%3De1000546%26doi%3D10.1371%2Fjournal.ppat.1000546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Liu, J. O.</span><span> </span><span class="NLM_article-title">Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">198</span><span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00756.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1111%2Fj.1600-065X.2008.00756.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=19290928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=184-198&author=J.+O.+Liu&title=Calmodulin-dependent+phosphatase%2C+kinases%2C+and+transcriptional+corepressors+involved+in+T-cell+activation&doi=10.1111%2Fj.1600-065X.2008.00756.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation</span></div><div class="casAuthors">Liu, Jun O.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">184-198</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The second messenger calcium plays an essential role in mediating the T-cell receptor (TCR) signaling pathway leading to cytokine prodn. and T-cell clonal expansion.  The immunosuppressive drugs cyclosporine A and FK506 have served both as therapeutic agents and as mol. probes for unraveling the protein phosphatase calcineurin as a rate-limiting enzyme involved in the transmission of calcium signal from the cytosol into the nucleus to reprogram gene expression.  The use of mouse knockout models has helped to verify and further elucidate the functions of different isoforms of calcineurin in both helper T-cell activation and thymocyte development.  In addn. to calcineurin, three other classes of calmodulin-binding proteins have also been shown to play important roles in calcium signaling in T cells.  Thus, Cabin 1 and class II histone deacetylases have been found to constitute a novel calcium-signaling module in conjunction with the transcription factor myocyte enhance factor family and the transcriptional coactivator p300 to suppress and activate cytokine gene transcription in a calcium-dependent manner.  The calmodulin-dependent protein kinases II and IV were also shown to play neg. and pos. regulatory functions, resp., in TCR-mediated cytokine prodn.  The crosstalks among these and other signal transducers in T cells form an extensive nonlinear signaling network that dictates the final outcome of the TCR signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2geWtFLdom7Vg90H21EOLACvtfcHk0lhObn7DmHbLAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rF&md5=c2647ba7175f0e9d556b6902c96b4e04</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00756.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00756.x%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26atitle%3DCalmodulin-dependent%2520phosphatase%252C%2520kinases%252C%2520and%2520transcriptional%2520corepressors%2520involved%2520in%2520T-cell%2520activation%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D184%26epage%3D198%26doi%3D10.1111%2Fj.1600-065X.2008.00756.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Goto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hishiki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hijikata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimotohno, K.</span><span> </span><span class="NLM_article-title">Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">884</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2006.03.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1016%2Fj.bbrc.2006.03.059" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2006&pages=879-884&author=K.+Gotoauthor=K.+Watashiauthor=T.+Murataauthor=T.+Hishikiauthor=M.+Hijikataauthor=K.+Shimotohno&title=Evaluation+of+the+anti-hepatitis+C+virus+effects+of+cyclophilin+inhibitors%2C+cyclosporin+A%2C+and+NIM811&doi=10.1016%2Fj.bbrc.2006.03.059"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2006.03.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2006.03.059%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DMurata%26aufirst%3DT.%26aulast%3DHishiki%26aufirst%3DT.%26aulast%3DHijikata%26aufirst%3DM.%26aulast%3DShimotohno%26aufirst%3DK.%26atitle%3DEvaluation%2520of%2520the%2520anti-hepatitis%2520C%2520virus%2520effects%2520of%2520cyclophilin%2520inhibitors%252C%2520cyclosporin%2520A%252C%2520and%2520NIM811%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2006%26volume%3D343%26spage%3D879%26epage%3D884%26doi%3D10.1016%2Fj.bbrc.2006.03.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Hopkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scorneaux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wring, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeill, Y.</span><span> </span><span class="NLM_article-title">SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">672</span><span class="refDoi"> DOI: 10.1128/AAC.00660-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1128%2FAAC.00660-09" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=660-672&author=S.+Hopkinsauthor=B.+Scorneauxauthor=Z.+Huangauthor=M.+G.+Murrayauthor=S.+Wringauthor=C.+Smitleyauthor=R.+Harrisauthor=F.+Erdmannauthor=G.+Fischerauthor=Y.+Ribeill&title=SCY-635%2C+a+novel+nonimmunosuppressive+analog+of+cyclosporine+that+exhibits+potent+inhibition+of+hepatitis+C+virus+RNA+replication+in+vitro&doi=10.1128%2FAAC.00660-09"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1128%2FAAC.00660-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00660-09%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DS.%26aulast%3DScorneaux%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DMurray%26aufirst%3DM.%2BG.%26aulast%3DWring%26aufirst%3DS.%26aulast%3DSmitley%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DR.%26aulast%3DErdmann%26aufirst%3DF.%26aulast%3DFischer%26aufirst%3DG.%26aulast%3DRibeill%26aufirst%3DY.%26atitle%3DSCY-635%252C%2520a%2520novel%2520nonimmunosuppressive%2520analog%2520of%2520cyclosporine%2520that%2520exhibits%2520potent%2520inhibition%2520of%2520hepatitis%2520C%2520virus%2520RNA%2520replication%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D660%26epage%3D672%26doi%3D10.1128%2FAAC.00660-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Paeshuyse, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaul, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Clercq, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenwirth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumont, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scalfaro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neyts, J.</span><span> </span><span class="NLM_article-title">The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">770</span><span class="refDoi"> DOI: 10.1002/hep.21102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fhep.21102" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2006&pages=761-770&author=J.+Paeshuyseauthor=A.+Kaulauthor=E.+De+Clercqauthor=B.+Rosenwirthauthor=J.+M.+Dumontauthor=P.+Scalfaroauthor=R.+Bartenschlagerauthor=J.+Neyts&title=The+non-immunosuppressive+cyclosporin+DEBIO-025+is+a+potent+inhibitor+of+hepatitis+C+virus+replication+in+vitro&doi=10.1002%2Fhep.21102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fhep.21102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.21102%26sid%3Dliteratum%253Aachs%26aulast%3DPaeshuyse%26aufirst%3DJ.%26aulast%3DKaul%26aufirst%3DA.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DRosenwirth%26aufirst%3DB.%26aulast%3DDumont%26aufirst%3DJ.%2BM.%26aulast%3DScalfaro%26aufirst%3DP.%26aulast%3DBartenschlager%26aufirst%3DR.%26aulast%3DNeyts%26aufirst%3DJ.%26atitle%3DThe%2520non-immunosuppressive%2520cyclosporin%2520DEBIO-025%2520is%2520a%2520potent%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520replication%2520in%2520vitro%26jtitle%3DHepatology%26date%3D2006%26volume%3D43%26spage%3D761%26epage%3D770%26doi%3D10.1002%2Fhep.21102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Zydowsky, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etzkorn, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stolz, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, C. T.</span><span> </span><span class="NLM_article-title">Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1092</span><span class="NLM_x">–</span> <span class="NLM_lpage">1099</span><span class="refDoi"> DOI: 10.1002/pro.5560010903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fpro.5560010903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1338979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADyaK3sXhs1Cisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1992&pages=1092-1099&author=L.+D.+Zydowskyauthor=F.+A.+Etzkornauthor=H.+Y.+Changauthor=S.+B.+Fergusonauthor=L.+A.+Stolzauthor=S.+I.+Hoauthor=C.+T.+Walsh&title=Active+site+mutants+of+human+cyclophilin+A+separate+peptidyl-prolyl+isomerase+activity+from+cyclosporin+A+binding+and+calcineurin+inhibition&doi=10.1002%2Fpro.5560010903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition</span></div><div class="casAuthors">Zydowsky, Lynne D.; Etzkorn, Felicia A.; Chang, Howard Y.; Ferguson, Stephen B.; Stolz, Lesley A.; Ho, Susanna I.; Walsh, Christopher T.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1092-9</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    </div><div class="casAbstract">Based on recent x-ray structural information, 6 site-directed mutants of human cyclophilin A (hCyPA) involving residues in the putative active site (His-54, Arg-55, Phe-60, Gln-111, Phe-113, and His-126) were constructed, overexpressed, and purified from Escherichia coli to homogeneity.  Mutant proteins W121A, H54Q, R55A, F60A, Q111A, F113A, and H126Q were assayed for peptidylprolyl cis-trans-isomerase (PPIase) activity, their ability to bind the immunosuppressive drug, cyclosporin A (CsA), and phosphoprotein phosphatase 2B (calcineurin) inhibition in the presence of CsA.  The results indicated that H54Q, Q111A, F113A, and W121A retained 3-15% of the catalytic efficiency (kcat/Km) of wild-type recombinant hCyPA.  The remaining 3 mutants (R55A, F60A, and H126Q) each retained <1% of the wild-type catalytic efficiency, indicating the participation of these residues in PPIase catalysis.  Each of the mutants bound to a CsA affinity matrix.  Mutants R55A, F60A, F113A, and H126Q inhibited calcineurin in the presence of CsA, whereas W121A did not.  Although CsA is a competitive inhibitor of PPIase activity, was able to complex with enzymically inactive cyclophilins and inhibit the phosphatase activity of calcineurin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm1wQYRf-R9rVg90H21EOLACvtfcHk0lilqeaYqpl9Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhs1Cisrc%253D&md5=a68ce94f777c5aec962caefc083d7b8c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fpro.5560010903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.5560010903%26sid%3Dliteratum%253Aachs%26aulast%3DZydowsky%26aufirst%3DL.%2BD.%26aulast%3DEtzkorn%26aufirst%3DF.%2BA.%26aulast%3DChang%26aufirst%3DH.%2BY.%26aulast%3DFerguson%26aufirst%3DS.%2BB.%26aulast%3DStolz%26aufirst%3DL.%2BA.%26aulast%3DHo%26aufirst%3DS.%2BI.%26aulast%3DWalsh%26aufirst%3DC.%2BT.%26atitle%3DActive%2520site%2520mutants%2520of%2520human%2520cyclophilin%2520A%2520separate%2520peptidyl-prolyl%2520isomerase%2520activity%2520from%2520cyclosporin%2520A%2520binding%2520and%2520calcineurin%2520inhibition%26jtitle%3DProtein%2520Sci.%26date%3D1992%26volume%3D1%26spage%3D1092%26epage%3D1099%26doi%3D10.1002%2Fpro.5560010903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Davis, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campagna-Slater, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finerty, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paramanathan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tempel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouyang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenmesser, E. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhe-Paganon, S.</span><span> </span><span class="NLM_article-title">Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases</span> <span class="citation_source-journal">PLoS Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1000439</span><span class="refDoi"> DOI: 10.1371/journal.pbio.1000439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1371%2Fjournal.pbio.1000439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=20676357" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=e1000439&author=T.+L.+Davisauthor=J.+R.+Walkerauthor=V.+Campagna-Slaterauthor=P.+J.+Finertyauthor=R.+Paramanathanauthor=G.+Bernsteinauthor=F.+MacKenzieauthor=W.+Tempelauthor=H.+Ouyangauthor=W.+H.+Leeauthor=E.+Z.+Eisenmesserauthor=S.+Dhe-Paganon&title=Structural+and+biochemical+characterization+of+the+human+cyclophilin+family+of+peptidyl-prolyl+isomerases&doi=10.1371%2Fjournal.pbio.1000439"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1000439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1000439%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DT.%2BL.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DCampagna-Slater%26aufirst%3DV.%26aulast%3DFinerty%26aufirst%3DP.%2BJ.%26aulast%3DParamanathan%26aufirst%3DR.%26aulast%3DBernstein%26aufirst%3DG.%26aulast%3DMacKenzie%26aufirst%3DF.%26aulast%3DTempel%26aufirst%3DW.%26aulast%3DOuyang%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DW.%2BH.%26aulast%3DEisenmesser%26aufirst%3DE.%2BZ.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26atitle%3DStructural%2520and%2520biochemical%2520characterization%2520of%2520the%2520human%2520cyclophilin%2520family%2520of%2520peptidyl-prolyl%2520isomerases%26jtitle%3DPLoS%2520Biol.%26date%3D2010%26volume%3D8%26spage%3De1000439%26doi%3D10.1371%2Fjournal.pbio.1000439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Mikol, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pflugl, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walkinshaw, M. D.</span><span> </span><span class="NLM_article-title">X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex at 2.1 A resolution</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">234</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">–</span> <span class="NLM_lpage">1130</span><span class="refDoi"> DOI: 10.1006/jmbi.1993.1664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1006%2Fjmbi.1993.1664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=8263916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADyaK2cXmvVyktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=1993&pages=1119-1130&author=V.+Mikolauthor=J.+Kallenauthor=G.+Pfluglauthor=M.+D.+Walkinshaw&title=X-ray+structure+of+a+monomeric+cyclophilin+A-cyclosporin+A+crystal+complex+at+2.1+A+resolution&doi=10.1006%2Fjmbi.1993.1664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex at 2.1 Å resolution</span></div><div class="casAuthors">Mikol, Vincent; Kallen, Joerg; Pfluegl, Gaston; Walkinshaw, Malcolm D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1119-30</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    </div><div class="casAbstract">The crystal structure of a complex between recombinant human cyclophilin A (Cyp) and cyclosporin A (CsA) has been detd. from a novel orthorhombic crystal form that contains only one monomer of complex per asym. unit rather than five in the previously detd. tetragonal structure.  The structure has been refined at 2.1 Å resoln. to a crystallog. R-factor of 16.7%.  The conformation of Cyp is practically unchanged with respect to the tetragonal form.  A certain no. of previously undefined side-chains have been located in the electron d. and a very detailed picture of the ordered solvent structure has been obtained.  The interactions between CsA and Cyp are conserved.  A network of the possibly conserved, water-mediated contacts is described.  The structure of CsA in the monomeric complex is similar to that of the decameric complex, but shows a few small differences in the so-called effector domain of CsA, probably due to differences in crystal environment.  The fact that this monomeric crystal form can be obtained shows that the formation of pentamer or decamer complexes is not a generally obsd. phenomenon and is not a prerequisite for biol. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqShxtMu0I3LLVg90H21EOLACvtfcHk0ljYSAL_2YnW3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvVyktw%253D%253D&md5=fd63ff4984fd51b3b45c97a07ca80b75</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1993.1664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1993.1664%26sid%3Dliteratum%253Aachs%26aulast%3DMikol%26aufirst%3DV.%26aulast%3DKallen%26aufirst%3DJ.%26aulast%3DPflugl%26aufirst%3DG.%26aulast%3DWalkinshaw%26aufirst%3DM.%2BD.%26atitle%3DX-ray%2520structure%2520of%2520a%2520monomeric%2520cyclophilin%2520A-cyclosporin%2520A%2520crystal%2520complex%2520at%25202.1%2520A%2520resolution%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1993%26volume%3D234%26spage%3D1119%26epage%3D1130%26doi%3D10.1006%2Fjmbi.1993.1664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Ngouansavanh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span> </span><span class="NLM_article-title">Alcohols in isonitrile-based multicomponent reaction: Passerini reaction of alcohols in the presence of o-iodoxybenzoic acid</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3495</span><span class="NLM_x">–</span> <span class="NLM_lpage">3497</span><span class="refDoi"> DOI: 10.1002/anie.200600588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fanie.200600588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsVKjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=3495-3497&author=T.+Ngouansavanhauthor=J.+Zhu&title=Alcohols+in+isonitrile-based+multicomponent+reaction%3A+Passerini+reaction+of+alcohols+in+the+presence+of+o-iodoxybenzoic+acid&doi=10.1002%2Fanie.200600588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Alcohols in isonitrile-based multicomponent reaction: Passerini reaction of alcohols in the presence of o-iodoxybenzoic acid</span></div><div class="casAuthors">Ngouansavanh, Tifelle; Zhu, Jieping</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3495-3497</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An alc. instead of an aldehyde was found to be an effective reaction partner in the three-component Passerini reaction (P-3CR) in the presence of o-iodoxybenzoic acid (IBX).  Thus, by simply heating a soln. of an alc. R1CH2OH [R1 = n-Pr, Ph, PhCH2, AcO(CH2)5, PhCH2OCONHCH2, (R)-AcNHCH(CH2Ph), etc.], a carboxylic acid R2CO2H [R2 = Me, Ph, (S)-MeOCHPh, etc.], an isonitrile R3NC (R3 = Me3C, MeO2CCH2, cyclohexyl, PhCH2), and IBX at 40°C, an oxidn./P-3CR sequence occurred smoothly to afford the corresponding α-acyloxy carboxamides R2CO2CHR1CONHR3 in good to excellent yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3YQSdopRvPLVg90H21EOLACvtfcHk0ljYSAL_2YnW3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsVKjsbg%253D&md5=980ba4cd01faccb27f9d385253c1eb1c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fanie.200600588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200600588%26sid%3Dliteratum%253Aachs%26aulast%3DNgouansavanh%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DJ.%26atitle%3DAlcohols%2520in%2520isonitrile-based%2520multicomponent%2520reaction%253A%2520Passerini%2520reaction%2520of%2520alcohols%2520in%2520the%2520presence%2520of%2520o-iodoxybenzoic%2520acid%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2006%26volume%3D45%26spage%3D3495%26epage%3D3497%26doi%3D10.1002%2Fanie.200600588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Domling, A.</span><span> </span><span class="NLM_article-title">Recent developments in isocyanide based multicomponent reactions in applied chemistry</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span><span class="refDoi"> DOI: 10.1021/cr0505728</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0505728" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FhslyntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2006&pages=17-89&author=A.+Domling&title=Recent+developments+in+isocyanide+based+multicomponent+reactions+in+applied+chemistry&doi=10.1021%2Fcr0505728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in isocyanide based multicomponent reactions in applied chemistry</span></div><div class="casAuthors">Domling Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Chemical reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-89</span>
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtCMEx7SbgjiM8MEzWGjS9fW6udTcc2eaIjBy4MQ7T27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FhslyntA%253D%253D&md5=33b233fa9ca718d7e0e6db6fee49e5fd</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fcr0505728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0505728%26sid%3Dliteratum%253Aachs%26aulast%3DDomling%26aufirst%3DA.%26atitle%3DRecent%2520developments%2520in%2520isocyanide%2520based%2520multicomponent%2520reactions%2520in%2520applied%2520chemistry%26jtitle%3DChem.%2520Rev.%26date%3D2006%26volume%3D106%26spage%3D17%26epage%3D89%26doi%3D10.1021%2Fcr0505728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Borawski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troke, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puyang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibaja, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mickanin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighton-Davies, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornellataracido, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baryza, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tallarico, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joberty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bantscheff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouwmeester, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathy, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Compton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiedmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaither, L. A.</span><span> </span><span class="NLM_article-title">Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">10058</span><span class="NLM_x">–</span> <span class="NLM_lpage">10074</span><span class="refDoi"> DOI: 10.1128/JVI.02418-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1128%2FJVI.02418-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=19605471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFyrurjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2009&pages=10058-10074&author=J.+Borawskiauthor=P.+Trokeauthor=X.+Puyangauthor=V.+Gibajaauthor=S.+Zhaoauthor=C.+Mickaninauthor=J.+Leighton-Daviesauthor=C.+J.+Wilsonauthor=V.+Myerauthor=I.+Cornellataracidoauthor=J.+Baryzaauthor=J.+Tallaricoauthor=G.+Jobertyauthor=M.+Bantscheffauthor=M.+Schirleauthor=T.+Bouwmeesterauthor=J.+E.+Mathyauthor=K.+Linauthor=T.+Comptonauthor=M.+Labowauthor=B.+Wiedmannauthor=L.+A.+Gaither&title=Class+III+phosphatidylinositol+4-kinase+alpha+and+beta+are+novel+host+factor+regulators+of+hepatitis+C+virus+replication&doi=10.1128%2FJVI.02418-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication</span></div><div class="casAuthors">Borawski, Jason; Troke, Philip; Puyang, Xiaoling; Gibaja, Veronica; Zhao, ShanChaun; Mickanin, Craig; Leighton-Davies, Juliet; Wilson, Christopher J.; Myer, Vic; Taracido, Ivan Cornella; Baryza, Jeremy; Tallarico, John; Joberty, Gerard; Bantscheff, Marcus; Schirle, Markus; Bouwmeester, Tewis; Mathy, Joanna E.; Lin, Kai; Compton, Teresa; Labow, Mark; Wiedmann, Brigitte; Gaither, L. Alex</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10058-10074</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Host factor pathways are known to be essential for hepatitis C virus (HCV) infection and replication in human liver cells.  To search for novel host factor proteins required for HCV replication, we screened a subgenomic genotype 1b replicon cell line (Luc-1b) with a kinome and druggable collection of 20,779 siRNAs.  We identified and validated several enzymes required for HCV replication, including class III phosphatidylinositol 4-kinases (PI4KA and PI4KB), carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), and mevalonate (diphospho) decarboxylase.  Knockdown of PI4KA could inhibit the replication and/or HCV RNA levels of the two subgenomic genotype 1b clones (SG-1b and Luc-1b), two subgenomic genotype 1a clones (SG-1a and Luc-1a), JFH-1 genotype 2a infectious virus (JFH1-2a), and the genomic genotype 1a (FL-1a) replicon.  In contrast, PI4KB knockdown inhibited replication and/or HCV RNA levels of Luc-1b, SG-1b, and Luc-1a replicons.  The small mol. inhibitor, PIK93, was found to block subgenomic genotype 1b (Luc-1b), subgenomic genotype 1a (Luc-1a), and genomic genotype 2a (JFH1-2a) infectious virus replication in the nanomolar range.  PIK93 was characterized by using quant. chem. proteomics and in vitro biochem. assays to demonstrate PIK93 is a bone fide PI4KA and PI4KB inhibitor.  Our data demonstrate that genetic or pharmacol. modulation of PI4KA and PI4KB inhibits multiple genotypes of HCV and represents a novel druggable class of therapeutic targets for HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Zjz0O33L9bVg90H21EOLACvtfcHk0lhF1vAikRR3HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFyrurjN&md5=f823b4ac8a9efd864fced393cf487c94</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1128%2FJVI.02418-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02418-08%26sid%3Dliteratum%253Aachs%26aulast%3DBorawski%26aufirst%3DJ.%26aulast%3DTroke%26aufirst%3DP.%26aulast%3DPuyang%26aufirst%3DX.%26aulast%3DGibaja%26aufirst%3DV.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DMickanin%26aufirst%3DC.%26aulast%3DLeighton-Davies%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DMyer%26aufirst%3DV.%26aulast%3DCornellataracido%26aufirst%3DI.%26aulast%3DBaryza%26aufirst%3DJ.%26aulast%3DTallarico%26aufirst%3DJ.%26aulast%3DJoberty%26aufirst%3DG.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DSchirle%26aufirst%3DM.%26aulast%3DBouwmeester%26aufirst%3DT.%26aulast%3DMathy%26aufirst%3DJ.%2BE.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DCompton%26aufirst%3DT.%26aulast%3DLabow%26aufirst%3DM.%26aulast%3DWiedmann%26aufirst%3DB.%26aulast%3DGaither%26aufirst%3DL.%2BA.%26atitle%3DClass%2520III%2520phosphatidylinositol%25204-kinase%2520alpha%2520and%2520beta%2520are%2520novel%2520host%2520factor%2520regulators%2520of%2520hepatitis%2520C%2520virus%2520replication%26jtitle%3DJ.%2520Virol.%26date%3D2009%26volume%3D83%26spage%3D10058%26epage%3D10074%26doi%3D10.1128%2FJVI.02418-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span> </span><span class="NLM_article-title">A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication</span> <span class="citation_source-journal">Virus Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">155</span><span class="NLM_x">, </span> <span class="NLM_fpage">406</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span><span class="refDoi"> DOI: 10.1016/j.virusres.2010.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1016%2Fj.virusres.2010.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=21144873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVygug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2011&pages=406-414&author=Y.+Wuauthor=Q.+Liaoauthor=R.+Yangauthor=X.+Chen&title=A+novel+luciferase+and+GFP+dual+reporter+virus+for+rapid+and+convenient+evaluation+of+hepatitis+C+virus+replication&doi=10.1016%2Fj.virusres.2010.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication</span></div><div class="casAuthors">Wu, Yang; Liao, Qingjiao; Yang, Rongge; Chen, Xinwen; Chen, Xulin</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">406-414</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein, we describe the development of a monocistronic dual reporter virus for monitoring hepatitis C virus (HCV) replication.  The recombinant construct encodes for the humanized Renilla luciferase (hRLuc) reporter gene inserted upstream of the viral open reading frame and a green fluorescent protein (GFP) gene inserted into the C-terminus of non-structural protein 5A (NS5A) of the JFH1 viral genome.  The viral RNA replicated efficiently in transfected cells and infectious virions could be produced without obvious attenuation of viral replication.  The viral titer of the dual reporter virus was comparable to that of single reporter viruses.  The expression levels of these two reporter genes correlated well with HCV replication in the presence or absence of antiviral agents.  Moreover, because of the direct visibility of GFP fluorescence and the correlation between GFP pos. cell nos. and hRLuc activity, the optimal time for measuring hRLuc activity was detd.  This novel infectious system is a time saving and cost effective method for studying the interaction between viruses and host cells as well as for screening anti-HCV drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9qp1EawGtcLVg90H21EOLACvtfcHk0lhF1vAikRR3HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVygug%253D%253D&md5=4e720e693e9f83adc0433547bf5d3689</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2010.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2010.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLiao%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DA%2520novel%2520luciferase%2520and%2520GFP%2520dual%2520reporter%2520virus%2520for%2520rapid%2520and%2520convenient%2520evaluation%2520of%2520hepatitis%2520C%2520virus%2520replication%26jtitle%3DVirus%2520Res.%26date%3D2011%26volume%3D155%26spage%3D406%26epage%3D414%26doi%3D10.1016%2Fj.virusres.2010.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Jang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Achary, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.</span><span> </span><span class="NLM_article-title">Synthesis and anti-influenza virus activity of 4-oxo- or thioxo-4,5-dihydrofuro[3,4-c]pyridin-3(1H)-ones</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">66</span><span class="NLM_x">–</span> <span class="NLM_lpage">75</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2014.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1016%2Fj.antiviral.2014.04.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2014&pages=66-75&author=Y.+J.+Jangauthor=R.+Acharyauthor=H.+W.+Leeauthor=H.+J.+Leeauthor=C.+K.+Leeauthor=S.+B.+Hanauthor=Y.+S.+Jungauthor=N.+S.+Kangauthor=P.+Kimauthor=M.+Kim&title=Synthesis+and+anti-influenza+virus+activity+of+4-oxo-+or+thioxo-4%2C5-dihydrofuro%5B3%2C4-c%5Dpyridin-3%281H%29-ones&doi=10.1016%2Fj.antiviral.2014.04.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DY.%2BJ.%26aulast%3DAchary%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DH.%2BW.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DC.%2BK.%26aulast%3DHan%26aufirst%3DS.%2BB.%26aulast%3DJung%26aufirst%3DY.%2BS.%26aulast%3DKang%26aufirst%3DN.%2BS.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520anti-influenza%2520virus%2520activity%2520of%25204-oxo-%2520or%2520thioxo-4%252C5-dihydrofuro%255B3%252C4-c%255Dpyridin-3%25281H%2529-ones%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D107%26spage%3D66%26epage%3D75%26doi%3D10.1016%2Fj.antiviral.2014.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Kim, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auh, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, B. C.</span><span> </span><span class="NLM_article-title">beta-propeller phytase hydrolyzes insoluble Ca(2+)-phytate salts and completely abrogates the ability of phytate to chelate metal ions</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">10216</span><span class="NLM_x">–</span> <span class="NLM_lpage">10227</span><span class="refDoi"> DOI: 10.1021/bi1010249</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi1010249" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=10216-10227&author=O.+H.+Kimauthor=Y.+O.+Kimauthor=J.+H.+Shimauthor=Y.+S.+Jungauthor=W.+J.+Jungauthor=W.+C.+Choiauthor=H.+Leeauthor=S.+J.+Leeauthor=K.+K.+Kimauthor=J.+H.+Auhauthor=H.+Kimauthor=J.+W.+Kimauthor=T.+K.+Ohauthor=B.+C.+Oh&title=beta-propeller+phytase+hydrolyzes+insoluble+Ca%282%2B%29-phytate+salts+and+completely+abrogates+the+ability+of+phytate+to+chelate+metal+ions&doi=10.1021%2Fbi1010249"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fbi1010249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1010249%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DO.%2BH.%26aulast%3DKim%26aufirst%3DY.%2BO.%26aulast%3DShim%26aufirst%3DJ.%2BH.%26aulast%3DJung%26aufirst%3DY.%2BS.%26aulast%3DJung%26aufirst%3DW.%2BJ.%26aulast%3DChoi%26aufirst%3DW.%2BC.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DKim%26aufirst%3DK.%2BK.%26aulast%3DAuh%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DJ.%2BW.%26aulast%3DOh%26aufirst%3DT.%2BK.%26aulast%3DOh%26aufirst%3DB.%2BC.%26atitle%3Dbeta-propeller%2520phytase%2520hydrolyzes%2520insoluble%2520Ca%25282%252B%2529-phytate%2520salts%2520and%2520completely%2520abrogates%2520the%2520ability%2520of%2520phytate%2520to%2520chelate%2520metal%2520ions%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D10216%26epage%3D10227%26doi%3D10.1021%2Fbi1010249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Chow, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rincon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. J.</span><span> </span><span class="NLM_article-title">Requirement for transcription factor NFAT in interleukin-2 expression</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2300</span><span class="NLM_x">–</span> <span class="NLM_lpage">2307</span><span class="refDoi"> DOI: 10.1128/MCB.19.3.2300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1128%2FMCB.19.3.2300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10022916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADyaK1MXhsFCjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=2300-2307&author=C.+W.+Chowauthor=M.+Rinconauthor=R.+J.+Davis&title=Requirement+for+transcription+factor+NFAT+in+interleukin-2+expression&doi=10.1128%2FMCB.19.3.2300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement for transcription factor NFAT in interleukin-2 expression</span></div><div class="casAuthors">Chow, Chi-Wing; Rincon, Mercedes; Davis, Roger J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2300-2307</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The nuclear factor of activated T cells (NFAT) transcription factor is implicated in expression of the cytokine interleukin-2 (IL-2).  Binding sites for NFAT are located in the IL-2 promoter.  Furthermore, pharmacol. studies demonstrate that the drug cyclosporin A inhibits both NFAT activation and IL-2 expression.  However, targeted disruption of the NFAT1 and NFAT2 genes in mice does not cause decreased IL-2 secretion.  The role of NFAT in IL-2 gene expression is therefore unclear.  Here the authors report the construction of a dominant-neg. NFAT mutant (dnNFAT) that selectively inhibits NFAT-mediated gene expression.  The inhibitory effect of dnNFAT is mediated by suppression of activation-induced nuclear translocation of NFAT.  Expression of dnNFAT in cultured T cells caused inhibition of IL-2 promoter activity and decreased expression of IL-2 protein.  Similarly, expression of dnNFAT in transgenic mice also caused decreased IL-2 gene expression.  These data demonstrate that NFAT is a crit. component of the signaling pathway that regulates IL-2 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu9KAT181x5rVg90H21EOLACvtfcHk0lglPtuOhsBB7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsFCjsrg%253D&md5=5221377e3a321c531aeade22a4dd0109</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1128%2FMCB.19.3.2300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.19.3.2300%26sid%3Dliteratum%253Aachs%26aulast%3DChow%26aufirst%3DC.%2BW.%26aulast%3DRincon%26aufirst%3DM.%26aulast%3DDavis%26aufirst%3DR.%2BJ.%26atitle%3DRequirement%2520for%2520transcription%2520factor%2520NFAT%2520in%2520interleukin-2%2520expression%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1999%26volume%3D19%26spage%3D2300%26epage%3D2307%26doi%3D10.1128%2FMCB.19.3.2300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Hopkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallay, P.</span><span> </span><span class="NLM_article-title">Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection</span> <span class="citation_source-journal">Viruses</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">2558</span><span class="NLM_x">–</span> <span class="NLM_lpage">2577</span><span class="refDoi"> DOI: 10.3390/v4112558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.3390%2Fv4112558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=23202494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSrtrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=2558-2577&author=S.+Hopkinsauthor=P.+Gallay&title=Cyclophilin+inhibitors%3A+an+emerging+class+of+therapeutics+for+the+treatment+of+chronic+hepatitis+C+infection&doi=10.3390%2Fv4112558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection</span></div><div class="casAuthors">Hopkins, Sam; Gallay, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2558-2577</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The advent of the replicon system together with advances in cell culture have contributed significantly to our understanding of the function of virally-encoded structural and nonstructural proteins in the replication cycle of the hepatitis C virus.  In addn., in vitro systems have been used to identify several host proteins whose expression is crit. for supporting such diverse activities as viral entry, RNA replication, particle assembly and the release of infectious virions.  Among all known host proteins that participate in the HCV replication cycle, cyclophilins are unique because they constitute the only host target that has formed the basis of pharmaceutical drug discovery and drug development programs.  The introduction of the nonimmunosuppressive cyclophilin inhibitors into clin. testing has confirmed the clin. utility of CsA-based inhibitors for the treatment of individuals with chronic hepatitis C infection and has yielded new insights into their mechanism(s) of action.  This review describes the biochem. evidence for the potential roles played by cyclophilins in supporting HCV RNA replication and summarizes clin. trial results obtained with the first generation of nonimmunosuppressive cyclophilin inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZzgAJ1L1MN7Vg90H21EOLACvtfcHk0lglPtuOhsBB7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSrtrrE&md5=ec08cd3fcb01f3d38ee8a04e98c9195a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3390%2Fv4112558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv4112558%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DS.%26aulast%3DGallay%26aufirst%3DP.%26atitle%3DCyclophilin%2520inhibitors%253A%2520an%2520emerging%2520class%2520of%2520therapeutics%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520infection%26jtitle%3DViruses%26date%3D2012%26volume%3D4%26spage%3D2558%26epage%3D2577%26doi%3D10.3390%2Fv4112558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Kaufmann, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robb, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. A.</span><span> </span><span class="NLM_article-title">Mechanism of action of cyclosporin A: inhibition of lymphokine secretion studied with antigen-stimulated T cell hybridomas</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">3107</span><span class="NLM_x">–</span> <span class="NLM_lpage">3111</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=1984&pages=3107-3111&author=Y.+Kaufmannauthor=A.+E.+Changauthor=R.+J.+Robbauthor=S.+A.+Rosenberg&title=Mechanism+of+action+of+cyclosporin+A%3A+inhibition+of+lymphokine+secretion+studied+with+antigen-stimulated+T+cell+hybridomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaufmann%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DA.%2BE.%26aulast%3DRobb%26aufirst%3DR.%2BJ.%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26atitle%3DMechanism%2520of%2520action%2520of%2520cyclosporin%2520A%253A%2520inhibition%2520of%2520lymphokine%2520secretion%2520studied%2520with%2520antigen-stimulated%2520T%2520cell%2520hybridomas%26jtitle%3DJ.%2520Immunol.%26date%3D1984%26volume%3D133%26spage%3D3107%26epage%3D3111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Hopkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobardt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterji, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Rivera, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallay, P. A.</span><span> </span><span class="NLM_article-title">The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">3888</span><span class="NLM_x">–</span> <span class="NLM_lpage">3897</span><span class="refDoi"> DOI: 10.1128/AAC.00693-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1128%2FAAC.00693-12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=3888-3897&author=S.+Hopkinsauthor=M.+Bobardtauthor=U.+Chatterjiauthor=J.+A.+Garcia-Riveraauthor=P.+Limauthor=P.+A.+Gallay&title=The+cyclophilin+inhibitor+SCY-635+disrupts+hepatitis+C+virus+NS5A-cyclophilin+A+complexes&doi=10.1128%2FAAC.00693-12"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1128%2FAAC.00693-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00693-12%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DS.%26aulast%3DBobardt%26aufirst%3DM.%26aulast%3DChatterji%26aufirst%3DU.%26aulast%3DGarcia-Rivera%26aufirst%3DJ.%2BA.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DGallay%26aufirst%3DP.%2BA.%26atitle%3DThe%2520cyclophilin%2520inhibitor%2520SCY-635%2520disrupts%2520hepatitis%2520C%2520virus%2520NS5A-cyclophilin%2520A%2520complexes%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D3888%26epage%3D3897%26doi%3D10.1128%2FAAC.00693-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Foster, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stonehouse, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, M.</span><span> </span><span class="NLM_article-title">Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">7460</span><span class="NLM_x">–</span> <span class="NLM_lpage">7464</span><span class="refDoi"> DOI: 10.1128/JVI.00393-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1128%2FJVI.00393-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=21593166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslCisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=7460-7464&author=T.+L.+Fosterauthor=P.+Gallayauthor=N.+J.+Stonehouseauthor=M.+Harris&title=Cyclophilin+A+interacts+with+domain+II+of+hepatitis+C+virus+NS5A+and+stimulates+RNA+binding+in+an+isomerase-dependent+manner&doi=10.1128%2FJVI.00393-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner</span></div><div class="casAuthors">Foster, Toshana L.; Gallay, Philippe; Stonehouse, Nicola J.; Harris, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7460-7464</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">NS5A plays a crit., yet poorly defined, role in hepatitis C virus genome replication.  The protein consists of 3 domains, each of which is able to bind independently to the 3' untranslated region (UTR) of the viral pos. strand genomic RNA.  The peptidyl-prolyl isomerase cyclophilin A (CypA) binds to domain II, catalyzing cis-trans isomerization.  CypA inhibitors such as cyclosporine (CsA) were shown to inhibit hepatitis C virus (HCV) replication.  We show here that CypA stimulated domain II RNA binding activity, and this stimulation was abrogated by CsA.  An isomerase mutant of CypA (H126Q) failed to bind to domain II and did not stimulate RNA binding.  Finally, we demonstrate that the RNA binding of 2 domain II mutants, the D316E and D316E/Y317N mutants, previously shown to exhibit CypA independence for RNA replication, was unaffected by CypA.  This study provides an insight into the mol. mechanism of CypA activity during HCV replication and further validates the use of CypA inhibitors in HCV therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ-kLl4Y8V4rVg90H21EOLACvtfcHk0lipesjo7qw4Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslCisr4%253D&md5=2dfe5029d201ae08880f75e860df60fc</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1128%2FJVI.00393-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00393-11%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DT.%2BL.%26aulast%3DGallay%26aufirst%3DP.%26aulast%3DStonehouse%26aufirst%3DN.%2BJ.%26aulast%3DHarris%26aufirst%3DM.%26atitle%3DCyclophilin%2520A%2520interacts%2520with%2520domain%2520II%2520of%2520hepatitis%2520C%2520virus%2520NS5A%2520and%2520stimulates%2520RNA%2520binding%2520in%2520an%2520isomerase-dependent%2520manner%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D7460%26epage%3D7464%26doi%3D10.1128%2FJVI.00393-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Blight, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolykhalov, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">Efficient initiation of HCV RNA replication in cell culture</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">1972</span><span class="NLM_x">–</span> <span class="NLM_lpage">1974</span><span class="refDoi"> DOI: 10.1126/science.290.5498.1972</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1126%2Fscience.290.5498.1972" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=11110665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BD3cXoslKgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2000&pages=1972-1974&author=K.+J.+Blightauthor=A.+A.+Kolykhalovauthor=C.+M.+Rice&title=Efficient+initiation+of+HCV+RNA+replication+in+cell+culture&doi=10.1126%2Fscience.290.5498.1972"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient initiation of HCV RNA replication in cell culture</span></div><div class="casAuthors">Blight, Keril J.; Kolykhalov, Alexander A.; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">5498</span>),
    <span class="NLM_cas:pages">1972-1974</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a global health problem affecting an estd. 170 million individuals worldwide.  We report the identification of multiple independent adaptive mutations that cluster in the HCV nonstructural protein NS5A and confer increased replicative ability in vitro.  Among these adaptive mutations were a single amino acid substitution that allowed HCV RNA replication in 10% of transfected hepatoma cells and a deletion of 47 amino acids encompassing the interferon (IFN) sensitivity detg. region (ISDR).  Independent of the ISDR, IFN-α rapidly inhibited HCV RNA replication in vitro.  This work establishes a robust, cell-based system for genetic and functional analyses of HCV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPYOuqOjy-ZbVg90H21EOLACvtfcHk0lipesjo7qw4Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXoslKgsL4%253D&md5=67eb65d15efc36854faf3940db9a5d91</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1126%2Fscience.290.5498.1972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.290.5498.1972%26sid%3Dliteratum%253Aachs%26aulast%3DBlight%26aufirst%3DK.%2BJ.%26aulast%3DKolykhalov%26aufirst%3DA.%2BA.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DEfficient%2520initiation%2520of%2520HCV%2520RNA%2520replication%2520in%2520cell%2520culture%26jtitle%3DScience%26date%3D2000%26volume%3D290%26spage%3D1972%26epage%3D1974%26doi%3D10.1126%2Fscience.290.5498.1972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Kumthip, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chusri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jilg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fusco, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantip, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongsawat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maneekarn, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">8581</span><span class="NLM_x">–</span> <span class="NLM_lpage">8591</span><span class="refDoi"> DOI: 10.1128/JVI.00533-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1128%2FJVI.00533-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=22674974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtF2jtLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=8581-8591&author=K.+Kumthipauthor=P.+Chusriauthor=N.+Jilgauthor=L.+Zhaoauthor=D.+N.+Fuscoauthor=H.+Zhaoauthor=K.+Gotoauthor=D.+Chengauthor=E.+A.+Schaeferauthor=L.+Zhangauthor=C.+Pantipauthor=S.+Thongsawatauthor=A.+O%E2%80%99Brienauthor=L.+F.+Pengauthor=N.+Maneekarnauthor=R.+T.+Chungauthor=W.+Lin&title=Hepatitis+C+virus+NS5A+disrupts+STAT1+phosphorylation+and+suppresses+type+I+interferon+signaling&doi=10.1128%2FJVI.00533-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling</span></div><div class="casAuthors">Kumthip, Kattareeya; Chusri, Pattranuch; Jilg, Nikolaus; Zhao, Lei; Fusco, Dahlene N.; Zhao, Hong; Goto, Kaku; Cheng, Du; Schaefer, Esperance A.; Zhang, Leiliang; Pantip, Chansom; Thongsawat, Satawat; O'Brien, Amornrat; Peng, Lee F.; Maneekarn, Niwat; Chung, Raymond T.; Lin, Wenyu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8581-8591</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Responses to alpha interferon (IFN-α)-based treatment are dependent on both host and viral factors and vary markedly among patients infected with different hepatitis C virus (HCV) genotypes (GTs).  Patients infected with GT3 viruses consistently respond better to IFN treatment than do patients infected with GT1 viruses.  The mechanisms underlying this difference are not well understood.  In this study, we sought to det. the effects of HCV NS5A proteins from different genotypes on IFN signaling.  We found that the overexpression of either GT1 or GT3 NS5A proteins significantly inhibited IFN-induced IFN-stimulated response element (ISRE) signaling, phosphorylated STAT1 (P-STAT1) levels, and IFN-stimulated gene (ISG) expression compared to controls.  GT1 NS5A protein expression exhibited stronger inhibitory effects on IFN signaling than did GT3 NS5A protein expression.  Furthermore, GT1 NS5A bound to STAT1 with a higher affinity than did GT3 NS5A.  Domain mapping revealed that the C-terminal region of NS5A conferred these inhibitory effects on IFN signaling.  The overexpression of HCV NS5A increased HCV replication levels in JFH1-infected cells through the further redn. of levels of P-STAT1, ISRE signaling, and downstream ISG responses.  We demonstrated that the overexpression of GT1 NS5A proteins resulted in less IFN responsiveness than did the expression of GT3 NS5A proteins through stronger binding to STAT1.  We confirmed that GT1 NS5A proteins exerted stronger IFN signaling inhibition than did GT3 NS5A proteins in an infectious recombinant JFH1 virus.  The potent antiviral NS5A inhibitor BMS-790052 did not block NS5A-mediated IFN signaling suppression in an overexpression model, suggesting that NS5A's contributions to replication are independent of its subversive action on IFN.  We propose a model in which the binding of the C-terminal region of NS5A to STAT1 leads to decreased levels of P-STAT1, ISRE signaling, and ISG transcription and, ultimately, to preferential GT1 resistance to IFN treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg79F_jnivs7Vg90H21EOLACvtfcHk0libktKr5xN7rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtF2jtLjP&md5=c3eff494e9a562ff514e2650469b0996</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1128%2FJVI.00533-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00533-12%26sid%3Dliteratum%253Aachs%26aulast%3DKumthip%26aufirst%3DK.%26aulast%3DChusri%26aufirst%3DP.%26aulast%3DJilg%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DFusco%26aufirst%3DD.%2BN.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DD.%26aulast%3DSchaefer%26aufirst%3DE.%2BA.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DPantip%26aufirst%3DC.%26aulast%3DThongsawat%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DA.%26aulast%3DPeng%26aufirst%3DL.%2BF.%26aulast%3DManeekarn%26aufirst%3DN.%26aulast%3DChung%26aufirst%3DR.%2BT.%26aulast%3DLin%26aufirst%3DW.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520disrupts%2520STAT1%2520phosphorylation%2520and%2520suppresses%2520type%2520I%2520interferon%2520signaling%26jtitle%3DJ.%2520Virol.%26date%3D2012%26volume%3D86%26spage%3D8581%26epage%3D8591%26doi%3D10.1128%2FJVI.00533-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Zimmermann, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gassler, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nattermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luedde, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trautwein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tacke, F.</span><span> </span><span class="NLM_article-title">Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e21381</span><span class="refDoi"> DOI: 10.1371/journal.pone.0021381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1371%2Fjournal.pone.0021381" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e21381&author=H.+W.+Zimmermannauthor=S.+Seidlerauthor=N.+Gasslerauthor=J.+Nattermannauthor=T.+Lueddeauthor=C.+Trautweinauthor=F.+Tacke&title=Interleukin-8+is+activated+in+patients+with+chronic+liver+diseases+and+associated+with+hepatic+macrophage+accumulation+in+human+liver+fibrosis&doi=10.1371%2Fjournal.pone.0021381"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0021381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0021381%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DH.%2BW.%26aulast%3DSeidler%26aufirst%3DS.%26aulast%3DGassler%26aufirst%3DN.%26aulast%3DNattermann%26aufirst%3DJ.%26aulast%3DLuedde%26aufirst%3DT.%26aulast%3DTrautwein%26aufirst%3DC.%26aulast%3DTacke%26aufirst%3DF.%26atitle%3DInterleukin-8%2520is%2520activated%2520in%2520patients%2520with%2520chronic%2520liver%2520diseases%2520and%2520associated%2520with%2520hepatic%2520macrophage%2520accumulation%2520in%2520human%2520liver%2520fibrosis%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De21381%26doi%3D10.1371%2Fjournal.pone.0021381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Flisiak, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinman, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jablkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kryczka, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawlowska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heathcote, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolas-Metral, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosgurin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liz, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scalfaro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porchet, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crabbe, R.</span><span> </span><span class="NLM_article-title">The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1460</span><span class="NLM_x">–</span> <span class="NLM_lpage">1468</span><span class="refDoi"> DOI: 10.1002/hep.22835</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1002%2Fhep.22835" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=1460-1468&author=R.+Flisiakauthor=S.+V.+Feinmanauthor=M.+Jablkowskiauthor=A.+Horbanauthor=W.+Kryczkaauthor=M.+Pawlowskaauthor=J.+E.+Heathcoteauthor=G.+Mazzellaauthor=C.+Vandelliauthor=V.+Nicolas-Metralauthor=P.+Grosgurinauthor=J.+S.+Lizauthor=P.+Scalfaroauthor=H.+Porchetauthor=R.+Crabbe&title=The+cyclophilin+inhibitor+Debio+025+combined+with+PEG+IFNalpha2a+significantly+reduces+viral+load+in+treatment-naive+hepatitis+C+patients&doi=10.1002%2Fhep.22835"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2Fhep.22835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22835%26sid%3Dliteratum%253Aachs%26aulast%3DFlisiak%26aufirst%3DR.%26aulast%3DFeinman%26aufirst%3DS.%2BV.%26aulast%3DJablkowski%26aufirst%3DM.%26aulast%3DHorban%26aufirst%3DA.%26aulast%3DKryczka%26aufirst%3DW.%26aulast%3DPawlowska%26aufirst%3DM.%26aulast%3DHeathcote%26aufirst%3DJ.%2BE.%26aulast%3DMazzella%26aufirst%3DG.%26aulast%3DVandelli%26aufirst%3DC.%26aulast%3DNicolas-Metral%26aufirst%3DV.%26aulast%3DGrosgurin%26aufirst%3DP.%26aulast%3DLiz%26aufirst%3DJ.%2BS.%26aulast%3DScalfaro%26aufirst%3DP.%26aulast%3DPorchet%26aufirst%3DH.%26aulast%3DCrabbe%26aufirst%3DR.%26atitle%3DThe%2520cyclophilin%2520inhibitor%2520Debio%2520025%2520combined%2520with%2520PEG%2520IFNalpha2a%2520significantly%2520reduces%2520viral%2520load%2520in%2520treatment-naive%2520hepatitis%2520C%2520patients%26jtitle%3DHepatology%26date%3D2009%26volume%3D49%26spage%3D1460%26epage%3D1468%26doi%3D10.1002%2Fhep.22835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Pan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramakrishnaiah, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fouraschen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Ruiter, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwekkeboom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tilanus, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Laan, L. J.</span><span> </span><span class="NLM_article-title">Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi)</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1330</span><span class="NLM_x">–</span> <span class="NLM_lpage">1339</span><span class="refDoi"> DOI: 10.1136/gutjnl-2011-300449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;key=10.1136%2Fgutjnl-2011-300449" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=1330-1339&author=Q.+Panauthor=V.+Ramakrishnaiahauthor=S.+Henryauthor=S.+Fouraschenauthor=P.+E.+de+Ruiterauthor=J.+Kwekkeboomauthor=H.+W.+Tilanusauthor=H.+L.+Janssenauthor=L.+J.+van+der+Laan&title=Hepatic+cell-to-cell+transmission+of+small+silencing+RNA+can+extend+the+therapeutic+reach+of+RNA+interference+%28RNAi%29&doi=10.1136%2Fgutjnl-2011-300449"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2011-300449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2011-300449%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DQ.%26aulast%3DRamakrishnaiah%26aufirst%3DV.%26aulast%3DHenry%26aufirst%3DS.%26aulast%3DFouraschen%26aufirst%3DS.%26aulast%3Dde%2BRuiter%26aufirst%3DP.%2BE.%26aulast%3DKwekkeboom%26aufirst%3DJ.%26aulast%3DTilanus%26aufirst%3DH.%2BW.%26aulast%3DJanssen%26aufirst%3DH.%2BL.%26aulast%3Dvan%2Bder%2BLaan%26aufirst%3DL.%2BJ.%26atitle%3DHepatic%2520cell-to-cell%2520transmission%2520of%2520small%2520silencing%2520RNA%2520can%2520extend%2520the%2520therapeutic%2520reach%2520of%2520RNA%2520interference%2520%2528RNAi%2529%26jtitle%3DGut%26date%3D2012%26volume%3D61%26spage%3D1330%26epage%3D1339%26doi%3D10.1136%2Fgutjnl-2011-300449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1CWA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1CWA','PDB','1CWA'); return false;">PDB: 1CWA</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i43"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01064">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_00083"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01064">10.1021/acs.jmedchem.5b01064</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_001.csv">CSV</a>)</p></li><li><p class="inline">Synthesis and characterization of the compounds, molecular docking, and details of the biological assays (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_001.csv">jm5b01064_si_001.csv (1.76 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01064/suppl_file/jm5b01064_si_002.pdf">jm5b01064_si_002.pdf (3.19 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01064&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01064%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-24%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01064" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667980bf4e031964","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
